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Abstract
D-3 phosphoinositides produced by the activated lipid kinase 
phosphatidylinositol 3-kinase (PI 3-K) regulate a diverse array of cellular 
biological responses in T cells including proliferation, differentiation, migration 
and apoptosis. These functional responses can be checked by inositol 
phosphatases such as SHIP and PTEN which metabolise the lipid PI(3,4,5)P3 
and thus ultimately regulate PI(3,4,5)P3-dependent signalling cascades. 
Expression of these important phosphatases was determined in commonly used 
leukemic T cell lines as well as peripheral human T-lymphoblasts. The cell line 
Jurkat lacked expression of both SHIP and PTEN whereas the CEM and MOLT- 
4 T cell lines expressed SHIP but not PTEN. T-lymphoblasts derived from 
healthy volunteers, as expected, expressed both phosphatases. This difference 
in phosphatase expression was associated with alterations in D-3 
phosphoinositide profiles and in the activation status of PI(3,4,5)P3-dependent 
signalling molecules including protein kinase B (PKB).
Evidence is presented that SHIP is a downstream target for CD28-activated 
protein tyrosine kinases and can itself co-associate with in vitro kinase activity. 
This tyrosine phosphorylation of SHIP following CD28 stimulation was shown to 
be independent of PI 3-K activation. Following stimulation, SHIP was shown to 
bind to the adapter protein p62dok and GRID, which may help mediate the 
biological function(s) of SHIP. The in vitro assays revealed phosphatase activity 
of SHIP to be constitutive in vitro with no significant enhancement being 
observed following CD28 stimulation. PTEN, unlike SHIP, was not tyrosine 
phosphorylated following CD28 stimulation but did co-precipitate with in vitro 
kinase activity and with several unidentified phosphoproteins, all of which 
appear to form part of a multimeric protein complex that assembles post CD28 
stimulation.
The role of PPARy, a member of the nuclear hormone superfamily and its 
various ligands were assessed for their inhibitory effects on T cell proliferation. 
The prostaglandin 15dPGJ2, a proposed natural ligand for PPARy, proved to be 
a potent inhibitor of primary T cell and SEB-activated T-lymphoblasts 
proliferation in response to various stimuli. The synthetic PPARy agonist,
XIV
troglitazone inhibited T cell proliferation induced by a ‘physiological’ stimulus 
(IL-2 or CD3/CD28) but ineffective at inhibiting T cells induced by the non- 
physiological stimulus PMA/lonomycin. On an equimolar basis, troglitazone was 
found to be a less potent inhibitor as 15dPGJ2. In addition the structurally 
related synthetic compound ciglitazone had no detectable inhibitory effect on T 
cell proliferation irrespective of the stimulus used. These data adds to the 
existing evidence that certain PPARy agonists may have therapeutic potential in 
T cell-mediated anti-inflammatory disorders.
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Overview of T-lymphocyte function
Lymphocytes provide both the specificity and memory that are key 
characteristics of what is termed the adaptive or acquired immune response. B 
cells and T cells are the two major populations of lymphocytes involved in the 
adaptive immune response. T cells originate from precursor stem cells in the 
bone marrow and migrate to the thymus where they mature into antigen specific 
T cells that are non-responsive to self-antigens. T cells can be grouped into two 
subpopulations: T helper (Th) cells and T cytotoxic (Tc) cells which can be 
identified by the expression of the cell surface antigen markers CD4 and CD8 
respectively (figure 1). Th cells provide help to B cells via direct cell interactions 
and by producing cytokines that are critical for B cell proliferation and 
differentiation. Th cells can be further sub divided into Th1 and Th2, which are 
characterised by their cytokine expression profile (figure 1). Th cells can only 
recognise antigen via the T cell receptor (TCR) when it is associated with class 
II major histocompatability complex (MHC) proteins expressed on antigen 
presenting cells (APCs). Tc cells recognise antigen in complex with MHC class I 
proteins and, as their name suggests, mediate the killing of infected cells, 















Figure 1: Maturation of T cells. Precursor lymphoid stem cells (LSC) derived from the bone 
marrow migrate and mature into T cells in the thymus. Expression of T cell surface markers 
such as CD4 and CD8 determine the biological fate of the T cell. Thus expression of CD8 
renders the cell a cytotoxic T cell. In contrast, expression of CD4 defines the cell as a T helper 
cell that can be further subdivided into Th1 and Th2 subsets characterised by their cytokine 
expression profiles.
T Cell Development
Progenitor T cells are attracted to the thymus via chemotactic signals and 
proliferate and differentiate along several different developmental pathways to 
generate functionally distinct subpopulations of mature T cells. These T cell 
developmental pathways also correlate with TCR-gene rearrangements giving 
rise to the enormous range of diversity and specificity exhibited by T cells. 
Thymic T cells (thymocytes) exhibit changes in various surface receptors during 
T cell development which can be tracked via flow cytometry. Initially, immature 
thymocytes lack detectable surface levels of the co-receptors CD4 and CD8 
and are thus referred to as double negative thymocytes. These can differentiate 
into T cells bearing ap TCR or 8y TCR. The majority of these thymocytes 
develop ap TCR and also begin to express both the CD4 and CD8 co-
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receptors. However it is estimated that most thymocytes (-90%) do not mature 
and are eliminated by apoptosis due to the failure to produce functional TCR 
during TCR gene rearrangement. CD4+/CD8+ double positive thymocytes 
further differentiate into either single positive CD4+ or CD8+ thymocytes and 
enter rounds of positive and negative selection to produce mature T 
lymphocytes. The mechanisms underlying the transition of double positives to 
single positive thymocytes is currently being unravelled and there is growing 
evidence for a role of the mitogen activated protein kinase 1 (MAPK) signalling 
in this process (Germain 2002). In general, high levels of MAPK-1 signalling 
promotes the generation of CD4+ single positive thymocytes whilst interference 
of MAPK1 activity results in the production of CD8+ thymocytes (Sharp et al
1997). Positive selection ensures that thymocytes expressing TCRs can 
recognise and interact with cells bearing MHC molecules whilst those that do 
not are eliminated by apoptosis. MHC-restricted thymocytes that survive 
positive selection undergo negative selection, during which those that bind too 
strongly to MHC proteins or self-antigens are, again, eliminated by apoptosis. 
Thereby tolerance to self-antigens is achieved by removing potentially auto­
reactive T cells. Thymocytes that bind self-MHC proteins weakly are able to 
survive and develop into mature T lymphocytes and enter into the periphery.
The Immunological Synapse
T-lymphocyte activation requires multiple receptor interactions between the 
TCR bearing T cell and the APC containing a recognisable antigenic peptide in 
complex with the MHC proteins for a sustained period of time. The point of 
contact between the T cell and APC has been termed the immunological 
synapse, and been shown to be a highly ordered platform that favours signal 
transduction (Monks et al 1998 and van der Merwe et al 2000). The use of 
fluorescently labelled receptors, incorporated into T cells and APCs has allowed 
‘real-time’ visualisation of the formation of the immunological synapse by 
confocal microscopy (Grakouwi et al 1999). At the initial point of contact, T cells 
stop migrating and a central adhesion junction is formed between LFA-1 and 
ICAM-1 (figure 2). MHC-peptide and TCR molecules are presumed to interact 
and ‘sample’ each other outside the central adhesion junction. During the next 5
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minutes MHC-peptide and the TCR relocate into the centre of the contact area 
with ICAM-1/LFA-1 receptors shifting outside of the centre to form a peripheral 
stabilisation ring (figure 2). The mature immunological synapse has also been 
defined as a supramolecular activation cluster (SMAC) characterised with 
increased densities of receptors and signalling molecules. The centre of the 
mature SMAC contains co-receptors such as CD4/CD8 and co-stimulatory 
receptor pairs such as CD28/B7, CD2 and its ligand CD48 (Wulfing and Davis
1998). These receptors may serve to act as ‘molecular rulers’ in the synapse by 
excluding larger inhibitory receptors as well as providing biochemical signals to 
the T cell (figure 2). This occurs with the transmembrane protein tyrosine 
phosphatase CD45, a negative regulator of T cell activation, is excluded from 
the mature synapse (Rogers et al 1996). The synapse is reported to be stable 
for upto 1 hour after its initial formation (Monks et al 1998), within a time frame 
correlated with full T cell activation.
The immunological synapse and SMAC formation occurs within membrane 
rafts, sphingolipid/cholesterol-enriched membrane microdomains found in all 
mammalian cell types. These dynamic membrane microdomains were initially 
characterised by their lack of solubility in Triton-X100. Essential signalling 
components in T cell activation are enriched in membrane rafts, for example the 
src protein tyrosine kinase (PTK) p56lck (Montixi et al 1998), tyrosine 
phosphorylated TCR £ chain (Kosugi et al 1999), CD28 (Viola et al 1999) and 
the adapter LAT (Lin et al 1999). In contrast CD45 a tyrosine phosphatase, has 
a low affinity for membrane rafts (Rogers et al 1996) and therefore excluded 
from the synapse. Membrane rafts therefore provide an effective platform to 
concentrate positive signalling molecules whilst excluding inhibitory 
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Figure 2. Model for immunological synapse (IS) formation between a T cell and an APC. An 
initial inner adhesion ring platform is formed between ICAM 1 and LFA-1 receptors with TCR 
and accessory receptors around the periphery (left panel). Within the time frame of 
approximately 5 minutes the TCR, CD28, CD2 and their corresponding ligands migrate into the 
centre and can begin to signal. The adhesion molecules forming a stable outer ring resembling 
a ‘bullseye’ structure (right panel).
Models of T lymphocyte activation.
The multiple receptor interactions of the immunological synapse between T 
cells and APCs culminate in a series of ordered events. An early activation 
marker is the production and secretion of IL-2, a growth factor for T cells as well 
as a whole host of cytokines. This coincides with the upregulation of the IL-2 
receptor (IL-2R), CD69 and CD40L. T cells then enter a proliferative phase from 
quiescent cells to blast transformed T cells before entering a differentiation 
phase, which may require several rounds of cell division. T cells receive their 
primary signal via antigen/MHC presented by APC. However, this is insufficient 
for optimal activation, with accessory or co-stimulatory receptors providing the
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additional input to exceed the thresholds set by the T cell. This has led to the 
concept of the 2 signal model with regards to T cell activation, with the 
TCR/CD3 complex supplying signal 1 and co-stimulatory receptors e.g. CD28 
engaged with the B7 receptors, providing signal 2 (figure 3). Failure of the T cell 
to receive this co-stimulatory signal can push the cell in to a state of annergy or 
unresponsive to further antigenic encounter or even apoptosis. The 2-signal 
model for T cell activation has been updated and modified with the discovery of 
additional co-stimulatory receptors such as the CD28 homologue ICOS (Hutloff 
et al 1999). CD28-primed T cells upregulate ICOS that can interact with B7 
related proteins, which are thought to drive Th2 differentiation into effector cells. 
T lymphocyte activation can be controlled via inhibitory receptors such as 
CTLA-4 (Lee et al 1998), structurally related to CD28, which can outcompete 
CD28 for B7 binding thus denying the T cell co-stimulatory input. The 
biochemical response to some of the key receptor engagements in T cell 
signalling will be further considered.
APC





Signal 1 Signal 2
ACTIVATION
Figure 3. The 2 signal model for T cell activation. Engagement of TCR with MHC/antigen 
induces the specificity and primary signal (signal 1) of the T cell which alone is insufficient for 
full activation. Ligation of co-stimulatory receptors (signal 2) such as CD28 and CD2 exceed 
inhibitory thresholds and in conjunction with signal 1 drive cell-proliferation, T-lymphoblast 
formation and IL-2 secretion.
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TCR signalling.
TCR-mediated tyrosine phosphorylation and regulation of adapter 
proteins.
The primary biochemical response to TCR stimulation via MHC-antigen 
complex or anti-CD3 mAb is the activation of src family PTK such as Lck and 
Fyn. This correlates with a rapid increase in phospho-tyrosine content of a 
number of src PTK substrates, within 5 seconds of TCR triggering (June et al 
1990). Binding of Lck to the CD4/CD8 co-receptors places it into juxtaposition 
with the TCR and enables the kinase to phosphorylate motifs termed 
immunoreceptor tyrosine-based activation motifs (ITAM) present on e, y and 5 
subunits of the CD3 complex and on the TCRC chain (figure 4). Phosphorylated 
ITAMs serve as docking sites for Src Homology 2 (SH2) domain containing 
signalling molecules in which to propagate cell signalling. The syk family PTK 
member ZAP-70 is able to bind a tyrosine phosphorylated ITAM on the TCR<  ^
chain (Chan et al 1991) and then become activated by CD4/CD8-assocaited 
Lck-mediated phosphorylation (figure 4).
A major substrate for ZAP-70 is the adapter protein LAT (Zhang et al 1998). 
Tyrosine phosphorylated LAT is able to recruit phospholipase C y (PLCy) to the 
membrane via its SH2 domain and become tyrosine phosphorylated itself. LAT 
has proved to be a central player in directing signal transduction in T cells. 
Tyrosine phosphorylated LAT is able to recruit and associate with signalling 
proteins such as Grb-2 and SLP-76, the lipid kinase Phosphatidyl inositol 3- 
kinase (PI 3-K) and the protooncogene c-Cbl, thereby integrating diverse 
biochemical signals. The importance of LAT is highlighted in the LAT-deficient 
Jurkat T cell line, in which the TCR-mediated tyrosine phosphorylation of key 










Figure 4: Activation of TCR. Following stimulation via antigen, ITAM motifs become tyrosine 
phosphorylated via the CD4-coreceptor-bound PTKs p56lck and pSSA1, which were primed via 
dephosphorylated and acivated by the transmembrane phosphatase CD45. Phosphorylated 
ITAMs can bind to SH2 domain containing proteins including ZAP-70 that can be further 
positively regulated by p56lck and subsequently allow initiation of cell signalling.
Effector pathways downstream from the TCR -  Calcium dependent signal.
Active, tyrosine phosphorylated PLCy cleaves phosphatidlyinositol 4,5- 
bisphosphate and generates the well-characterised second messengers 
inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 production 
initiates the depletion of intracellular Ca2+ stores. The resultant Ca2+ flux 
coupled with the presence of DAG, results in the activation of PKC (Weiss et al 
1987). The rise in intracellular Ca2+ levels leads to the activation of the 
serine/threonine phosphatase calcineurin, which can dephosphorylate the 
transcription factor Nuclear Factor of Activated T cells (NFAT). This 
dephosphorylation event promotes translocation of NFAT from the cytosol to the 
nucleus where it can participate along with the AP-1 family of transcription 
factors in the regulation of IL-2 gene transcription (Jain et al 1995). PKC 
signalling pathways are also believed to impinge on the AP-1 and NFAT 
transcription factors (figure 5).
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TCR-mediated regulation of the Mitogen Activated Protein Kinases 
(MAPK)
LAT along with its 9 conserved phosphorylatable tyrosine residues is central to 
linking the TCR to downstream mitogenic signals. This is primarily achieved via 
the recruitment of the adapter Grb-2 in complex with the guanine nucleotide 
exchange factor Sos to phosphorylated LAT. Membrane targeted Sos, now in 
juxtaposition with inactive GDP-bound Ras, is able to GTP-load and hence 
activate Ras. GTP-Ras is able to recruit the mitogen Raf-1 to the membrane 
where it can activate by serine/threonine phosphorylation Mek kinase which in 
turn can activate the MAPKs, Erk 1 and Erk 2 (figure 5). This well characterised 
pathway has been shown to be essential in thymocyte differentiation (Alberola- 
llla et al 1995). Targets for Erk 1 and Erk 2 in T cells include the transcription 
factors Elk-1 and serum response factor (Turner et al 1997) which impinge on 
response elements regulating cytokine transcription.
TCR-mediated activation of PI 3-K
PI-3K can couple to stimulated TCR via the transmembrane adapter proteins 
LAT (Zhang et al 1998) and TRIM (Bruyns et al 1998). These associations 
occur through interaction of the regulatory p85 domain with YxxM motifs on the 
adapter protein. Recruitment of PI 3-K elevates levels of D-3 phosphoinositides 
(Ward et al 1992) which can interact with proteins bearing Pleckstrin Homology 
(PH) domains (figure 5). Membrane targeted proteins can drive anti-apoptotic 
signals and cytoskeletal rearrangements (PI 3-K signalling cascades are 
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Figure 5. TCR coupling to intracellular signalling cascades following stimulation via 
MHC/antigen. Binding of the TCR to antigen leads to rapid tyrosine phosphorylation via co- 
receptor bound p56Lck Subsequent phosphorylation of ZAP-70 results in the tyrosine 
phosphorylation of transmembrane adapter proteins including LAT and TRIM that acts as a 
molecular scaffold. The Grb-2-Sos protein complex interacts with LAT thus allowing the 
activation of the Ras/MAPK pathway. LAT also recruits PLCy where it can be activated leading 
to hydrolysis of PI (4,5)P2 forming IP3 and DAG, hence initiating the calcium-signalling pathway. 
Both TRIM and LAT can bind to the p85 adapter subunit of PI 3-K thus initiating activation of PI 
3-K driven cascades. LAT can also bind the guanine nucleotide exchange factor Vav via the 
adapter protein SLP-76. Vav can positively regulate Rac, another GTPase implicated in actin 
reorganisation. The culmination of these signalling cascades is necessary for transcription of 
cytokines important in initiating T cell activation.
Costimulatory receptors: CD28/B7 families
Secondary signals termed co-stimulation are needed alongside stimulation of 
the TCR by antigen to achieve full activation of the T cell. These co-stimulatory 
signals are provided by the CD28 family members upon engagement of their B7 
ligands. The CD28/B7 family members are listed in table 1. These receptors 
share several common structural and functional features but interestingly can 
orchestrate varied biological outcomes of the T cell upon appropriate ligand
Introduction 11
engagement (table 1). The biological function of each of the CD28 receptor 
family members will be discussed in more detail with particular emphasis on 
CD28.
RECEPTOR LIGAND(S) BIOLOGICAL CONSEQUENCE
CD28 B7.1 and B7.2 ACTIVATION
CTLA-4 B7.1 and B7.2 INHIBITION
ICOS B7h/ LICOS/ B7H2 ACTIVATION
PD-1 B7H1/ PD-L-1 INHIBITION
Table 1: CD28 family of receptors, their ligands and biological outcomes upon receptor 
engagement.
CD28-Structure and expression
CD28 is a non-tyrosine kinase, type 1 transmembrane receptor expressed on 
95% of CD4+ and 50% on CD8+ T cells. CD28 is composed of two glycosylated 
44 kDa chains containing a single disulphide-linked immunoglobulin domain. 
The mature protein contains 202 amino acid residues, 41 of which comprise a 
short, species conserved, cytoplasmic domain that initiates CD28-derived 
signals. The ligands for CD28 and its structural homologue CTLA-4 are the B7 
family of receptors namely, B7.1 (CD80) and B7.2 (CD86) that are expressed 
on professional APCs such as dendritic cells, monocytes and activated B cells 
(June et al 1994). The B7 ligands are also members of the immunoglobulin 
superfamily. Interestingly, both B7.1 and B7.2 ligands bind to CTLA-4 more 
avidly than CD28 (Linsey et al 1994). Lacking catalytic activity, CD28 
generates cell signals by recruiting cellular proteins. There are 4 potential 
tyrosine residues on CD28, which once phosphorylated could bind to SH2 
domain containing proteins. Tyrosine173 in the CD28 cytoplasmic tail falls within 
the YxxM sequence motif that predicts binding of PI 3-K when phosphorylated. 
There are also two proline rich regions that conform to SH3 domain consensus 
binding sites and that are known to be important in the binding of Lck (Holdarf et 
al 1999 and figure 6).
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Characterisation of CD28 signal transduction has revealed some controversial 
differences due to the particular T cell model being used and mode of 
activation. Like TCR signalling, stimulation of CD28 leads to rapid activation of 
PTK and tyrosine phosphorylation within the cytoplasmic tail that can be 
abrogated by treatment with herbimycin A (Lu et al 1992). Analysis of tyrosine 
phosphorylated proteins in T cell lysates following CD3 or CD28 stimulation 
reveal similar patterns but there are unique CD28-mediated tyrosine 
phosphorylated proteins of 62 kDa, 75 kDa and 100 kDa implying CD28 utilises 
distinct as well as similar signalling pathways to CD3 (Vandenberghe et al 
1992). Both B7 ligands have been shown to be equivalent in terms of their 
ability in regulating PTK (Nunes et al 1996). Under in vitro conditions Lck has 
been shown only to phosphorylate Y173 within the CD28 cytoplasmic tail whilst 
the Tec family kinase ITK is able to phosphorylate all four tyrosine residues 
(King et al 1997 and figure 6). ITK is activated and recruited to CD28 via a Lck 
and PI 3-K dependent mechanisms, thus placing Lck and PI-3K upstream of 
ITK in CD28 signalling events (Lu et al 1998).
CD28 association with PI 3-K
CD28 can couple to PI 3-K via a rapid and sustained physical association of the 
regulatory p85 subunit of PI 3-K interacting with the (p)Y173 YxxM motif as 
predicted (Pages et al 1994 and figure 7). This is accompanied by a sustained 
elevation in D-3 phosphoinositides in particular PI (3,4,5) P3, a potent second 
messenger system (Ward et al 1992). CD28 was subsequently shown to 
activate the PI 3-K effector PKB in a wortmannin dependent fashion (Parry et al 
1997). The role of PI 3-K in CD28-mediated costimulation is discussed in more 
detail later.
CD28 coupling to MAPK signalling pathways
CD28 binding to Grb2 at (p) Y173 and subsequent activation of Ras/Erk pathway 
has been reported (Nunes et al 1994). These experiments were performed by 
cross-linking CD28 with agonistic mAbs. Subsequent ligation of CD28 with B7.1
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did not induce similar effects suggesting differential regulation of CD28 
signalling cascades with different stimuli.
Both TCR and CD28 can mediate the tyrosine phosphorylation of the guanine 
nucleotide exchange factor Vav, thus displaying a point of integration between 
TCR and CD28 signalling pathways (Salojin et al 1999). Vav is able to regulate 
the activity of rac by GTP loading, which leads to the activation of the JNK 
MAPK pathway via PAK. Formation of these JNK cascades can regulate NF-kB 
and AP-1 transcription factor complexes and regulate IL-2 production via 
binding to the appropriate response element (figure 7).
Additional downstream targets for CD28
The adapter protein p62dok is a target for CD28 but not CD3 -activated PTK. 
The role of this multifunctional adapter protein has still yet to be validated, but 
has been reported to be involved in the conversion of GTP-Ras to inactive 
GDP-Ras in B cells and thus the regulation of mitogenic signalling through 
associating with Ras-GAP proteins. The proto-oncogene adapter protein Cbl is 
also a target for tyrosine phosphorylation following CD28/CD3 ligation (Nunes et 
al 1996). Cbl has been proposed to negatively regulate cell signalling through 
targeting proteins for degradation. A newly identified adapter Grid has recently 
been described as also binding to the (p) Y173xxM motif via its own SH2 domain 
with binding kinetics similar to PI3-K (Ellis et al 2000). Grid, which is structurally 
related to Grb-2 and principally expressed in T cells, possesses an SH3-SH2- 
SH3 domain structure and co-immunoprecipitates with the adapters SLP-76 and 
p62dok. The interaction of Grid with p62dok may serve as a mechanism for its 
tyrosine phosphorylation.
Cbl has been postulated as a negative regulator of T cell activation by targeting 
Syk PTK for degradation. There is also evidence that Cbl can influence CD28 
activation by suppressing TCR-mediated Vav activation (Chiang et al 2000). 
Tyrosine phosphorylation of PLCy and resultant Ca2+ flux has also been 
described at least in the Jurkat cell line. Again there seems to be some degree 
of controversy over the particular T cell model used and mode of activation as
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the co-stimulatory signal appears to be insensitive to inhibition of cyclosporin A 
and thus independent of Ca2+ and calcineurin.












Figure 6: Structure of CD28 and CTLA-4 showing relevant residues and domains in forming 
protein-protein interactions. Both CD28 and CTLA-4 contain tyrosine residues which once 
phosphorylated can form docking sites with SH2 containing proteins; for example the p85 
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Figure 7: Signal transduction by the T cell co-stimulatory molecule CD28. Ligation of CD28 by 
the B7 ligands mediates the tyrosine phosphorylation of the cytoplasmic tail of CD28. This 
allows docking of signalling molecules such as PI 3-K via SH2 domains. Lipid products of PI 3-K 
are able to mediate the activation of PKB, which has multiple downstream effectors and can 
ultimately regulate gene expression via NFkB. Multiple substrates can be phosphorylated by 
CD28-activated-PTK including the exchange factor Vav. GTP-loaded Vav can regulate the 
Jnk/MAPK cascades that can also regulate gene expression.
Inducible costimulator (ICOS).
ICOS is a novel T cell immune receptor whose surface expression is induced on 
activated T cells (Hutloff et al 1999). ICOS shares 30-40% sequence homology 
to CD28/CTLA-4 and the ICOS gene maps to the CD28 locus (2q 33-34), which 
suggests ICOS may function as a costimulator and that the gene products of 
CD28/CTLA-4/ICOS arose by gene duplication (Coyle et al 2000). ICOS, like 
CD28, contains an extracellular Ig domain and a YxxM motif in the cytoplasmic 
tail (Hutloff et al 1999). Its expression is reported to be enhanced by CD28 
ligation. A novel B7-like ligand has recently been identified for ICOS and termed 
B7-H2. This molecule shares 20% sequence homology with B7.1 (Wang et al 
2000). Much progress has been made with regards to the function of ICOS and
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appears that it is vital for effective T helper sell responses (Tafyri et al 2001 and 
Hutloff et al 1999). This is supported by the observation that T cells from ICOS'7' 
deficient mice fail to produce IL-4 when stimulated (Dong et al 2001). Therefore 
it appears therefore that ICOS may be a critical component in the induction of 
humoral immune responses, moreover its blockade may provide a novel 
therapeutic approach for the treatment of inflammatory disease such as asthma 
(table 2).
Cytotoxic T lymphocyte associated antigen-4 (CTLA-4)
Lymphocyte responses are determined by the interplay of both stimulatory and 
inhibitory signals with the strength and timing of the appropriate signal deciding 
the outcome. CTLA-4 (CD152) is a member of the CD28 class of receptors, 
sharing the same B7 ligands and exhibiting 30% sequence homology. Unlike 
CD28, however, CTLA-4 mediates an inhibitory signal and acts to attenuate 
immune responses (Thompson et al 1997). CTLA-4 surface expression is low or 
absent in resting T cells and resides mainly in intracellular vesicles through its 
encoded intracellular localisation motif. Upon stimulation, CTLA-4 containing 
vesicles traffic to the cell surface, although overall surface expression is still 
modest even at its peak 72 hours post stimulation (Algere et al 1996). Low 
expression of CTLA-4 is somehow compensated by the 20-100-fold increased 
affinity for the B7 ligands when compared to CD28. CTLA-4 has a shorter 
cytoplasmic tail than CD28 and lacks intrinsic enzymatic activity, but does 
contain tyrosine residues capable of being phosphorylated, including a YxxM 
motif (figure 5). The essential, regulatory role of CTLA-4 in controlling the 
immune respons is drastically demonstrated in CTLA-4 "7" knockout mice. Their 
phenotype is embryonic lethal due to massive lymphoproliferation and multiple 
organ destruction (Tivol et al 1997).
The signalling mechanisms by which CTLA-4 delivers its inhibitory actions are 
poorly defined. Recent evidence suggests that CTLA-4 regulate cell cycle 
progression but not apoptosis. Primarily, this can be shown due to a by down- 
regulation of IL-2 production (Brunner et al 1999). Stimulation of CTLA-4 leads 
to its tyrosine phosphorylation by Lck allowing its subsequent interaction with 
SH2 domain containing proteins. As expected PI 3-K can bind to (p)YxxM motif
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(Schenider eta l 1995). SHP-1 and SHP-2, protein tyrosine phosphatases, have 
both reported to bind CTLA-4 (Lee et al 1998), as has the serine/threonine 
phosphatase PP2A (Chaung et al 2000). However these protein interactions 
with CTLA-4 remain controversial, as the experiments were performed using 
phospho-CTLA-4 peptide fragments to ‘fish out’ potential interacting molecules 
and may not therefore, representative of what actually occurs in vivo following 
receptor stimulation. Recruitment of stimulated, phosphatase-bound, CTLA-4 
complexes to the immunological synapse can be visualised as regulating a 
number of key mitogenic proteins as well a means to sequestering B7 signals. 
The blockade of these surface antigens has potentially wide reaching 
therapeutic implications.
Program Death-1 (PD-1)
PD-1 is a 50-55 kDa type I transmembrane protein of the Ig superfamily 
expressed on mature T and B cells following activation (Ishida et al 1992). PD-1 
shares about 30% homology with CD28 and CTLA-4 and as its name suggests, 
plays an important role in down regulating T cell activity. The ligands for PD-1, 
designated PD-L, are also members of the Ig superfamily and are expressed on 
a wide range of cell types. PD-1 contains a consensus an immunoreceptor 
tyrosine-based inhibition motif (ITIM) in the cytoplasmic tail. ITIMs are thought 
to mediate negative signalling events via the recruitment of phosphatases 
(discussed in more detail later). The cytoplasmic tyrosine phosphatase SHP-2 
has been reported to bind to the ITIM on PD-1 (Freeman et al 2000) and may 
be a part of the mechanism of PD-1 inhibitory regulation.
Therapeutic implications of costimulatory molecule blockade
As the importance of costimulatory molecules in T cell function emerged it 
became apparent that blockade of such signals could be of potential therapeutic 
value in T cell-mediated immunological disorders. Utilising the high affinity of 
CTLA-4 for its respective B7 ligands, a CTLA-4-lg fusion protein has shown 
promise in inhibiting islet xenograft rejection and has been also shown to induce 
immune tolerance (Lenschow et al 1992). CTLA-4-lg are able to block T cell 
proliferation by binding to B7 ligands with high affinity on APC thus denying T
Introduction 18
cells co-stimulatory signals through CD28. In addition, the severity of 
experimental autoimmune encephalitis in rodents, an experimental model of 
rodent multiple sclerosis can also be reduced with CTLA-4-lg (Croxford et al
1998). Promising phase I trials of CTLA-4-lg have already been completed in 
the treatment of patients with autoimmune psoriasis vulgaris (Abrams et al
1999). The diverse range of human diseases in which CD28/B7 blockade may 
hold promise is highlighted in table 2. The recent identification of other 
costimulatory molecules such as ICOS, which is expressed primarily on Th2 
cells, could provide another target for therapeutic blockade and may hold 














Table 2: Human diseases where blockage of CD28/B7 co-stimulation could have therapeutic 
potential.
Phosphoinositide 3-kinase
Phosphoinositide 3-kinases (PI 3-K) are a family of lipid kinases that are able to 
phosphorylate the D-3 position of the inositol head group of phosphoinositide 
lipids, and thereby generating bioactive second messengers, in particular 
phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) (figure 8). The lipid 
products of PI 3-K, collectively termed D-3 phosphoinositides, regulate cell 
signalling by interacting with and recruiting proteins containing the pleckstrin 
homology (PH) domain to the membrane where its activity can be regulated. 
The last decade has witnessed extraordinary interest into PI3-K signalling due 
to the fact of the increasingly diverse array of cellular processes that PI 3-K is 
involved in. PI 3-K family members can be grouped into three main classes on
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Figure 8 Schematic structure of PI (3,4,5)P3 Phosphorylation of D-3 position hydroxyl group on
PI (4,5)P2 by PI 3-K forming the bioactive second messenger PI (3,4,5)P3.
Class 1 PI 3-K
It is generally believed that the class 1a isoform of PI 3-K is the most important 
with regards to lymphocyte activation. This class of enzymes is comprised of a 
110 kDa catalytic subunit that can associate with specific adapter units termed 
p85 (figure 9). Class 1a PI 3-Ks are also have a distinguished by their ability to 
interact with ras through a unique ras-binding domain. Within the 1a class of PI 
3-K there are multiple isoforms of each subunit, a, p and y forms of the p85 
subunit and a, p and 8 forms of the p110 catalytic subunit (Vanhaesebroeck et 
al 1997). Interestingly, the expression of 1105 is restricted to leukocytes 
(Chantry et al 1997) whereas the other catalytic subunits are more widely 
distributed perhaps indicating a central role for this subunit in leukocyte 
signalling. Recent evidence has also shown that p1105 can autophosphorylate
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on Ser1039, with a resultant negative effect on its lipid kinase activity 
(Vanhaesebroeck et al 1999). A recent mechanism in negatively regulating PI 3- 
K signalling has been proposed with the discovery of a novel kinase termed 
SH2-doamin containing kinase-1 (SHK-1). This novel dual specificity kinase 
abrogates PI 3-K-dependent-chemotaxis and impairs the activation of PKB, a 
downstream marker of PI 3-K activation (Moniakis et al 2001).
The p85 adapter subunit is able to recognise and associate via its SH2 domains 
with the (p)YXXM motif (where x is any amino acid) present on the 
intracytoplasmic tail of many cell surface receptors including CD28 and CD2 
(figure 6). Thus, following stimulation and tyrosine phosphorylation of the YXXM 
motif, p85 is able to recruit p110 from the cytoplasm to the inner leaflet of the 
membrane where its substrates are localised. p85 is able to mediate signals via 
SH3 domain interaction of PTK such as p59^n, enhancing IL-2 transcription in T 
cells independently of the p110 catalytic subunit (Kang et a! 2002).
Class 1B PI 3-K is identified by the p110y catalytic subunit associated with a 
unique 101 kDa regulatory adapter subunit (figure 9). The crystal structure of 
p110y has been elucidated (Walker et al 1999). The p100y/p101 heterodimers 
are regulated by the G(3y subunits of G proteins, and therefore signal through 
seven transmembrane G protein coupled receptors including those for 
chemokines. This has lead to the theory of class 1b PI 3-K being involved in 
migration along chemotactic gradients. This is consistent with the observed 
CD28 for B7 binding thus denying the T cell co-stimulatory input. The 
biochemical response to some of the key
Class II PI 3-K
Class II PI 3-Ks contain a defining C-terminal C2 domain allowing it to bind 
phospholipids in a Ca2+ dependent manner and are thus predominately 
membrane located (figure 9). Three isoforms of class II PI 3-K exist in humans, 
PI 3-K C2a, p and y encoded by separate genes. The preferred substrates for 
class II PI 3-K is PI(4)P distinguishing it from class I PI 3-Ks which have a 
preference for PI(4,5)P2. There have been no firm indications that this class of 
PI 3-K bind to adapter subunits or are capable of interacting with ras. The
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regulation of this class of PI 3-K and their coupling to signalling pathways in 
response to extracellular stimuli are not well understood. Chemokines such as 
monocyte chemoattractant protein-1 (MCP-1) can induce an increase in lipid 
kinase activity in class II PI3-K immunoprecipitates (Turner et al 1998).
Class III PI3-K
Class III PI 3-Ks only utilises Ptdlns as a substrate and is likely to be 
responsible for the generation of phosphatidylinositol 3-phosphate (PI3P) in cell 
membranes (figure 9). A single class of this PI 3-K has been identified in 
mammalian cells and this is a homologue of the yeast vesicular sorting protein 
Vps34p; suggesting a role for it in the membrane trafficking of proteins.
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Figure 9. Schematic structures of the different class catalytic subunits of PI 3-K. Each contain a 
conserved catalytic domain with varied in vitro substrate specificity but contain different 
regulatory motifs including ras binding domain in class I and a C2 domain exhibited by class II 
PI 3-K. Specific adapter subunits are capable of binding to particular catalytic subunits as 
indicated.
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Approaches to study PI 3K function
There are two widely used inhibitors of PI 3-K, wortmannin and LY 294002, both 
of which have proved invaluable in dissecting PI 3-K signalling pathways. Both 
inhibitors function by blocking the ATP-binding site of the catalytic subunit of PI 
3-K thereby preventing phosphate transfer. Wortmannin is a non-competitive, 
cell-permeable fungal metabolite with an I C 5 0  of 5nM. LY294002 has a higher 
I C 5 0  of approximately 1 juM and is more widely used than wortmannin because 
of its greater half-life and stability, even though it does not inhibit class II PI 3K- 
C2a. The role of PI 3-K in CD28-mediated co-stimulation has been assessed 
using such pharmacological inhibitors. Both wortmannin and the structurally 
unrelated LY294002 can abrogate co-stimulation and IL-2 production in primary 
T cells (Ward et al 1995). Accordingly, site directed mutagenesis of the Y 173 
residue within CD28 has also been linked to impaired co-stimulation. However 
the role of PI 3K in CD28-mediated costimualtion is still controversial, some 
laboratories having shown that PI 3-K is somewhat dispensable for co­
stimulation in Jurkat and murine T cells (Truitt et al 1996).
Genetic approaches have also been used to functionally assess PI 3K. For 
example, deficient mice exhibit impaired B cell development and
premature death (Fruman et al 1999). Deletion of p110a however has been 
shown to be embryonic lethal, suggesting an essential role for this subunit in 
development (Bi et al 1999). In contrast p110y knockout mice are still viable but 
have impaired immune cell function. For example, neutrophils and 
macrophages display impaired chemotaxis to chemotatic stimuli (Condliffe et al
1999).
D-3 Phosphoinositides and phosphoinositide binding domains
Pl(3)P is constitutively present in mammalian cells and lipid levels remain 
largely unaltered upon cellular stimulation. In contrast, levels of PI(3,4)P2 and 
Pl(3,4,5)P3 are very low making up less than 1% of the Ptdlns pool although
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concentrations increase markedly upon cell stimulation. Proteins are able to 
interact with these D-3 phosphoinositides through specific binding domains.
The FYVE domain is named after the first four proteins shown to contain it -Fab  
1p, YOTB, Vac 1p and early endosome antigen 1. FYVE domains are 
approximately 80 amino acids in length, are characterised by the presence of 
cysteine rich zinc-finger-like motifs and are able to interact with Pl(3)P. Such 
domains are frequently found in proteins involved in vesicular trafficking events. 
The molecular basis of PI(3)P binding by FYVE domains is attributed to a 
positively charged patch of amino acids ((R/K)(R/K)HHCR) on an antiparallel 
beta sheet. Phox domains (PX), named for their presence in p40/7phox 
subunits in NADPH oxidase, are another recently characterised protein 
component capable of selective binding to Pl(3)P (Kanai et al 2001).
The best-characterised D-3 phosphoinositide-binding domain however is the PH 
domain, named through its homology to domains in the protein pleckstrin 
(Lemmon et al 1996). The six conserved residues lie in the N-terminal region of 
the PH domain in a Lys-X-Sma-X6-n-Arg/Lys-X-Arg-Hyd-Hyd motif (where ‘X’ is 
any amino acid, ‘Sma’ is a small amino acid and ‘Hyd’ is a hydrophobic acid) 
and this has been shown to mediate or be responsible for PI(3,4,5)P3 binding 
(Isakoff et al 1998). Approximately 250 proteins expressed in humans contain 
such domains, with many having a varying affinity for particular D-3 
phosphoinositides (Dowler et al 2001). Some of the proteins with varying 3- 




















Table 3: D-3 phosphoinositide binding domains and some examples of preferred lipid- 
interacting proteins. Note that PKB and DAPP are able to interact with both PI(3,4,)P2 and
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PI(3,4,)P2 (Dowler eta! 2001). Abbreviations: TAPP-1 tandem PH-domain-containing protein, 
DAPP-1 dual adapter for phosphotyrosine and 3-phosphoinositides.
Downstream effectors of PI 3K dependent signalling cascades 
PKB
PKB, a member of the AGC kinase family, is a serine/threonine protein kinase 
whose activity is wholly dependent on the generation of D-3 phosphoinositides 
via PI 3-K. PKB can positively and negatively regulate a plethora of target 
proteins and is therefore viewed as a critical upstream mediator of multiple 
biological processes (figure 10). In resting, unstimulated cells PKB resides in 
the cytoplasm, upon addition of stimulus to the cells and formation of 
Pl(3,4,5)P3, the PH domain of PKB mediates the cellular relocation to the inner 
surface of the membrane and also inducing a conformational change exposing 
regulatory phosphorylation sites (Meier et a11997). The kinase activity of PKB is 
regulated by phosphorylation on residues Thr308 and Ser473 (figure 9). The PH 
domain containing protein, phosphoinositide dependent kinases-1 (PDK-1) is 
able to phosphorylate Thr308, whereas an uncharacterised PDK-2 is thought to 
be responsible for the phosphorylation at Ser473 (Alessi et al 1997 and figure 9). 
Recent evidence indicates that PDK-2 may in fact be PDK-1, as it has been 
demonstrated that PDK-1 can associate with a PDK-1 interacting fragment-1 
(PIF-1) which subsequently allows phosphorylation of both residues of PKB 
(Balendran et al 1999). The phosphorylation status of PKB in vivo can be 
monitored upon cellular stimulation via Western blotting of whole cell lysates 
with specific anti-phospho-PKB antibodies. The translocation and activation of 
PKB can be inhibited by pre-treatment with the PI 3-K kinase inhibitor 
wortmannin, further indicating the essential role of PI 3-K in this signalling 
pathway.
Another downstream target for PDK-1 is p70S6 kinase, which is also a member 
of the AGC kinase family (Alessi et al 1997). PDK-1 phosphorylates p70S6 
kinase on residue thr252 within the carboxyl tail leading to its activation. This 
family of rapamycin sensitive kinases catalyse the phosphorylation of the 40S 
ribosomal subunits leading to increased translation of mRNA and hence protein
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synthesis. Accordingly inhibition of PDK-1 activation blocks downstream 
activation of p70S6 kinase and blocks G1-S phase transition of the cell cycle 
(Flynn et al 2000). Embryonic stem cells that lack PDK-1 have greatly reduced 
PKB and p70S6 kinase activity in response to cellular stimulation (Williams et al
2000). PKC members namely PKC£ and PKC5 can be phosphorylated in the 
activation loop sites by PDK-1 in a 3’-phosphoinositide-dependent manner 
(Legood et al 1998). PKC£ can mediate the activation of mitogen/Erk-1 kinase 








Figure 10: Diagram of PKB activation. PKB is recruited to the cell membrane via its PH domain 
interaction with PI(3,4,5)P3 undergoing a conformational change and exposing regulatory 
phosphorylation sites. Subsequent phosphorylations on residues Thr308 and Ser473 by PDK- 
1/PDK-2 lead to activation of PKB that initiates PKB driven signalling pathways. In vitro studies 
suggest that Pif-1 may substitute for PDK-2 in certain cellular contexts.
The activity of PKB has been intimately linked to cellular survival. It can 
phosphorylate the apoptotic protein BAD on residue Ser136 causing it to 
disassociate from, and relieve the inhibition of, the pro-survival protein Bcl-xL
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(Datta et al 1997). PKB recognises consensus sequences in caspase 9 and 
PKB-mediated phosphorylation can inactivate its protease activity. PKB is also 
able to phosphorylate and negatively regulate members of the Forkhead 
transcription factors, which are responsible for the regulation of apoptotic genes 
including Bc I-Xl (Brunet et al 1999). Forkhead transcription factors are thought 
to promote the expression of Fas ligand, a key cell surface molecule that 
initiates apoptotic-signalling pathways. PKB is also able to positively regulate 
the activity of transcription factors. It can phosphorylate Ik B, an inhibitory 
component of N Fk B transcription factor, and mediate its degradation. Removal 
of this inhibitory constraint allows N F k B to move into the nucleus and bind to 
appropriate response elements (Kane et al 1999).
CD28 has been reported to activate PKB in a wortmannin dependent fashion 
(Parry et al 1997). CD28-mediated PKB activation can activate pro-survival 
pathways and increase expression of Bcl-xL, a cell survival factor (figure 8). 
Consistent with PKBs pro-survival effects, CD28 has also been shown to be 
resistant to the apoptotic effect of fas (CD95) ligation (Mcleod et al 1998). The 
role of PKB in co-stimulation is still a matter for debate. Recent evidence has 
shown that CD28-mediated activation of PKB is central in upregulation of IL-2 
and IFNy but not Th2 cytokines (Kane et al 2001).
Glycogen Synthase kinase 3 (GSK3) is a multi-functional serine threonine 
kinase which lies downstream from PKB. As its name suggests GSK-3 is able to 
positively regulate the activity of glycogen synthase. GSK3 is able to 
phosphorylate cyclins especially cyclin-D1, and promotes their degradation 
(Ref-Diehl et al 1998). Phosphorylation of GSK3 by PKB inhibits its catalytic 
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Figure 11: Multiple cellular targets for PKB. The serine threonine kinase PKB can positively and 
negatively regulate a host of substrates and therefore impinge upon multiple cellular processes 
including transcription, translation, apoptosis, glucose transport and cell division.
PI 3-K regulation of Tec family protein kinases
TEC family kinases, which include Tec and bruton’s tyrosine kinase (BTK), are 
not membrane anchored like src kinases. The amino terminal PH domain can 
bind to PI 3-K products, which allows membrane localisation and subsequent 
phosphorylation by src kinases to achieve activation (Debnath et al 1999). 
Accordingly, PH domain mutation in Tec kinase as seen in X-linked 
agammaglobulinema (XI_A) leads to defective Tec activation (Vihnen et al
2000). Activated Tec can phosphorylate PLCy which results in IP3 and DAG 
generation from PI(4,5)P2 and results in Ca2+ mobilisation.
PI 3-K regulation of small GTPases
There is accumulating evidence that PI 3-K plays an essential role in regulating 
the actin cytoskeleton by coupling to small GTPases. Small GTPases cycle 
between an inactive GDP-bound and an active GTP-bound form. PI 3-K is able
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to indirectly regulate the activity of such GTPases by modulating the activity of 
exchange factors that control GTP-loading. For example, CD28-activated-PI 3-K 
is able to regulate the activity of Rac, a regulator of actin remodelling, via 
activating the guanine nucleotide exchange factor Vav which can bind D-3 
phosphoinositides via PH domains (Klasen et al 1998). Vav-mediated activation 
of Rac can be inhibited by pre-treatment with PI 3-K inhibitors. Other GTPases 
such as the Arf family of proteins, which regulate membrane traffic, are also 
implicated in PI 3-K-driven signalling cascades although the mechanism by 
which they achieve this remain unclear.
PH-domain containing adapter proteins
A variety of adapter proteins that associate with PI 3-K lipid products have been 
identified and their function are starting to be analysed. The adapter protein 
p62dok contains an array of motifs involved in cell signalling including SH2/SH3 
and PH domains. However no evidence has been found to suggest that the PH 
domain of p62dok interacts with D-3 phosphoinositides to date. The adapter 
p62dok may play a specific role in CD28-mediated co-stimulation as it a unique 
substrate for CD28 but not CD3-activated PTK (Nunes et al 1996). GTPase 
activating proteins (GAPs), which convert active GTP-bound Ras into the 
inactive GDP-bound state, have been reported to associate with p62dok, 
implying a role for this adapter in controlling mitogenic signals. p62dok has also 
been found to associate with the SH2 domain containing inositol 5’poly- 
phosphatase (SHIP) which will be discussed in more detail later.
The family of Grb-2 related adapter-binding proteins (GAB) also contain PH 
domains. These adapters can orchestrate protein-protein interactions with Grb- 
2, She and p85 in response to IL-3 stimulation (Craddock et al 1997). Like 
p62dok, Gab-2 is also a target for PTK following cell stimulation by IL-3. This 
enables it to interact with SH2 domain containing proteins including the protein 
tyrosine phosphatase SHP-2.
The adapter proteins termed TAPP and DAPP also contain PH domains but are 
novel due to the fact that they can bind PI(3,4)P2 with high affinity (Dowler et al 
1999). This class of lipid is thought to be a product the action of 5’
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phosphatases such as SHIP (discussed later). Such adapter proteins may 
recruit uncharacterised effectors and initiate PI(3,4)P2 driven signal transduction 
thus increasing the scope and diversity of PI 3-K signalling.
Metabolism of PI(3,4,5)P3 by inositol phosphatases
Small increases in D-3 phosphoinositides in cells can result in the initiation of 
diverse functional responses. It is therefore of major importance that the levels 
of these bioactive lipid second messengers are tightly regulated. The cell has 
adapted a variety of mechanisms to achieve this through expressing distinct 
phosphatases that remove particular phosphate residues from the inositol ring, 
thus antagonising the action of PI 3-K. The following sections will introduce the 
3’ and 5’ families of phosphatidylinositol phosphatases and their role in 
modulating PI 3-K-mediated signalling cascades.
PTEN
The tumour suppressor, phosphatase and tensin homologue deleted on 
chromosome 10 (PTEN), is a 3’ phosphatase capable of dephosphorylating 
Pl(3,4,5)P3 to PI(4,5)P2 and thus acts in opposition to PI 3-K. The chromosomal 
location of PTEN (10q23) has been linked with cancers including those of the 
brain, bladder and prostate, where partial or entire loss of chromosome 10 is 
exhibited (Lundgren et al 1988). Linkage analysis of Cowden’s disease, a 
cancer predisposition syndrome, has also implicated the PTEN locus (Nelen et 
al 1996). These and other findings suggested that PTEN was a novel tumour- 
suppressor that plays a vital role in controlling cell growth, and that its loss 
leads to formation of several types of cancer.
The PTEN gene encodes a 55 kDa protein, which contains the 
cysteine/arginine-based structure motif present in a variety of dual-specificity 
phosphatases (Myers et al 1997). In vitro analysis revealed that PTEN could de- 
phosphorylate a limited array of acidic phosphotyrosine and phosphothreonine 
protein substrates (Myers et al 1997). Further analysis of PTEN function 
revealed that PTEN exhibits 3’ phosphatase activity towards PI(3,4,5)P3 
(Maehama et al 1998). The lipid phosphatase activity of PTEN was 
subsequently shown to be critical for its tumour suppressor function (Myers et al
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1998). PTEN consists of 403 amino acids with the phosphatase domain lying 
within the N-terminal region (figure 12). PTEN is expressed in all tissue and cell 
types in humans. The crystal structure of PTEN has been determined and 
revealed an enlarged active site capable of accommodating its phosphoinositide 
substrate (Lee et al 1999). Recently PTEN2 a membrane-associated, testis 
specific isoform was described (Wu et al 2001). This novel enzyme is able to 
dephosphorylate PI(3,4,5)P3 in vitro but seems to have a preference for the 
related D-3 phosphoinositide lipid PI(3,5)P2- The carboxyl-terminal region 
contains two PEST sequences and a PDZ motif (postsynaptic density protein), 
which is dispensable for tumour suppressor function (Goergescu et al 1999). 
PEST sequences function in targeting proteins with short intracellular half-lives 
for protein degradation whereas PDZ domains have been implicated in 
mediating protein-protein interactions. The c-terminus of PTEN is believed to be 
important for maintaining protein stability as C-terminal deletion mutants are 
rapidly degraded (Vazquez et al 2000).
Phosphatase m otif P D Z  domain
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Figure 12: Schematic structure of PTEN protein showing relevant functional domains. PTEN is 
composed of an N-terminal 3’-phosphatase region and a C-terminal region containing two PEST 
sequences involved in targeting proteins for degradation, and a PDZ domain which can mediate 
protein-protein/membrane interactions. Within the C-terminus of PTEN lay serine/threonine 
residues, which can be phosphorylated and may confer protein stability.
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Approaches used to study PTEN function: PTEN deficient cell lines and 
PTEN knockouts
PTEN has been overwhelmingly linked to the suppression of the PI 3-K pathway 
(Simpson et al 2001). The role of PTEN in controlling cellular processes and 
development is dramatically seen in mice PTEN’1' knockouts that die early in 
embryogenesis (Di Cristofano et al 1998). PTEN*1' heterozygotes are 
susceptible to a broad range of tumours and also develop an autoimmune 
disorder through the Fas-induced death of activated T cells (Di Cristofano et al 
1999). Interestingly, T cell-specific deletion of the PTEN gene results in defects 
in central and peripheral tolerance, implying a central role for this phosphatase 
in T cell homeostasis and self-tolerance (Suzuki et al 2001). Introduction of 
PTEN into PTEN null cells leads to rapid downregulation of PKB activity as 
exhibited by the decreased levels of phospho-PKB. Overexpression of PTEN 
reduces Gi cell cycle progression and inhibition of the PKB signalling pathways 
(Ramaswamy et al 1999) and can inhibit the activation of Rac (Kim et al 2002).
Regulation of PTEN activity
How expression, catalytic activity and localisation of PTEN is regulated is still 
unclear. It can be phosphorylated in vivo by casein kinase 2 (CK2) at its 
carboxyl tail especially, on Ser370 (Vazquez et al 2000). Phosphorylation of 
PTEN has been linked to increased protein stability and may mediate PTEN 
function. Additionally, phosphorylation of PTEN has been reported to induce its 
participation in an undefined protein complex (Vazquez et al 2001). In vitro, 
PTEN has been reported to interact with focal adhesion kinase (FAK) and 
cause its dephosphorylation (Tamura et al 1999). The exact nature of these 
protein interactions is unclear, but is probably mediated via PTENs PDZ 
domain. PTEN expression is also a target for regulation in mammalian cells. 
The early growth response-1 (egr-1) transcription factor has been reported to 
directly activate the PTEN gene and increase its expression during irradiation 
induced signalling (Virolle et al 2001). Accordingly, egr-1'7' mice are not capable 
of upregulating PTEN expression after exposure to ultra-violet light. The
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Peroxisome Proliferator Receptors y (PPARy) and the anti-inflammatory nature 
of PPARy agonists have also been reported to upregulate PTEN protein 
expression (Patel et al 2001). The PPAR family of nuclear hormone receptors 
will be discussed in more detail.
Other D-3 Phosphatases: Myotublarin
Myotublarin is another class of 3-phosphoinositide phosphatase. Studies have 
implicated myotublarin in the regulation of Pl(3)P  lipid levels, which have shown 
to be crucial in intracellular trafficking events (Corvera 2001). Inactivating 
mutations in the genes encoding myotublarin leads to the onset of X-linked 
myotublar myopathy indicating the important regulatory role of this 
phosphatase. Another myotublarin related protein MTMR3 has been identified 
and shown to have novel PI(3,5)P2 substrate specificity in vitro and in vivo, thus 
defining the first route for the cellular production of PI(5)P (Walker et al 2001).
Inositol 5-Phosphatases
There are numerous inositol 5-phosphatases, all of which are magnesium- 
dependent phosphomonoesterases, that can be grouped into 4 broad classes 
depending on their substrate specificity (table 4). There are 4 known substrates 
for 5-phosphatases namely the water-soluble lns(1,4,5)P3 and lns(1,3,4,5)P4 
and the lipids Pl(4,5)P2 and PI(3,4,5)P3. As their name suggests, 5- 
phosphatases selectively catalyse the dephosphorylation from position 5 on the 
inositol ring and members of this family are defined by two signature motifs 
(FI)WXGDXN(F/Y)R and (R/N)XP(S/A)(WT)(C/T)DR(lA/)(L/l) which define the 
proteins as inositol polyphosphate 5’phosphatases (Jefferson et al 1996). The 
following sections will focus on the group III 5’phosphatases that comprise the 
SH2 domain containing Inositol 5’ (poly)-Phosphatase (SHIP) and related 
proteins.
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Table 4: Table to summarise the grouping of inositol 5-(poly)-phosphatases, their substrate 
specificity and function. Type III phosphatases comprise the SHIP proteins that will be 
discussed in more detail in this section.
SHIP proteins: Structure and expression
The diverse role of SHIP in modulating inositol signalling has been the focus of 
much research. SHIP exhibits selective specificity to inositol substrates that are 
phosphorylated on the 3’ position on the inositol ring i.e. PI-3K products (Damen 
et al 1996) and therefore generate the products Pl(3,4)P2 and lns(3,4)P2 
respectively (figure 13). SHIP was initially observed as a 145 kDa protein that 
becomes tyrosine phosphorylated in response to cytokine receptor stimulation
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(Damen et al 1993). SHIPs enzymatic activity does not appear to be dependent 
on tyrosine phosphorylation. Rather, it is believed that SHIP is a constitutively 
active cytosolic protein, and therefore its cellular localisation is critical to its 
mechanism of action towards its substrates (Phee et al 2000). Edmunds et al, 
however, have demonstrated a correlation with tyrosine phosphorylation of 
SHIP following CD28 stimulation and an increase in phosphatase activity 
towards an lns(1,3,4,5)P4 substrate in vitro.
PI3-K
PI(4,5 P I ( 3 , 4 , 5 ) / > 3
PTEN > SHIP
PI(3,4)P2
Figure 13: Metabolism of PI(3,4,5)P3 by the phosphatases PTEN and SHIP. PTEN directly 
antagonises the catalytic activity of PI 3-K whereas the 5-phosphatase SHIP is able to generate 
another D-3 phosphoinositide PI(3,4)P2 potentially initiating PI(3,4)P2 driven signalling 
cascades.
The human SHIP gene has been mapped to chromosome 2 between 2q36 and 
2q37 (Ware et al 1996). SHIP contains 1190 amino acid residues and a 
plethora of motifs that can mediate multiple protein-protein interactions (figure 
14). It contains a conserved N-terminal SH2 domain that is vital for its ability to 
associate with signalling proteins. The central region of SHIP encodes the 5- 
phosphatase domain, whilst the C-terminal contains phosphotyrosine binding 
sites (PTB) and several putative PxxP motifs that may mediate interactions with 
proteins containing SH3 domains. C-terminal truncations of SHIP result in the 
generation of 135 and 125 kDa isoforms of SHIP (Damen et al 1998). 
Interestingly, it has been reported that p135 SHIP can substitute for p145 SHIP 
in inhibitory signalling in B cells (March et al 2000). The C-terminus of SHIP,
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although lacking catalytic activity, is essential for hydrolysis of Pl(3,4,5)P3 and 
the resultant inhibition of PI(3,4,5)P3 (Damen et al 2001) and FcyRIIBI inhibitory 
signalling events in B cells (Aman et al 2000). Membrane targeting of these 
SHIP mutants was able to restore the activity suggesting that the C-terminus is 
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Figure 14: Schematic structure of p145 SHIP showing relevant functional domains and 
approximate scale in amino acids of the mature protein. SHIP contains an N-terminal SH2 
domain which can interact with specific phosphotyrosine residues and a central, conserved 
5’phosphatase catalytic domain. The c-terminal contains several motifs involved with protein- 
protein interactions including proline rich (PxxP) motifs and motif that are involved with PTB 
interactions.
Expression of SHIP is restricted to haemopoietic cells and in cells of the testis 
(Liu et al 1998), although the role of this membrane-localised phosphatase in 
spermatogenesis is unclear. In 1997, a second 5’phosphatase was cloned 
containing homology to the type-ill phosphatase SHIP and was therefore 
termed SHIP 2 (Pesesse et al 1997). In contrast to SHIP, SHIP2 is ubiquitously 
expressed in all tissue types and is co-expressed with SHIP in T and B 
lymphocytes, however the degree of functional overlap between the two 
phosphatases, if any, are poorly defined (Bruyns et al 1999). Its mRNA levels 
being particularly high in heart, skeletal muscle. SHIP 2 has the same substrate 
specificity as SHIP i.e. it only hydrolyses the 5’-phosphate residue on D-3- 
phosphorylated inositides or phosphatidylinositides. SHIP 2 possesses the
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same overall structure as SHIP, with an N-terminal SH2 domain, a central 5’ 
phosphatase domain and proline-rich/PTB motifs at the C-terminus.
SHIP2 exhibits 40% overall sequence homology to SHIP and migrates at 155 
kDa on SDS-PAGE gels. SHIP and SHIP2 however display little homology to 
the 3’-phosphatase PTEN. A novel form of SHIP termed s-SHIP (stem cell 
SHIP) has recently been identified and is expressed in embryonic and 
haemopoietic cells, but not in lineage-committed or mature haemopoietic cells 
(Tu et al 2001). This novel 104 kDa splice variant of mature SHIP lacks an N- 
terminal SH2 domain and does not become tyrosine phosphorylated following 
cellular stimulation (unlike other SHIP isoforms).
SHIP knockout mice
Mice which are SHIP'7' are viable and almost indistinguishable from their 
wildtype littermates. SHIP"7' mice do not appear to have an increased 
susceptibility to cancer, although they do exhibit haemopoietic perturbations 
and a decreased life span (Helgason et al 1998). Macrophages from SHIP'7' 
mice have decreased Fey receptor-mediated phagocytic capability, implying a 
role of SHIP in phagocytosis (Cox et al 2001). The SHIP gene therefore has not 
been designated as a tumour suppressor like PTEN as FTEAT7' mice exhibit a 
far more severe phenotype being embryonic lethal. The presence of other SHIP 
homologues such as SHIP2 may be able to compensate somewhat for loss of 
SHIP, in deficient mice, as SHIP2 is also expressed in haematopoietic cells. 
Lack of SHIP in SHIP'7' mice has been reported to play critical roles in B cell 
development and responsiveness (Helgason et al 2000). B cells derived from 
such mice display enhanced proliferation and therefore suggesting that SHIP 
may play a role as a negative regulator of immune cell signalling. In addition 
neutrophils and mast cells from SHIP'7' mice have been shown to be less 
susceptible to programmed cell death induced by various apoptotic stimuli or by 
growth factor withdrawal (Liu et al 1999). Interestingly, SHIP 2 has been 
proposed to control insulin sensitivity as mice SHIP 2 '7' mice lead to increased 
sensitivity to insulin that results in perinatal death (Clement et al 2001). Adult 
mice heterozygous for SHIP 2 have increase glucose tolerance, characterised
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by increased recruitment of glucose transporters (GLUT 4) and glycogen 
synthesis.
Biological roles of SHIP in cell signalling
The diverse mechanisms of SHIPs biological function in haemopoietic cells are 
beginning to be unravelled. SHIP has been proposed to be a negative regulator 
of the PI 3-K signalling pathway through hydrolysis of PI(3,4,5)P3 (Liu et al
1999). This reduction in PI(3,4,5)P3 correlates with reduced PKB activity and 
cellular survival despite the in vitro data suggesting that PKB can associate with 
the lipid product of SHIP hydrolysis, Pl(3,4,)P2. The mechanism of SHIPs 
negative regulation of PKB activity probably occurs via regulating its membrane 
localisation from the plasma membrane to the cytoplasm (Carver et al 2000 and 
figure 15). Presumably cytosolic PKB is unable to mediate its anti-apoptotic 
signals thus rendering the cell more susceptible to apoptosis.
Figure 15: Model for regulation of PKB activity by SHIP. Cell stimulation can induce PI 3-K to 
elevate Pl(3,4,5)P3 levels and mediate the activation of PKB and its downstream effectors. 
Membrane localisation of SHIP can result in the hydrolysis of PI(3,4,5)P3 to PI(3,4)P2 which 





It is interesting to note that SHIP is a downstream target for a large number of 
cytokine receptor/antigen receptor-activated PTK (Liu et al 1997 and Edmunds 
et al 1999). The kinase(s) responsible for the tyrosine phosphorylation of SHIP 
remain undefined. In T cells, recombinant p56lck has been demonstrated to 
phosphorylate SHIP (Lamkin et al 1997). The tyrosine phosphorylation of SHIP 
has been linked to its cellular redistribution form the cytosol to the plasma 
membrane (Edmunds et al 1999). The adapter proteins She and Grb-2, 
important positive mediators of the Ras/MAPK mitogenic pathways are able to 
bind to SHIP following cellular stimulation (Damen et al 1996 and Harmer et al
1999). She is able to bind to tyrosine phosphorylated SHIP via PTB domain 
interaction with NPXY motifs and also via the SH2 domain of SHIP as 
determined by co-immunoprecipitation studies of wildtype and mutant SHIP 
(Lamkin et al 1997 and Liu et al 1997). The functional consequences of these 
protein interactions are presently unclear. SHIP may employ these adapters to 
serve its membrane localisation and subsequent positioning to its PI(3,4,5)P3 
substrate. Alternatively, SHIP may sequester these adapters and disrupt the 
Sos/Shc/Grb2 protein scaffold, thereby potentially negatively regulating the 
Ras/MAPK pathway (Tridandapani et al 1997 and figure 16). The 
consequences of these protein-protein interactions clearly deserve further 
investigation.
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Figure 16: Potential mechanism for the regulation of MAPK/ERK mitogenic pathways by SHIP 
following cellular stimulation. SHIP can become tyrosine phosphorylated by unidentified tyrosine 
kinases, which interact with proteins with SH2/PTB domains. SHIP is thus able to sequester 
proteins/co-factors (i.e. Shc/Grb-2) involved in activating ras thus leading to down-modulation of 
ras effector pathways.
Another prominent protein that can bind to SHIP following cellular stimulation is 
the protein tyrosine phosphatase SHP-2 (Sattler et al 1997). This interaction 
occurs within the SH-2 domain of SHIP, as assessed by immunoprecipitation 
studies, although these interactions may be mediated indirectly via other 
proteins (Liu et al 1997). Following cellular stimulation and tyrosine 
phosphorylation, SHIP is subject to dephosphorylation possibly by SHP-2. The 
effect of dephosphorylation is to alter SHIPs cellular distribution and down- 
regulate functional activity.
The amino terminal SH2 domain of SHIP binds selectively for immunoreceptor 
tyrosine-based inhibition motifs (ITIM). These motifs are found on various 
inhibitory receptors that following tyrosine phosphorylation recruit proteins, 
including SHIP and the protein tyrosine phosphatase SHP-1, to the receptor,
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thus initiating inhibitory signalling events. Many of the negative signalling 
capabilities of SHIP proteins have been elucidated by the study of the Fey 
receptors in B cells.
Positive signals in B cells are generated when antigen encounters and 
crosslinks B cell receptors (BCR), with resultant activation of PI 3-K and 
generation of PI(3,4,5)P3. The non-receptor Tec-family kinase, Bruton tyrosine 
kinase (Btk), can then interact with PI(3,4,5)P3 via its PH domain, thereby 
tethering it to the membrane and allowing it to activate PLCy2. This lipase can 
then hydrolyse the abundant lipid PI(4,5)P2 to form DAG and IP3 which activate 
PKC and respectively stimulate the release of Ca2+ (figure 17). All these positive 
signals culminate in B cell proliferation and the generation of high affinity 
antibodies beneficial to the host. In contrast, negative signalling in B cells 
occurs when saturated levels of antibody co-ligate the BCR with the FcyRIIB. 
This receptor crosslinking ultimately generates inhibitory signals, which 
abrogates B cell proliferation and differentiation. A key step in this inhibition is 
the recruitment of SHIP, via its SH2 domain, to the ITIM motif in the FcyRIIB, 
placing it in juxtaposition with PI(3,4,5)P3 and converting it to PI(3,4,)P2. This 
eliminates the high affinity binding site for Btk and mediates its return to the 
cytoplasm (Bolland et al 1998 and Scharenberg et al 1998). SHIP is therefore 
able to attenuate Ca2+ signals in B cells leading to reduced B cell proliferation 
and susceptibility to apoptosis (figure 17).
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Figure 17: SHIP attenuation of calcium signalling following BCR/FcyRIIB inhibitory signalling. 
Stimulation of BCR results in recruitment of PI 3-K and formation of PI(3,4,5)P3 which forms 
high affinity binding sites for Btk and PLCy. Subsequent activation of PLCy results in activation 
of the calcium-signalling pathway. Antibody co-ligation with FcyRIIb results in the tyrosine 
phosphorylation of ITIMs within its cytoplasmic tail that can recruit SHIP. The subsequent 5’- 
phosphatase action on PI(3,4,5)P3 disrupts membrane association of BTK thus blocking PLCy- 
mediated Ca2+ flux.
SHIP binding to the phosphorylated HIM in the FcyRIIB receptor has been 
correlated with a decrease in activation of MAPK. A possible mechanism for this 
observation may be explained by the ability of SHIP to interact with the PH 
domain containing adapter protein p62dok. SHIP has been shown to associate 
with tyrosine phosphorylated p62dok via is SH2 domain leading to a decrease 
in Erk activity following FcyRIIB stimulation (Tamir et al 2000). This adapter 
protein has been previously characterised as binding to p120-rasGAP protein, 
which can accelerates the conversion of ras-GTP into inactive ras-GDP and 
thus negatively regulates the MAPK pathway (figure 18). Such a protein 
assembly has been observed in CD 150 signalling a co-receptor expressed in T 
and B cells also known as SLAM and has been linked to the inhibition of 







Figure 18: SHIP regulation of MAPK/Erk signalling via regulation of Ras. SHIP is able to 
associate via its SH2 domain to the adapter protein p62 that complexes with the p120-rasGAP, 
which is able to mediate the conversion of active-GTP-bound ras to inactive-GDP-bound ras 
thus negatively regulating MAPK signalling cascades.
SHIP has been mainly thought of as exerting negative or inhibitory signals. 
However, there are situations where SHIP actually enhances a functional 
response. In a myeloid cell line overexpression of wildtype SHIP significantly 
enhanced cell adhesion to intracellular adhesion molecules 1 (ICAM1), whereas 
expression of a phosphatase ‘dead’ SHIP had no positive effect (Rey-Ladino et 
al 1999). This implies that the increase in Pl(3,4)P2 levels following SHIP- 
mediated hydrolysis of PI(3,4,5)P3 may be of importance in cell adhesion. SHIP 
has been shown to set thresholds for the degranulation of mast cells. 
Degranulation, with subsequent release of inflammatory mediators, can be 
achieved via an IgE-mediated mechanism involving PI 3-K. Interestingly, IgE 
addition to SHIP'7' mast cells, but not in wildtype counterparts, resulted in 
massive degranulation (Huber et al 1998). The c-terminus of SHIP was shown 
to be essential for this effect as assessed by the use of mutant SHIP constructs 
(Damen et al 2001).
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Peroxisome Proliferator-Activated Receptors (PPAR)
The PPARs were identified as nuclear receptors that upon appropriate agonistic 
treatment could increase the size and number of peroxisomes in rodents 
(Issemann et al 1990). The peroxisome is a subcellular organelle with wide 
ranging functions including removal of molecular oxygen and the synthesis of 
glyceroiipids. Initial characterisation of PPARs revealed that the receptor 
functioned in lipid metabolism by regulating genes involved in p-oxidation and 
fatty acid metabolism within the peroxisome organelle thus regulating lipid 
metabolism (Dryer et al 1993). These ligand-dependent nuclear transcription 
factors comprise a family of three subtypes termed PPARa, PPARp/S and 
PPARy, each encoded by three separate genes and displaying a distinct pattern 
of tissue expression and ligand specificity (table 5). The function of the PPARs 
is generally far removed from the biochemistry and proliferation of the 
peroxisome organelle itself.
Upon ligand binding, PPARs undergo a conformational change and form 
heterodimers with 9c/'s-retonoic acid receptors (RXR) and bind to specific 
peroxisome proliferator response elements (PPRE) in their target genes (figure 
19). PPREs consist of a direct repeat of the nuclear receptor hexameric 
AGGTCA recognition sequence separated by one or two nucleotides (Ijenberg 
et al 1997). Structurally PPARs contain a variable N-terminal domain containing 
a DNA binding motif that includes two zinc fingers. The c-terminus contains a 
dimerisation domain and a large hydrophobic pocket that allows ligand binding 
(Nolte et al 1998). Ligand-dependent transcription of the PPARs requires a 
highly conserved motif, termed activating function-2 (AF-2) located at the C- 
terminus of the protein. AF-2 domains are common in ligand-dependent nuclear 
receptors and are required for effective interaction with co-activating proteins 
and therefore regulation of target genes. Although PPAR-p/8 is widely 
expressed it’s ligands and function are ill-defined (table 5). The lack of any 
characterised ligand for the PPARp/8 isoforms place them in the category of an 
orphan receptors. PPAR a/y isoforms have a more restricted tissue expression
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and a more defined function (table 5). The following sections will focus on the 
role of PPARy isoform in inflammatory responses in haemopoietic cells.

























Table 5: Distinguishing characteristics of the isoforms of the PPARs. The ligands and function 
for the PPAR p/5 isoform are poorly characterised. PPARa is expressed predominately in 
muscle, liver and kidney tissues and its natural ligands are Leukotriene B4. PPARy is found 
abundantly expressed in adipose tissue and immune cells and has many potential natural 
agonists, the best characterised being prostaglandin J2.
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Figure 19: Mechanism of action for gene regulation by PPARy. Ligand-activated PPARy is able 
to form a heterodimer with the retonoic acid receptor and bind to specific PPARy response 
elements (PPRE) upstream of target genes and modulate their expression. PPREs consist of a 
direct repeat of the nuclear receptor hexameric AGGTCA recognition sequence separated by 
one or two nucleotides.
Function of PPARy
PPARy is the most intensively studied PPAR isoform and is known to participate 
in an increasingly diverse array of biological responses. PPARy receptors are 
abundantly expressed in adipocytes and expressed at lower levels in 
hepatocytes and haemopoietic cells including T cells (Harris et al 2001). There 
are two distinct isoforms of PPARy termed PPARy-1 and PPARy-2 differing by a 
30 amino acid extension within the N-terminal domain, which differ in their 
tissue distribution (Mukherjee et al 1997). The natural ligand for PPARy is the 
prostaglandin 15-deoxy-A12,14-prostaglandinJ2 (15d-PGJ2), a product of 
arachidonic acid breakdown via a cyclooxgenase (COX) dependent mechanism 
(figure 20). Synthetic tyrosine-based thiazolidinediones (TZDs) compounds are 
selective agonists for PPARy and include troglitazone, pioglitazone and
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ciglitazone, which have made clinical headway’s in the treatment of type II 
diabetes by sensitising tissues to the effects of insulin (Grossman et al 1997). 
However troglitazone has recently been withdrawn for clinical treatment due to 
adverse effects on the liver. Interestingly, these drugs were initially developed 
without knowledge of their molecular target and their mechanism of the action 
remains poorly defined.
PPARy activation promotes cell differentiation in a variety of cell types and has 
been proposed as a master regulator of adipocyte differentiation. PPARy is able 
to upregulate genes essential for adipocyte fatty-acid uptake, glucose transport 
and lipogenesis (Kliewer et al 1995). Indeed retroviral expression of PPARy in 
cultured fibroblasts induced differentiation of these cells into adipocytes upon 
addition of PPARy agonists (Tontonoz et al 1994). More recently activation of 
PPARy has been shown to induce the differentiation of monocytes into 
macrophages and to regulate expression of the scavenger receptor CD36 
(Moore et al 2001). It has been reported that regulation of PPARy in adipocytes 
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Figure 20: Generation of 15d-PGJ2 from arachidonic acid. Cyclooxgenase and molecular 
oxygen forms the cyclic prostaglandin PGG2. Successive peroxidase and dehydration events 
leads to the generation of the PPARy ligand 15d-PGJ2.
Like P P A R a ,  P P A R y  has many reported anti-inflammatory effects. In 
macrophages, P P A R y  has been demonstrated to reduce cytokine production 
( T N F a ,  IL-1 IL-8) via treatment with 15d-PGJ2, used at micromolar levels, at the 
level of gene transcription (Zhang et al 2001). Macrophages treated with various 
P P A R y  agonists cannot be activated by various stimuli including I F N y  as 
assessed a reduction in markers of macrophage activation. T-lymphocytes also
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express the P P A R y  receptor and treatment with 15d-PGJ2 has been proposed 
to induce apoptosis in transformed murine T cells but interestingly not in normal 
human T cells (Harris et al 2002). T-lymphocytes activation can be inhibited by 
pre-treatment with P P A R y  agonists via reduction in IL-2 expression (Yang et al 
2000). The activated P P A R y  receptor was proposed to physically associate with 
NFAT, thus blocking NFAT binding to the IL-2 promoter with a concomitant 
reduction in gene expression. Other mechanisms have been proposed to 
decipher the role of P P A R y  in controlling gene expression. P P A R y  has been 
demonstrated to abrogate binding of the A P -1  complex and NFkB to their 
response elements in target genes (Chung et al 2000). P P A R y  agonists may 
possess an clinical potential in the treatment of T cell-mediated diseases 
including T cell leukaemia. In addition, P P A R y  ligands have also shown promise 
in inhibiting inflammation in epithelial cells (Su et al 1999), and may hold 
promise as a therapy in various inflammatory bowel diseases, including Crohn’s 





















Figure 20: Anti-inflammatory effects of PPARy. Upon ligand binding by 15d-PGJ2 or by TZDs, 
PPARy can regulate expression of chemokines, cytokines and the tumour suppressor PTEN 
thus exerting it’s anti-inflammatory effect. PPARy can also downregulate inducible nitric oxide 
synthase (iNOS) and cyclo-oxygenase-2 (COX-2) both involved in inflammation. PPARy 
therefore is an attractive drug-target in inflammatory disorders.
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PPARy receptors and agonists have also been demonstrated in various studies 
to regulate cell growth and tumour-growth in certain cell types of rodents and to 
lesser extent, in humans. The anti-proliferative effects of PPARy ligands in 
adipocytes had been established for some time before testing on malignant cell 
lines and tumours. Conflicting evidence from mice and humans has confused 
the role of PPARy ligands in controlling cell growth. Initial studies suggested that 
PPARy agonists promote tumorigenesis in mice (Leferbvre et al 1998) whereas 
a study in humans supports a protective role for these drugs in colon cancer 
(Saraff et al 1998). Clearly these discrepancies deserve further investigation. An 
exciting discovery has been the demonstration that PPARy ligands can mediate 
their tumour suppressor and anti-inflammatory actions via the upregulation of 
PTEN (Patel et al 2001). Rosiglitazone-activated-PPARy has been shown to 
bind too PPAR response elements upstream from the PTEN gene and 
upregulate PTEN protein expression to a level sufficient to antagonise the PI 3- 
K pathway, thereby reducing levels of active phosphorylated PKB and inhibiting 
cell growth in macrophages (figure 21). In the same study, SHIP2 phosphatase 
upregulation was found not to occur. The effect on SHIP expression was 
unfortunately not determined. This study also demonstrates that PPARy can 
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Figure 21: Mediation of tumour suppression by upregulation of PTEN  via a PPARy dependent 
mechanism. PPARy is able to bind to two PPRE within the PTEN  gene leading to its 
upregulation and suppression of PI 3-K driven pathways.
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Aims
PI 3-K has been proposed as a pivotal link in T cell activation and it follows, 
therefore, that D-3 phosphoinositides levels must be tightly regulated to ensure 
appropriate physiological responses (Ward et al 1996). The regulation of PI 3-K 
signalling and its major lipid product PI(3,4,5)P3 by the phosphatases SHIP and 
PTEN in response to different stimuli and in different cell types is currently an 
area of great interest. Research in human T cells has utilised a variety of T cell 
lines including the common leukemic cell lines Jurkat, CEM, MOLT-4, HUT 78 
as well as ‘normal’ primary T cells or T-lymphoblasts derived from human 
volunteers. The primary aims of this study were as follows:
1) To investigate expression of the inositol phosphatases SHIP and PTEN in 
the leukemic T cell lines and in T-lymphoblasts. The functional 
consequences of such phosphatase expression were assessed by 
determining the resting/stimulated ratios for cellular D-3 phosphoinositide 
lipid levels and attempt to relate this to activation status of downstream PI 3- 
K effector proteins e.g. PKB.
2) To investigate the regulation of SHIP and PTEN by the receptors CD3 and 
CD28 in T lymphoblasts and surrogate T cell lines. Additionally, to identify 
any potential protein complexes involving SHIP and PTEN that forms 
following CD28 stimulation.
3) To investigate expression of the P P A R y  receptor in a variety of T cell models 
and determine the ability of its ligands to inhibit proliferation under basal 
conditions and following stimulation with a variety of physiological 
(CD3/CD28, IL-2) and non-physiological (PMA/lonomycin) stimuli.
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MATERIALS and METHODS 
Materials
Materials and reagents including antibodies and radiochemicals used in this 
study are listed in appendix 1.
Methods 
Cell Culture
All cells were cultured at 37°C in an humidified incubator in an atmosphere of 
5% C02and 95% air. All cell lines and T-lymphoblasts were passaged every 2-3 
days or when cells reached 1-2x106 cells/ml. Cells were placed in liquid nitrogen 
for long term storage. Cells were pelted for 5 minutes at 400g and resuspended 
at 107 cells/ml in 20% FCS and 10% dimehtyl sulfoxide (DMSO). Cells were 
placed in cryovials and placed in an appropriate cooler overnight in an -80°C 
freezer before being placed in liquid nitrogen cylinders. Cells were recovered 
from liquid nitrogen by thawing rapidly in a 37°C water bath and washing three 
times in pre-warmed RPMI-1640 and cultured as appropriate.
Murine Hybridoma DC.27 T-cells
Murine hybridomas stably transfected with human CD28 (WT) or human CD28 
mutant containing point mutations at tyrosine amino acid residues 173 and 200 
in human CD28 (173/200) were a kind gift from Dr. D. Olive (INSERM, 
Marseilles, France). Murine hybridoma cells were grown in DMEM with 10% v/v 
FCS, 50 U/ml Penicillin, 50 pg/ml Streptomycin and 50 juM of p- 
Mercaptoethanol in 175cm3 tissue culture flasks. The cells grew in a semi­
adherent manner, and were passaged by mild agitation of the flask to dislodge 
adherent cells. Cells were spilt 1:4 and fed with fresh media every 3 days.
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Leukemic cell lines
Jurkat, CEM, MOLT-4 and HUT 78 leukemic cells (D. Cantrell, ICRF, UK) were 
grown in suspension in RPMI-1640 supplemented with 10% v/v FCS, 50 U/ml 
Penicillin and 50 ng/ml Streptomycin in 175cm3 tissue culture flasks. Cells were 
passaged every 2-3 days or when cells reached sufficient density they were 
split 1:4 into the original volume of pre-warmed media. Jurkat, CEM and MOLT- 
4 are all examples of established human leukemic T cell lines derived from the 
peripheral blood from Caucasian patients with an lymphoblast morphology. The 
T lymphoblast-like cell line Jurkat, has been invaluable tool to monitor T cell 
signal transduction (Weiss et al 1984). Studies using the Jurkat cell line led to 
the identification of the T cell growth factor IL-2 and its receptor (IL-2R). These 
discoveries through Jurkat cells provided the catalyst for T cell biology and the 
characterisation of signalling pathways through antigen receptors. The leukemic 
cell line CEM is a T lymphoblastoid cell line originally obtained from a 4-year-old 
Caucasian female with acute lymphoblastic leukaemia (Foley et al 1965). The 
MOLT-4 cell line was established from cells taken from a patient in relapse and 
also displays T-lymphoblast morphology (Minowada et al 1975). HUT 78 cells, 
derived from the peripheral blood from a patient with serazy syndrome, display 
properties like a mature helper T cell (Gootenberg et al 1981).
Chinese Hamster Ovary (CHO) Cells
CHO cells transfected with CD80 (CHO-B7.1+) and CD86 (CHO-B7.2+) and 
untransfected parental CHO cells (D. Sansom, Birmingham, UK) were grown in 
DMEM (without L-glutamine) with 10% v/v FCS, 50 U/ml Penicillin, 50 pg/ml 
Streptomycin and 20 juM of the nucleosides adenosine, cytidine, uridine, 
thymidine and guanosine. CHO cells grew in an adherent fashion and were 
passaged by trypsinisation. When the culture flask was confluent, media was 
removed and the cells were washed twice in calcium-free PBS (PBS-A) and 
overlayed with trypsin (0.5%)/EDTA was added to the flask. Cells were 
incubated briefly at 37°C and cells were dislodged from the flask by mild 
agitation. Trypsinisation was terminated by the addition 20 ml of fresh culture
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medium. Cells were pelleted at 400g for 5 minutes and passaged 1:5 into the 
original volume of pre-warmed media.
Peripheral Mononuclear Cell (PBMC) Preparation
Peripheral venous blood from healthy donors, free from medication was 
collected aseptically in 50 ml sterile syringes pre-loaded with heparin at 10 U/ml 
to prevent blood clotting using an 19-gauge needle. The blood was diluted 1:1 
with pre-warmed serum-free RPMI-1640 culture medium, mixed and carefully 
layered in 35 ml aliquots onto 15ml of Lymphoprep™ in 50 ml disposable 
polypropylene conical centrifuge tubes. Following centrifugation at 400g for 30 
minutes at room temperature the peripheral cell mononuclear layer was 
removed and washed three times in 50 ml volumes of RPMI at 400g for 10 
minutes and a cell count was performed using a haemacytometer.
T Lymphoblast Preparation
The PBMC isolate previously described was resuspended at 1x106/ml in RPMI- 
1640 containing 10% v/v FCS, 50 U/ml Penicillin and 50 ng/ml streptomycin. T 
lymphoblasts were prepared from the PBMC isolate by incubating PBMC with 1 
pg/ml of the super-antigen Staphylococcal Entertoxin B (SEB) for 72 hours 
(figure 22). After 72 hours, non-adherent cells were washed three times in 
RPMI-1640 to remove residual SEB and resuspended at 1x106 cells /ml in 
complete RPMI media and supplemented with human recombinant IL-2 at 20 
ng/ml every 48 hours for up to 10 days. T lymphoblasts were used for 
experimentation from day 8-14. Two days prior to experimentation the cells 
were washed 3 times in RPMI-1640 and resuspended in supplemented medium 
without IL-2 thus allowing the T lymphoblasts to accumulate in the Go-Gi phase 
of the cell cycle (Sotsios and Ward 2001).
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Figure 22: Isolation of PBMC and preparation of T-lymphoblasts. SEB-activated T-blasts were 
typically cultured for 10-12 days with IL-2 (20ng/ml). Twenty four hours prior to experimentation, 
cells were washed with serum-free media to accumulate cells in Go-Gt phase of cell cycle. 
Relevant receptor expression (e.g.CD28/CD3) was determined by flow cytometry.
Purification of T Lymphocytes by Negative Selection
Resting T lymphocytes were purified by the immuno-magnetic depletion of B 
cells, monocytes, dendritic cells, basophills, NK cells and platelets. The PBMC 
isolate was washed three times to remove residual lymphoprep™ at 350g for 10 
minutes and resuspended in 80 pi of PBS-A with 2mM EDTA and 1% w/v BSA 
for every 1x107 cells. 20 pi of a hapten-antibody cocktail containing anti-CD 11b, 
CD16, CD19, CD36 and CD56 antibodies, were added per 107 cells, mixed and 
incubated on ice for 15 minutes with occasional agitation. Cells were washed 
twice to remove excess antibody in PBS-A. Cells were then resuspended in 80 
pi of PBS-A/2mM EDTA/1% w/v BSA per 107 cells and 20 pi of anti-hapten 
microbeads was added per 107 cells, mixed and incubated on ice for 15 minutes 
with occasional agitation. Cells were washed to remove excess beads and
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resuspended in 500 pi of PBS-A/2mM EDTA/1% w/v BSA ready for loading onto 
a MACS CS column previously placed into a magnetic field of a MACS magnet 
separator. The PBMCs were added to the top of the PBS-A equilibrated column 
and unstained pure T cells were collected at the bottom into a sterilin tube. The 
column was washed several times with PBS-A and collected as described to 
achieve a greater yield of T cells. The collected T cell fraction was counted and 
viability was assessed by trypan blue exclusion. Purity of the T cell fraction was 
assessed by flow cytometry (figure 23).
FACS Analysis of cell surface antigens
5x104 cells were aliquoted into polypropylene FACS tubes and pelleted 400g for 
5 minutes. Cells were washed twice in PBS-A and resuspended in 50 pi of the 
appropriate primary staining (e.g. anti-CD28/CD3-Appendix 1) used at 10 pg/ml 
with 25 pi of FCS used to block non-specific binding of antibodies. Cells were 
shaken and incubated for 30 min at 4°C with occasional agitation by hand. 
Following incubation, cells were washed twice in ice cold PBS-A via 
centrifugation (400g for 5 minutes) and resuspended in 50 pi of diluted goat 
anti-mouse-FITC or anti-rabbit-FITC where appropriate, along with 25 pi of FCS 
as before. Cells were once again mixed by hand and incubated for 30 minutes 
at 4°C as previously described. Samples were washed as previously described 
in PBS-A and analysed immediately or stored in 250 pi of 2% paraformaldehyde 
overnight at 4°C. FACS analysis done using Becton Dickinson FACS Vantage 
with a 200nW 488nm argon laser with light being channelled by an FL-1 filter 
(520nm). Expression of cell surface receptors was confirmed by comparison 
with relevant isotype control (figure 23).








Figure 23: Confirmation of T cell purity by FACS. Freshly isolated primary T cells were 
incubated with anti-lgG2a isotype control and anti-CD3 mAb (UCHT-1) for desired times before 
staining with anti-mouse-FITC-conjugated secondary Ab. FACS analysis was achieved by 
Becton Dickinson FACS vantage using a 200nW 488nm argon laser with light being channelled 
by an FL-1 filter (520nm). T cell purification yields from peripheral blood were typically >95%.
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Preparation of Cells for Cell Signalling Experiments
Prior to signalling experiments, cells were harvested from tissue culture flasks 
and were pelleted by centrifugation (400g, 5min 20°C) and washed three times 
in serum-free RPMI-1640 to remove serum and growth factors. Where 
CHO/CHO-B7.1 cells were being used to stimulate T cells lines, cells were 
removed by trypsinisation as previously described. Cell viability was assessed 
by trypan blue exclusion and cell counts were performed using a 
haemacytometer. Cells were resuspended at 106-107 cells/ml in HEPES 
buffered serum-free RPMI-1640 in 0.5 ml volumes into eppendorf tubes. Cells 
were equilibrated in a 37°C waterbath for 30 minutes before experimentation.
Cell Stimulations
If inhibitors were being, these were diluted as appropriate and added to the 
desired cell aliquot for a minimum of 30 minutes prior to cell stimulation or 
according to manufacturer guidelines. T cell antibody stimulations e.g. anti- 
CD28/CD2/CD3 etc (Appendix 1) were achieved by using the appropriate 
antibody at a concentration of 5 jug/ml, which was placed into the lid of the 
eppendorf. This concentration of stimulating antibody was shown in previous 
studies to saturate all surface receptors i.e. antibody is in excess (Ward et al 
1992). Cells and antibodies were mixed by rapid inversion of the tube and 
incubated at 37°C for desired times. T-lymphoblasts were stimulated by the 
cytokine IL-2 at a concentration of 20 ng/ml. Again the cytokine (10 pi) was 
added to the lid of the tube and mixing was achieved by rapid inversion. T cells 
which were stimulated with CHO cells and cell CHO transfectants expressing 
B7.1/B7.2 were resuspended in HEPES buffered RPMI and added to the T cells 
to achieve a T cell: CHO cell ratio of 3:1 as performed in previous studies (Ward 
et al 1992). T cells were stimulated via co-sedimenting with CHO cells, 
achieved by mixing by microfuge and then pulsed in a microcentrifuge and 
incubated for desired times in a 37°C waterbath as previously described. Co­
sedimentation would result in cell-cell contact between CD28-bearing T cells 
and B7-bearing CHO cells.
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Cell Lysis and Preparation of Whole Cell Extracts
59
Cell stimulations were terminated in the following manner: rapid pulsing of cells 
in a microcentrifuge, removal of supernatant by aspiration and lysing In 500 p,l 
of ice-cold lysis buffer (appendix 2). Samples were incubated on ice for 15 
minutes to ensure full lysis and nuclear debris was sedimented by centrifugation 
at 13000g for 15 minutes at 4°C. Supernatants containing cellular proteins were 
transferred to a fresh eppendorf tube and used immediately or stored at -20°C. 
Samples were kept on ice as often as possible to avoid protein degradation.
Acetone Precipitation of Proteins
Total protein was precipitated by the addition of 0.7 ml of ice cold acetone to the 
whole cell lysate (500 pi). Samples were rotated for 15 minutes at 4°C and 
subjected to centrifugation at 13000g, 4°C for 15 minutes. The supernatant was 
removed by aspiration and protein pellets were dried in vacuo. The protein 
pellet was boiled in SDS-Lammeli (reducing) sample buffer and were subjected 
to SDS-PAGE or stored at -20°C.
Immunoprecipitation of cell extracts
Whole cell extracts were first pre-cleared to eliminate the possibility of non­
specific binding to the sepharose beads. Samples were pre-cleared by the 
addition of 20 pi of 50% slurry of Protein- A or-G and rotated for 30 minutes at 
4°C. Protein-A/G was removed by centrifugation and the supernatant was 
added to a fresh tube along with the appropriate immunoprecipitating antibody 
at a concentration recommended by manufacturers guidelines (typically 
betwwen 1-5 pg/ml). Samples were rotated for 2 hours at 4°C. Immune 
complexes were tagged by the addition of 20 pi of Protein-A or-G and were 
rotated for another hour at 4°C. Sepharose beads containing the immune 
complex were sedimented by centrifugation with supernatant being removed by
Materials and Methods 60
aspiration. Beads were washed 5 times in lysis buffer as previously described. 
At the final wash, excess lysis buffer was removed via flat-end Hamilton syringe 
and the immunoprecipitate/beads were boiled in 30 jul of SDS- Lammeli 
(reducing) sample buffer.
SDS-PAGE
Whole cell extracts, acetone precipitates and immunoprecipitates were 
separated using the BioRad Mini protean II equipment. Acrylamide gels (7.5- 
12%) were prepared as described in the table below. Polymerisation of the gels 
was achieved via the addition of appropriate volumes of APS and TEMED. After 
sample loading gels were electerophoresed at 60 V in running buffer (appendix
2) for 20 minutes until the samples were through the stacking gel whereupon 
voltage was increased to 160V for 1 hour. Alternatively proteins could be 
separated using 7-17% large gradient gels using vertical slab units SE400 
(Hoefer Scientific Instruments, San Francisco) which were run overnight at a 
constant voltage of 60V. Gel constituents are described in table 6:
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Mini Gels Gradient gels
% GEL 7% 17.5% 7% 10% STACK
Acrylamide (ml) 3.5 8.5 3.75 5 1.6
H20  (ml) 5.8 - 5.6 4.35 7.3
1M Tris pH 8.8 (ml) 5.6 5.6 5.6 5.6 -
10% SDS (ml) 0.25 0.25 0.25 0.25 -
Upper Buffer (ml) - - - - 3.5
Sucrose (g) - 1.5 - - -
10% APS (pi) 50 50 50 50 65
Temed (pi) 20 20 20 20 12
Final Volume (ml) 30 30 15 15 10
Table 6: Recipes for different percentage acrylamide gels commonly used for SDS-PAGE.
Gel transfer
Proteins were transferred onto nitrocelluose using a semi-dry transfer graphite 
electrode (Pharmacia, Biotech, Uppsal, Sweden). 3 mm paper and nitrocelluose 
was cut to the size of the gel and a gel transfer sandwich was prepared. This 
consisted of four pieces of 3 mm paper, pre wetted in semi-dry transfer buffer 
(appendix 2) which was then added to the anode electrode followed by the 
nitrocellulose acrylamide gel and finally another four pieces of 3mm paper. Air 
bubbles were removed by frequent rolling of the sandwich. The cathode 
electrode was applied and proteins were transferred for 1 hour at 1 mA per cm2.
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Immunoblotting
Following gel transfer the efficiency of transfer was visualised by the addition of 
ponceau-S stain which was subsequently removed by washing in dhfeO. 
Nitrocelluose membranes were then blocked in either 5% Marvel in TBS or by 
5% BSA 1% Ovalbumin in TBS, depending on the preference of the primary 
antibody (see Appendix 1 for blocking conditions for appropriate antibody), for 
at least 1 hour. Blocked membranes were then washed three times in TBS and 
0.05% (v/v) Tween-20 (TBS-T). Primary antibodies were diluted to the 
appropriate concentration (Appendix 1) in TBS and the appropriate blocking 
solution was added to a final concentration of 1% in accordance with 
manufacturer’s guidelines. Primary antibodies were applied for a minimum of 
three hours at room temperature or overnight at 4°C with shaking. The primary 
antibody was removed and the membrane washed three times for 10 minutes 
with TBS-T. A secondary antibody, consisting of horseradish-peroxidase 
conjugated immunoglobulins specific to the species the primary antibody was 
raised in was added to the membranes. Secondary antibodies were diluted to 
1:1000- 1:10000 in TBS-T and were incubated with the membrane for 1 hour at 
room temperature with shaking. Excess, unbound secondary antibody was 
removed as previously described. Antibody-bound proteins were detected using 
chemi-illuminescence reagent (ECL) and subjected to autoradiography. Where 
appropriate protein bands from western blots were quantified by densitometry 
using ‘gene snap’ software.
Stripping and reprobing of Gels
Determination of equal loading and transfer of blots were achieved by the 
following method: blots were washed with dH20  and submerged in stripping 
buffer (appendix 2) and then incubated in a waterbath for one hour at 60°C with 
occasional agitation by hand. Following stripping the blots were washed with 
copious amounts of TBS-T before blocking and reprobing with a different 
primary antibody as previously described.
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In Vitro Protein Kinase Assays
Immunoprecipitates were prepared as described previously. Sepharose- bound 
immune complexes were washed, as described, three times in ice-cold lysis 
buffer and twice in protein kinase assay buffer (appendix 2). At the final wash 
the immunoprecipitates were transferred to 1.5 ml screwlid Starstedt tubes. In 
vitro kinase activity was assayed utilising a method described by Ward et al 
1992. Briefly, in vitro kinase activity of the immunoprecipitates was initiated by 
addition of 20 pi of kinase assay buffer containing 10 pM (cold) ATP and 10 pCi 
of [ y - 32P ] - A T P .  Samples were mixed and incubated at room temperature (25°C) 
for 20 minutes. Reactions were terminated by the addition of 1 ml of lysis buffer 
containing 30 mM E D T A .  The immunoprecipitates were then washed a 
minimum of 8 times to remove excess isotope and drained and boiled in SDS- 
sample buffer (reducing) for 10 minutes. Proteins were electerophoresed 
overnight at 60 mA on a large gradient gel (7%-17%). Gels were then fixed in 
propan-2-ol: H20: acetic acid (50:130:20) for 1 hour, rinsed in dh^O and dried 
for 2 hours at 60°C. Fixed gels containing the radiolabelled proteins were 
exposed to Xomat film overnight at -70°C, with screen and visualised by 
autoradiography.
In Vivo 32-P Lipid Labelling
In vivo analysis of intact cellular D-3 phosphoinositide levels were assayed 
using a protocol developed by Morgan et al. Cells to be 32P metabolically 
labelled were harvested from culture flasks and depleted of endogenous 
phosphate by washing in 50 ml volumes of phosphate-free DMEM. Cells were 
washed three times (350g, 5 min, 25°C) and in between washes cells were 
incubated in a 37°C for 10 minutes to ensure efficient phosphate depletion. 
Cells were counted and resuspended at 20 x 106 cells/ml in 10 ml of phosphate 
free DMEM supplemented with saline-dialysed FCS (phosphate-free FCS) and 
20 mM HEPES in a small tissue culture flask. 1mCi of 32P orthophosphoric acid
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was added to the cells, gently mixed and incubated in a 37°C water bath for 4 
hours.
Following incubation with radioactive label, unincorporated label was removed 
by washing three times in phosphate free DMEM as described. Cells were 
resuspended in RPMI-1640 at 20 x106 cells/120 pi. Inhibitors to be studied were 
added to the required aliquot and incubated at 37°C in accordance with the 
manufacturers guidelines. Cells were then stimulated as previously described 
and incubated for desired times at 37°C typically between 1-10minutes. 
Reactions were terminated by the addition of 0.7 ml of ice-cold chloroform: 
methanol: H20 (32.6%: 65.3%: 2.1% v/v/v), mixed and added to ice, producing a 
homogenous primary extraction phase. To separate phases 200 pi of Folsh 
lipids (1 mg of Folsh Lipid in 100 ml of chloroform) and 200 pi of 5 mM 
Tetrabutyl ammoniumsulphate in 2.4 M HCI was added. Samples were mixed 
by vortexing and centrifuged at 1000g for 5 minutes to separate phases. The 
lower organic chloroform layer was removed to a fresh 1.5 ml screwlid starstedt 
tube containing 5 mM EDTA /1  M HCI. Samples were vortexed and centrifuged 
as before. The lower organic phase was removed to a fresh tube and dried in 
vacuo. Once dried, the extracted lipids were deacylated by the addition of 1 ml 
of 25% methylamine/methanol/N-butanol (4:4:1 v/v/v) per tube. Samples were 
vortexed vigorously and placed in a 53°C water bath for 40 minutes. 
Deacylation was terminated by rapid cooling on ice for 5 minutes before being 
dried in vacuo overnight.
Dried lipids were washed by resuspending in 0.5 ml of dH20  and 0.6 ml of 
Butan-1-ol/petroleum ether (bp 40-60 °C)/ ethyl formate (20:4:1, v/v). Samples 
were mixed by vortexing and centrifuged as before to separate phases. The 
upper phase was discarded and the lower water- soluble phase dried in vacuo. 
Dried, labelled inositides were resuspended in 100 pi of dH20 and analysed by 
HPLC using a 12.5 cm Whatman Patrisphere column.
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Labelled lipids were applied to the column at a flow rate of 1 ml/min and were
eluted from the column using a gradient based on the buffers A (dH20) and
Buffer B (1.25 M Ammonium phosphate (NH^HPC^ pH 3.8) over a sample run
of 90 minutes. The mixing of buffer B (which elutes deacylated P32-labelled
lipids) during sample runs were as follows: Omin, 0% B; 5min, 0% B; 45 min,
12%B; 60 min, 30% B; 61 min, 100% B; 65 min, 100% B; 66min 0% B; 90 min,
o% A and B. Eluates were mixed with three volumes of Flo-Scint IV scintillant
before being quantified by beta radio detector (Canberra Packard). Relevant
peaks were measured and recorded via Flo-One software. Identities of peaks
were compared with elution times for characterised D-3 phosphoinositides as
described by Ward et al (1993 and figure 24). Retention times varied due to
slight changes in room temperature and the age of the column.
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Figure 24: Flow chart to summarise the in vivo 32'P lipid labelling protocol. Inset,typical HPLC 
trace of a sample is showing comparative elution times of PI(3,4)P2, Pl(4,5)P2 and PI(3,4,5)P3.
In Vitro Phosphatase Assay
This phosphatase assay is based on the assay described by Damen (Damen et 
al 1996). Briefly, cells were prepared, stimulated, lysed and pre-cleared as 
previously described. Where appropriate, anti-SHIP and anti-PTEN 
immunoprecipitates were prepared from whole cell lysates. The phosphatase 
activity from these immunoprecipitates were determined by the in vitro 
hydrolysis of the substrate [3H]-lns (1,3,4,5) P4 (IP4). Immunoprecipitates were 
washed three times in lysis buffer and twice in phosphatase buffer (appendix 2). 
Drained immunoprecipitates were re-suspended in 25 pi of assay buffer and 16 
pM of [3H] IP4 (3pl) was added mixed and incubated at 25°C for 20 minutes. 
The assay was terminated by the addition of an acidified: chloroform: methanol 
solution (ratios), mixed by vortex and centrifuged at 1000g for 5 minutes. The
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lower aqueous phase was removed into a fresh tube and dried in vacuo. Dried 
inositides were re-suspended in 100 pi of dH20 and analysed by anion- 
exchange HPLC using a Patrisphere SAX column (Whatman) using the method 
described earlier. 1 ml fractions were collected into scintillation tubes and 3 ml 
of Flo Scint IV was added to each collected fraction. The levels of tritiated 
fractions were quantified using a 1209 Rack-Beta liquid scintillation counter. 
Elution times were compared against an untreated IP4 control where 3 pi of IP4 
was added to 97 pi of dH20 and run though the HPLC column.
Proliferation Assays
T cells (Resting T cells, T-Blasts or T leukemic cell lines) were re-suspended in 
RPMI-1640 supplemented with 10% FCS at a concentration of 1 x106 cells/ml. 
Cells were plated at 1 x105 cells/well in a sterile 96-well tissue culture plate. 
Treatments were performed in quintuplicate with inhibitors being incubated with 
the cells for the required length of time as appropriate. Cells were co-stimulated 
with antibody covalently coupled M-450 Dynabeads (Appendix 1) were done so 
at 3 bead: 1 cell ratio as described (Sotsios and Ward 2001). All wells were 
made up to a final volume of 200 pi with complete RPMI. Plates were incubated 
in a humidified cell incubator at 37°C for 48 hours and then pulsed with 1 pCi 
[3H]-thymidine (diluted in complete RPMI) per well for a further 14 hours. After 
the 72-hour incubation plates were harvested using an automated cell harvester 
into 96-well filter plates (Unifilter™) and washed three times to remove 
unincorporated [3H]-thymidine. 20 pi of Flo Scint IV was added to each well on 
the dried plate, sealed and [3H]-thymidine incorporation was subsequently 
measured with a p-scintillation counter (TopCount™). Mean data was plotted for 
each point and subjected to students’ T test to test for statistical significance.
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mRNA extraction and RT-PCR
RT-PCR was used to determine the expression of SHIP and PTEN mRNA. 
Total RNA was prepared by cells harvesting from tissue culture flasks and 
washing them once in serum-free RPMI and re-suspending at 5 x106 cells/ml in 
PBS. 1 ml of RNAzol™ was added to samples as well as 100 pi of chloroform. 
The sample was shaken vigorously and left on ice for 15 minutes and 
centrifuged at 13000g for 15 minutes at 4°C. The upper layer was transferred to 
a fresh tube containing 500 pi of isopropanol, which was mixed by vortexing and 
left on ice for a further 15 minutes. Samples were centrifuged as before and the 
supernatant removed. The RNA pellet was washed with ice-cold 75% ethanol 
and spun at 7500g for 8 minutes at 4°C. The supernatant was removed and air- 
dried before being re-dissolved in sterile distilled H20 and total RNA was 
quantified using a Gene Quant II RNA/DNA calculator (Pharmacia Biotech, 
Uppsal, Sweden).
Reverse Transcription
Reverse transcription took place in thin-walled PCR tubes. 1 pg of sample 
mRNA was added to PCR tube and diluted with 7.5 pi of dH20 along with 0.5 pg 
of oligo d’T. Secondary mRNA structures was denatured by heating to 65°C for 
5 minutes and storing at 4°C. Following denaturation, a reverse transcription 
mix was added to the appropriate mRNA consisting of 5x RT-Buffer (Promega), 
0.5 mM deoxynucleoside triphosphates, 1 U/pl RNasin and 10U/pl of Moloney- 
Murine Leukaemia Virus Reverse Transcriptase (MMLV-RT) to a final volume of 
25 pi. Samples were place in a PTC-100™ thermocycler and run at 42°C or 60 
minutes followed by 95°C for 5 minutes and then stored at 4°C.
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Polymerase Chain Reaction
Forward and reverse primers corresponding to coding sequences in the SHIP 
and PTEN genes were designed (appendix 3). PCR reactions were carried out 
in thin walled PCR tubes as in the RT reaction. 2 pi of cDNA was added to the 
tube and a PCR mix was added which included 25 pmol of forward (S’) and 
reverse (3’) primers, 10 X PCR buffer (Promega), 200 pM of dNTPs, 1U of Taq 
(Bioline) and diluted in dH20 to a volume of 25 pi. The expected size of the PCR 
products utilising SHIP and PTEN primers was 1 kb. Sample controls with no 
cDNA were included in the assays and run against all samples and also against 
the housekeeping gene (3-actin as a negative control. Samples were placed in 
the thermocycler and run at the following program: 1) 94°C, 90 seconds; 2) 
94°C, 30 seconds; 3) 58°C 30 seconds; 72 °C 40 seconds with steps 2 and 3 
repeated for 35 cycles; 72°C for 5 minutes and cooling to 4°C to finish. 5 pi of 
‘blue juice’ (Sigma) was added to each sample to aid loading prior to agarose 
gel electrophoresis.
Detection of PCR Products
A 1% agarose gel was made in 1X TBE (appendix 2) mixed with 1 pg/ml 
ethidium bromide, boiled and cast. 5 pi of samples (positive and negative) were 
loaded onto the gels and run against a 100 base pair ladder (Promega). 
Samples were electerophoresed at 100V/0.1 mA and resultant products were 




Expression of SHIP and PTEN mRNA in T Cell Leukemic Lines and T 
Lymphoblasts
SHIP was originally identified as a 145 kDa tyrosine phosphorylated protein 
associated with the adapter she after stimulation of blood cells by a variety of 
cytokines and growth factors. SHIP was subsequently cloned and found to be 
an inositol 5-phosphatase (Damen et al 1996). Further work has shown that 
expression of SHIP is restricted to cells of the haematopoietic system (Liu et al 
1997). In contrast the inositol phosphatase PTEN, has been shown to have a 
much wider expression, but is known to be mutated or deleted in a number of 
human cancers (Cantley and Neel 1999) and has therefore been designated as 
a tumour suppressor. Little is known about the expression of the phosphatases 
SHIP and PTEN in the leukemic cell lines CEM, MOLT-4 and HUT 78. These 
cell lines are often used as models to investigate T cell signal transduction so it 
was important to characterise the expression of SHIP and PTEN at the level of 
mRNA. Expression studies were achieved via RT-PCR of all leukemic cell lines 
and T-lymphoblasts (figure 25).
Analysis of RT-PCR reactions shows that SHIP mRNA is expressed in T- 
lymphoblasts and the leukemic lines Jurkat, CEM, MOLT-4 and HUT 78. A 
similar pattern was observed in that regards to expression of PTEN, all 
leukemic cell lines and T-lymphoblasts were positive for the expression of 
PTEN mRNA (figure 25).
Expression of SHIP and PTEN Proteins in Leukemic T Cell Lines and T- 
Lymphoblasts
Whole cell lysates (107 cells) were prepared from all leukemic cell lines and T- 
lymphoblasts and im mu no-blotted with anti-SHIP and anti-PTEN monoclonal 
Abs (figure 26). It was noted that Jurkat cells contained no detectable protein for 
both SHIP and PTEN although mRNA for both proteins can readily be detected 
(figures 25). The other leukemic cell lines had a different expression pattern.
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MOLT-4 and CEM cells contained protein for SHIP but contained no detectable 
levels of PTEN. Like Jurkat cells, both MOLT-4 and CEM cells contained mRNA 
for both SHIP and PTEN. T-lymphoblasts and the HUT-78 leukemic cell line 
were both positive for the expression of SHIP and PTEN at the level of protein 
and mRNA.
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Figure 25: Expression of PTEN mRNA in leukemic cell lines and T-lymphoblasts (A and B 
denoting different blood donors). mRNA from 5x106 cells was extracted and cDNA was 
prepared via a reverse transcriptsase reaction. Primers designed to SHIP and PTEN mRNA 
(appendix 3) was annealed with cDNA from T cell lines and analysed for expression of SHIP 
and PTEN via PCR as described in Materials and Methods. PCR products were resolved on a 
1% agarose gel and visualised by UV transillumination. Data is from a single experiment 
representative of three others.
Results 74









Figure 26: Expression of SHIP and PTEN in T cell lymphoblasts and leukemic cells. 107 cells 
were lysed, proteins were concentrated by acetone precipitation and samples boiled in lamelli 
sample buffer. Samples were subjected to SDS-PAGE, transferred onto nitrocellulose and 
immuno-blotted with anti-SHIP mAb and anti-PTEN mAb as described in Materials and  






Characterisation of cell surface markers on leukemic cell lines and T- 
lymphoblasts and CH0/CH0-B7.1+ cells.
The surface expression of relevant receptors was routinely monitored by flow 
cytometry. Expression of these cell markers verified their use in particular cell 
assays. CHO cells stably transfected with B7.1 (CHO-B7.1+), the natural ligand 
for CD28, were a useful functional tool to monitor CD28-mediated signalling 
events. CHO-B7.1+ offer a more physiological stimulus than anti-CD28 Abs and 
have been shown to be able to stimulate 3H-thymidine incorporation and 
PI(3,4,5)P3 accumulation in T cells (Ward et al 1995). CHO-B7.1+ were shown 
to constantly express B7.1 to a high level (-90%). Parental CHO cells were 
found to not express the B7.1 and were thus suitable for uses as negative 
controls (figure 27).
The T leukemic cell lines Jurkat, CEM, MOLT-4 and HUT 78 were also routinely 
monitored for expression of the cell surface receptors CD28 and CD3 binding 
compared to that of isotype-matched control antibodies. Jurkat cells expressed 
high levels of both CD28 (90%) and CD3 (55%) on the cell surface (figure 28). 
Other T cell leukemic cell lines exhibited lower levels of these T cell surface 
antigens. In particular MOLT-4 cells expressed reasonable levels of CD28 
(35%) but low levels of CD3 (<10%). CEM cells were also positive for CD28 
(50%) with lower levels of CD3 (18%). In contrast HUT-78 were routinely shown 
to have very low levels of both CD28 (<5%) and CD3 (<10%) expression. T- 
lymphoblasts from healthy human volunteers represent an alternative, more 
physiological cell model to study CD28 signal transduction. Each batch of SEB- 
activated T-lymphoblasts was monitored for the expression of CD3, CD28 and 
the IL-2 receptors before experimental use. Expression levels of CD28, CD3 
and IL-2R varied between individuals but were generally over 50% compared to 
isotype-matched control and thus suitable for signalling-based experiments. 
Typical expression levels of all cell surface markers in Leukemic cells and T- 
lymphoblasts are summarised (table 7 and figure 28/29).
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Jurkat CEM HUT 78 MOLT-4 T-Blast
CD28 90% 50% <5% 35% 50%
CD3 55% <20% 10% <10% 60%
IL-2 ND ND ND ND 65%
Table 7: Typical percentage expression of T cell surface markers against isotype controls. Nd = 
not determined.







Figure 27: Expression of B7.1 on Parental CHO and CHO-B7.1+ cells. 1x105 cells were 
analysed for B7.1 using a directly conjugated mAb towards B7.1, BB-1 (yellow bar on parental 
CHO/Green bar on CHO-B7.1+) and an isotype matched control (black line). Cells were 
analysed for expression using a Becton Dickinson FACS vantage as described in Materials and  
Methods. Results are from a single experiment representative of at least 3 others.
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Figure 28: Expression of CD28/CD3 receptors in leukemic T cell lines. 1x105 T cells were 
analysed for antigens using anti-CD28 and anti-CD3 mAbs against an isotype- matched control 
(black). Cells were stained with an FITC-conjugated goat anti-mouse secondary Ab and 
analysed on a Becton Dickinson FACS vantage as described in Materials and Methods. Results 
are from a single experiment representative of at least 3 others.
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Figure 29: Cell surface expression of CD28, CD3 and IL-2 receptor in SEB activated T- 
lymphoblasts. 1x105 T-lymphoblasts were analysed for antigens using anti-CD28, anti-CD3 and 
IL-2R (all green) mAbs against isotype matched controls (black). Cells were stained with an 
FITC-conjugated goat anti-mouse secondary Ab and analysed on a Becton Dickinson FACS 
vantage as described in Materials and Methods. Results are from a single experiment 
representative of at least 3 others.
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Investigation into D-3 phosphoinositide Levels in Jurkat Leukemic Cells
The leukemic cell line Jurkat has been central to many important discoveries in 
T cell biology and have been an invaluable tool in characterising cell signalling 
events (including PI 3-K signalling events) downstream from the TCR, IL-2R 
and costimulatory molecules such as CD28. The lipid products of PI 3-K 
regulate an extraordinary number of cellular processes confirming its role as a 
second messenger in signal transduction (Vanhaesebroeck et al 2001). Levels 
of D-3 Phosphoinositides are regulated by inositol phosphatases such as PTEN 
and SHIP which therefore regulate downstream effectors of PI 3-K signalling. 
Considering that T leukemic cell lines and lymphoblasts have differing 
expression of phosphatases (figure 26), it would be of interest to monitor basal 
and CD28/CD3 stimulated levels of D-3 phosphoinositides. Levels of D-3 
phosphoinositides can be measured in vivo by the metabolic labelling of intact 
cellular pools of ATP with 32P followed by lipid extraction, deacylation and 
separation and identification of phosphorylated lipids by HPLC analysis. Elution 
times of phosphoinositides are compared to known retention times of 3H 
labelled standards characterised by Ward et al (1995).
Upon labelling of Jurkat cells it was noted that there was considerable basal 
level of Pl(3,4,5)P3. Basal levels of Pl(3,4,5)P3 were shown to be around 4600 
cpm (figure 30 and table8). Following treatment with the PI3-K inhibitor LY 
294002 these levels were reduced to 1600 cpm after 60 minutes and further 
reducing to 264 cpm after 2-hours treatment (figure 30). Stimulation with CHO- 
B7.1+ cells resulted in a rapid accumulation of PI(3,4,5)P3. After 1 minute of 
CHO-B7.1+ stimulation Pl(3,4,5)P3 increased 4 times above basal levels. This 
increase was sustained unto 10 minutes where Pl(3,4,5)P3 levels have risen 15 
times (73000 cpm) above basal levels. These results are consistent with those 
previously reported by Ward et al (1995). It should also be noted that the rise in 
Pl(3,4,5)P3 after CHO-B7.1+ ligation was abrogated by pre-treatment with LY 
294002 confirming the role of PI 3-K in D-3 lipid accumulation. In contrast to the 
high basal levels of Pl(3,4,5)P3 in Jurkat cells, Pl(3,4)P2, a lipid thought to be a 
metabolic product of SHIP hydrolysis of Pl(3,4,5)P3) was found to be 
comparatively low at 170 cpm in unstimulated Jurkat cells (figure 30 and table 
8). Upon stimulation with CHO-B7.1+ cells, PI(3,4)P2 levels rose moderately to
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478 cpm (3-fold increase) after 10 minutes stimulation (figure 30). The increase 
was not as rapid when compared to the increase in PI(3,4,5)P3 accumulation 
following stimulation after 1 minute. It is clear Jurkat cells exhibit much higher 
levels of PI(3,4,5)P3 compared to PI(3,4)P2. Under basal conditions the ratio of 
PI(3,4,5)P3 to PI(3,4)P2 is 27.4 (table 8) whereas upon CD28 stimulation for 10 
minutes this ratio increase to 152.7. This marked increase in D-3 
phosphoinositide levels and PI(3,4,5)P3: Pl(3,4)P2 ratios at basal and CD28 
stimulated conditions may be partly explained by the lack of SHIP and PTEN 
which may check D-3 phosphoinositide levels in Jurkat cells.
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Figure 30: Measurement of PI(3,4,5)P3 (top panel) and Pl(3,4,5)P2 (bottom 













0 4- c ti








Basal LY T LY 5’ LY 10’ LY 30’ LY60’ LY B7.1 r  B7.1 5’ B7.1 B7.1 +
120' 10* LY
Treatment
F igu re 30: Measurement of PI(3,4,5)P3 and PI (3,4)P2 levels in Jurkat cells. Effect of LY294002 
and CHO-B7.1+. 2x107 cells /point of Jurkats were labelled with 32P, stimulated and lipids 
extracted. Following deacylation lipids were analysed by anion-exchange HPLC as described in 
Materials and Methods. PI(3,4,5)P3 is represented by the blue bars and PI (3,4)P2 is 








P I0 A 5 ) * :  PI(3,4)P2
Basal 4670 170 27
CD28 73000 478 152
10min
Table 8: D-3 phosphoinositide levels in basal and CD28 stimulated Jurkat T cells. Data is the 
mean cpm derived from 2 independent experiments.
Relevance of D-3 Phosphoinositide Levels to PI 3-K-Dependent Signalling 
Pathways in Jurkat Cells
D-3 phosphoinositides such as PI(3,4,5)P3 and Pl(3,4)P2 can recruit PH-domain 
containing proteins from the cytoplasm to the plasma membrane thus leading to 
its activation. PKB is an example of this in that it is able to interact with D3- 
phosphoinositides and become activated as a result of phosphorylation on 
Ser473 and Thr308 residues by the phosphoinositide-dependent kinases PDK1 
and PDK2. Immunoblotting using phospho-specific antibodies to PKB provides 
an indirect measure to cellular phospho-PKB levels, which relates to PKB 
activity. This approach was employed to compare basal and stimulated levels of 
phospho-PKB in the leukemic T cell line Jurkat and to attempt to equate these 
findings to both SHIP/PTEN protein expression and cellular D-3 
phosphoinositide levels measured by 32P in vivo lipid labelling.
Consistent with reported literature (Astoul et al 2001), it can be clearly seen that 
Jurkat cells have very high levels of basal phospho-PKB perhaps reflecting the 
high basal levels of PI(3,4,5)P3 measured in vivo (figure 31). Stimulation of 
Jurkat cells with B7.1 or with anti-CD3 mAb did not show a significant increase, 
if at all, in phospho-PKB levels perhaps indicating that PI 3-K signalling is at, or 
near, to saturation levels under basal conditions. Treatment of Jurkat cells with 
the PI 3-K inhibitor LY249002 did abolish basal levels of phospho-PKB over a 2- 
hour period (figure 31). The fact that Jurkat cells do not have the inositol 
phosphatases SHIP and PTEN to metabolise D-3 phosphoinositides may also
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reflect on the apparent slow conversion of phospho-PKB to dephosphorylated 
PKB. Antibodies to non-phosphorylated PKB verified approximate equal 
loading.
Figure 31: Basal and stimulated levels of phospho-PKB in Jurkat Cells
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Figure 31: Basal and stimulated levels of phospho-PKB in the Jurkat leukemic T cell line. 107 
cells per point were treated with LY294002 (10p.M) for 1 minute upto 2 hours as shown or 
stimulated with anti-CD28/CD3 mAbs (9.3/UCHT-1) used at 10pg/ml for 5 minutes. Cell lysates 
were resolved by SDS-PAGE, transferred onto nitrocellulose and immuno-blotted with an anti- 
Ser-473 phospho-PKB antibody. Equal loading was verified by stripping and re-probing with anti- 
PKB antibody. Pooled western blot data from two representative experiments were quantified by 
densitometric analysis and expressed as phospho-PKB: total PKB ratio.
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Basal and CD28/CD3 stimulated D-3 phosphoinositide levels in CEM 
leukemic T cell line
In view of the differing expression of lipid phosphatases between the T cell 
leukemic lines and T-lymphoblasts, it was hypothesised that accumulation of 
basal and stimulated levels of D-3 phosphoinositides may vary between cell 
lines. Thus, CEM cells (SHIP+/PTEN ) showed reduced basal levels of PI
(3.4.5)P3 when compared to Jurkats cells at the cell equivalent level (figure 32 
and table 9). However basal levels of PI (3,4)P2 were over ten times higher 
than Jurkat cells (1895 cpm). Ligation of CD28 or CD3 with CHO-B7.1+ or an 
anti-CD3 mAb (UCHT-1) resulted in a marked elevation of both PI(3,4,5)P3 and 
PI(3,4)P2. Pre-treatment of cells with LY294002 prior to CD28 stimulation 
abrogated the increase in D-3 phosphoinositides again suggesting a crucial role 
for PI 3-K in D-3 phosphoinositide generation. The lower Pl(3,4,5)P3: PI(3,4)P2 
ratio in basal and stimulated CEM cells compared to Jurkat cells suggests that 
SHIP expression in CEM cells may partially influence the accumulation of PI
(3.4.5)P3, converting it to PI (3,4)P2 which is found in considerable levels in this 
cell line.
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Figure 32: Measurement of PI(3,4,5)P3 and Pl(3,4,5)P2 basal and stimulated 
levels in CEM cells
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Figure 32: Measurement of PI(3,4,5)P3 and PI (3,4)P2 levels in CEM cells. Effect of LY294002 
and CH0-B7.1*. 2x107 cells /point of CEM were labelled with 32P, stimulated and lipids 
extracted. Following deacylation lipids were analysed by anion-exchange HPLC as described in 
Materials and Methods. PI(3,4,5)P3 is represented by the blue bars and PI (3,4)P2 is 








Basal 2500 1895 1.3
CD28 28726 4670 6.5
10min
Table 9: D-3 phosphoinositide levels in basal and CD28 stimulated CEM T cells. Data is the 
mean cpm derived from 2 independent experiments.
Results
Activation of PKB in CEM celis
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With the observation that Jurkat cells (PTEN7SHIP ) exhibit considerable basal 
levels of cellular Pl(3,4,5)Pz that could be linked to high basal levels of 
phosphorylated PKB at ser473, it was decided to investigate if similar 
observations were seen in CEM leukemic T cells (PTEN'/SHIP+). Indeed 
moderate basal levels of phospho-PKB could be seen in CEM cells (figure 33). 
Upon receptor stimulation of CD28 and CD3, modest increases in phospho- 
PKB above basal level can be observed that is further highlighted by 
densitometric analysis from pooled western blot data (figure 33 lower panel). 
This may suggest that basal levels of phospho-PKB in CEM cells are not quite 
at saturation levels. Again, treatment of CEM cells with the PI 3-K inhibitor 
LY294002, used at 10 pM, abolished phospho-PKB levels but an apparent 
faster rate compared to Jurkat cells perhaps due to the expression of SHIP in 
CEM cells which can dephosphorylate PI(3,4,5)P3 and potentially reduce PKB 
phosphorylation, perhaps by mediating its removal from the plasma membrane 
to the cytoplasm.
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Figure 33: Basal and stimulated levels of phospho-PKB in the CEM leukemic T cell line. 107 
cells per point were treated with LY294002 (10jiM) for 1 minute upto 2 hours as shown or 
stimulated with anti-CD28/CD3 mAbs (9.3/UCHT-1) used at 10ng/ml for 5 minutes. Cell lysates 
were resolved by SDS-PAGE, transferred onto nitrocellulose and immuno-blotted with an anti- 
Ser-473 phospho-PKB antibody. Equal loading was verified by stripping and re-probing with anti- 
PKB antibody. Pooled western blot data from two representative experiments were quantified by 
densitometric analysis and expressed as phospho-PKB: total PKB ratio.
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Basal and CD28/CD3 stimulated D-3 phosphoinositide levels in MOLT-4 
leukemic T cell line
The leukemic T cell line MOLT-4 has a similar inositol phosphatase expression 
as CEM cells in that it expresses SHIP but not PTEN (PTEN'/SHIP+). P32 
metabolic lipid labelling of CEM cells highlighted considerable levels of 
Pl(3,4)P2, the metabolic product of SHIP, which further increased upon cellular 
CD28/CD3 stimulation. In view of this finding it was investigated if MOLT-4 cells 
had similar basal and stimulated D-3 phosphoinositide profile.
Levels of PI(3,4,5)P3 were detectable in unstimulated MOLT cells and were 
comparable to that observed in CEM cells but were not as high as unstimulated 
Jurkats. Upon stimulation of CD28 and CD3 on MOLT cells D-3 
phosphoinositide levels increased (figure 34 and table 10) with Pl(3,4)P2 levels 
increasing 3.5-fold after 10 minutes CD28 ligation. Interestingly, basal levels of 
Pl(3,4)P2 were far lower than that observed in CEM cells. The ratio of 
PI(3,4,5)P3 to Pl(3,4)P2 of basal MOLT-4 cells was 3.5, close to the ratio 
observed in CEM cells but far lower than that observed in Jurkat cells which had 
a ratio of 27. PI(3,4,5)P3 levels only elevated 2-fold above basal following CD28 
ligation compared to a 15-fold increase observed in Jurkats although surface 
CD28/CD3 receptor levels were far lower than that observed in Jurkat cells 
(figure 28) and therefore the capacity to generate D-3 phosphoinositides upon 
cellular stimulation would be predicted to be reduced. Interestingly the 
PI(3,4,5)P3: PI(3,4)P2 ratio was similar to CEM (table 9/10) and the lower ratio 
indicates that Pl(3,4)P2 levels are much greater relative to Jurkats.
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Figure 34: Measurement of PI(3,4,5)P3 and PI(3,4,5)P2 basal and stimulated 
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Figure 34: Measurement of PI(3,4,5)P3 and PI (3,4)P2 levels in MOLT-4 cells. Effect of 
LY294002 and CH0-B7.1+. 2x107 cells /point of MOLT-4 were labelled with 32P, stimulated and 
lipids extracted. Following deacylation lipids were analysed by anion-exchange HPLC as 
described in Materials and Methods. PI(3,4,5)P3 is represented by the blue bars and PI(3,4)P2is 








Basal 2150 614 3.5
CD28 5055 1200 4.2
10min
Table 10: D-3 phosphoinositide levels in basal and CD28 stimulated MOLT-4 T cells. Data is 
the mean cpm derived from 2 independent experiments
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Basal and stimulated levels of phospho-PKB in MOLT-4 leukemic T cells
As with Jurkat and CEM cells it was investigated if MOLT-4 cells (SHIP+/PTEN) 
exhibited detectable basal levels of phospho-PKB. The MOLT-4 cell line had 
basal levels of phospho-PKB that could be reduced by treatment with the PI 3-K 
inhibitor LY294002 (figure 35). Interestingly the clearance rate of phospho-PKB 
levels upon addition of LY294002 was faster than that observed in Jurkat cells 
(figure 31). Levels of phospho-PKB were barely detectable by 60 minutes of 
addition of inhibitor whereas detectable levels were clearly visible at 60 minutes 
after inhibitor addition in Jurkat cells. A similar pattern was also observed in 
CEM cells. The expression of SHIP may contribute to this increased rate of 
phospho-PKB clearance in MOLT-4 cells.
Stimulation of MOLT-4 cells with anti-CD28/CD3 mAbs resulted in an marginal 
increase in cellular phospho-PKB above unstimulated levels (figure 35). This 
may suggest, like CEM cells, that PI 3-K/PKB signalling is not fully saturated 
compared to the apparent near saturated levels observed in Jurkat cells. It is of 
interest to note that despite the low CD3 (< 10%) surface expression as 
measured by FACS (figure 28) measurable increases in D-3 phosphoinositides 
and phospho-PKB levels were still observed upon CD3 stimulation.
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Figure 35: Basal and stimulated levels of phospho-PKB in the MOLT-4 leukemic T cell line. 107 
cells per point were treated with LY294002 (10pM) for 1 minute upto 2 hours as shown or 
stimulated with anti-CD28/CD3 mAbs (9.3/UCHT-1) used at 10pg/ml for 5 minutes. Cell lysates 
were resolved by SDS-PAGE, transferred onto nitrocellulose and immuno-blotted with an anti- 
Ser-473 phospho-PKB antibody. Equal loading was verified by stripping and re-probing with anti- 
PKB antibody. Pooled western blot data from two representative experiments were quantified by 
densitometric analysis and expressed as phospho-PKB: total PKB ratio.
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Basal and CD28/CD3 stimulated D-3 phosphoinositide levels in HUT 78 
leukemic T cell line
Results from this study have confirmed that the leukemic T cell line HUT 78 
expresses both SHIP and PTEN (SHIP+/PTEN+) whereas Jurkat cells express 
neither phosphatase and CEM and MOLT-4 express SHIP only. Observations 
so far suggest a role for these phosphatases in PI(3,4,5)P3 metabolism in T 
cells and the possible regulation of PKB signalling as determined by phospho- 
PKB levels in cell lysates. Lipid labelling of HUT 78 cells did reveal reduced 
basal and stimulated levels of D-3 phosphoinositides compared to all the other 
T cell lines tested thus far (figure 36). Very little PI(3,4,5)P3 (289cpm) could be 
detected in HUT 78 cells under basal conditions whereas PI(3,4)P2 could not be 
detected. Upon CD28 and CD3 stimulation approximate PI(3,4,5)P3 5-fold 
increased levels above basal were observed although far lower than those 
observed in other cell lines tested in this study. These increases in PI(3,4,5)P3 
were abrogated by the addition of LY 294002 prior to cellular stimulation. HUT 
78 cells did elicit modest detectable increases in Pl(3,4)P2 following stimulation 
although these levels were still very low (table 11 and figure 36).
It was not the aim of this study to directly compare phosphoinositide levels, with 
and without external stimulus to the different leukemic T cell lines. It should be 
stressed that different cell types may incorporate 32P differently, which may 
result in the apparent varying levels of D-3 phosphoinositides seen between cell 
lines. The different cell lines, which may differ in size, may also have different 
basal phosphoinositide lipid pool concentrations. CD28/CD3 receptor 
expression between the cell lines also significantly varied (figure 28) therefore a 
direct comparison between stimulated samples is not possible. However the 
data generated in this study does describe some interesting patterns in relating 
the relative expression of the phosphatases SHIP and PTEN with particular D-3 
phosphoinositide profiles and the suggestion that this may be linked to 
phospho-PKB levels in these cell lines.
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Basal and stimulated levels of phospho-PKB in HUT 78 cells
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In contrast to the other T cell lines examined, basal phospho-PKB levels in HUT 
78 cells (PTEN+/SHIP+) were very low and can just be seen visually upon 
analysis of the western blot (figure 37). As expected, addition of LY294002 
rapidly abolished detectable levels of phospho-PKB. Ligation of CD3 receptors 
by mAbs tended to increase levels of phospho-PKB, but not to extent observed 
in other stimulated cell lines (figure 37). This may be due in part to low 
CD28/CD3 receptor expression (<10% CD28/CD3 surface expression) that was 
observed on these cells during FACS staining (figure 28). Re-probing the blot 
with PKB verified equal loading and also showed that there were significant 
amounts of PKB expression. The fact that these cells express both PTEN and 
SHIP phosphatases could suggest that PI 3-K dependent phosphorylation of 
PKB is under more stringent control than the other cell lines tested which lack 
PTEN/SHIP. Thus the low levels of basal phospho-PKB observed in HUT 78 
cells may be a result of the efficient metabolism of Pl(3,4,5)P3 by the combined 
action of PTEN and/or SHIP.
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Figure 36: Measurement of basal and stimulated Pl(3,4,5)P3 and PI(3,4,5)P2 
















Figure 36: Measurement of Pl(3,4,5)P3 and PI (3,4)P2 levels in HUT 78 cells. 2x107 cells /point 
of HUT 78 cells were labelled with 32P, stimulated and lipids extracted. Following deacylation 
lipids were analysed by anion-exchange HPLC as described in Materials and Methods. 
PI(3,4,5)P3 is represented by the blue bars and PI(3,4)P2 is represented by the red bars. Data is 







Basal 289 <10 >30
CD28 1535 48 32
10min
Table 11: D-3 phosphoinositide levels in basal and CD28 stimulated HUT 78 T cells. Data is the 
mean cpm derived from 2 independent experiments.
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Figure 37: Basal and stimulated levels of phospho-PKB in HUT 78 cells
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Figure 37: Basal and stimulated levels of phospho-PKB in the HUT 78 cells. 107 cells per point 
were treated with LY294002 (10pM) for 1 minute upto 2 hours as shown or stimulated with anti- 
CD28/CD3 mAbs (9.3/UCHT-1) used at 10pg/ml for 5 minutes. Cell lysates were resolved by 
SDS-PAGE, transferred onto nitrocellulose and immuno-blotted with an anti-Ser-473 phospho- 
PKB antibody. Equal loading was verified by stripping and re-probing with anti-PKB antibody. 
Pooled western blot data from two representative experiments were quantified by densitometric 
analysis and expressed as phospho-PKB: total PKB ratio.
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Basal and Stimulated Levels of D-3 Phosphoinositides in T-Lymphoblasts
Metabolic lipid labelling of the T cell lines tested so far in this study has revealed 
interesting differences in D-3 phosphoinositide pools which may relate to the 
differential expression of the lipid phosphatases SHIP and PTEN. Many cell 
lines by their leukemic nature are defective in key enzymes (such as 
phosphatases SHIP and PTEN) involved in cellular metabolism. Thus it was 
deemed important for this study to assess the D-3 phosphoinositide lipid profile 
of ‘real’ T lymphoblasts, which are known to express both SHIP and PTEN 
(figure 26), derived from peripheral blood of healthy human volunteers.
SEB activated T-lymphoblasts (SHIP+/PTEN+) revealed detectable levels of 
PI(3,4,5)P3 (1100 cpm) at the basal level but with relatively low basal levels 
(101 cpm) of PI(3,4)P2 (Figure 38 and table 12). Levels of PI(3,4,5)P3 could be 
increased by approximately 4-fold by stimulating CD28 and IL-2 receptors 
present on T-blasts. A more modest increase was also observed upon CD3 
receptor stimulation. Stimulation of the IL-2 receptor has been previously 
reported to activate PI 3-K and induce formation of D-3 phosphoinositides 
(Ward et al 1992). The levels of PI(3,4)P2 also increased 3-fold upon CD28/IL-2 
receptor stimulation. The basal and stimulated PI(3,4,5)P3: PI(3,4)P2 ratios in T- 
blasts was 11 and 10 respectively. Interestingly these ratios fall in between 
those observed in Jurkat/HUT 78 and CEM/MOLT-4 cell lines. Elevation of 
PI(3,4,5)P3 by receptor stimulation in T-blasts could be abrogated by the PI 3-K 
inhibitor LY294002, indicating the crucial role for PI 3-K in the generation of D-3 
phosphoinositides (figure 38).
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Basal and stimulated levels of phospho-PKB in T-blasts
T-Lymphoblasts also contained detectable basal levels of phospho-PKB (figure 
39) which is expected as they had detectablelevels of PI(3,4,5)P3 defined by 
HPLC analysis. Basal levels of phospho-PKB were, once again, rapidly 
diminished (< 5 minutes) by pre-treatment with the PI 3-K inhibitor LY294002. 
Clearance of phospho-PKB levels upon addition of inhibitor was more rapid 
than that observed in Jurkat, CEM and MOLT-4 cell lines. Ligation of CD28 and 
CD3 clearly elevated phospho-PKB levels above those seen at basal levels with 
a clear increase of phospho-PKB: pan-PKB ratio compared to unstimulated 
samples (figure 39 lower panel). Approximate equal loading was verified by 
stripping the membranes and re-probing with PKB antibody.
The data generated may suggest that PI 3-K/PKB signalling is not saturated in 
basal, unstimulated T-blasts when compared with Jurkat cells. This may be due 
to in part the expression of SHIP and PTEN in T-blasts which may facilitate 
efficient metabolism of PI(3,4,5)P3 and the rapid dephosphorylation of PKB 
upon treatment of LY294002. In addition, the clear increase in phospho-PKB 
upon receptor ligation also correlates favourably with strong surface expression 
of CD3/28 as observed by FACS analysis (figure 28).
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Figure 38: Measurement of basal and stimulated Pl(3,4,5)^3 and Pl(3,4,5)^2 
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Figure 38: Measurement of PI(3,4,5)P3 and PI (3,4)P2 levels in T-lymphoblasts. 2x107 cells 
/point of T-blasts cells were labelled with 32P, stimulated and lipids extracted. Following 
deacylation lipids were analysed by anion-exchange HPLC as described in Materials and  
Methods. PI(3,4,5)P3 is represented by the blue bars and PI(3,4)P2 is represented by the red 
bars. Data is expressed as mean pooled data ± SEM from 2 independent experiments. Pooled 
western blot data from two representative experiments were quantified by densitometric 







Basal 1110 101 11
CD28 3890 378 10.3
10min
Table 12: D-3 phosphoinositide levels in basal and CD28 stimulated T-lymphoblasts Data is the 
mean cpm from 2 independent experiments.
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Figure 39: Basal and stimulated levels of phospho-PKB in the T-lymphoblasts. 107 cells per 
point were treated with LY294002 (10pM) for 1 minute upto 2 hours as shown or stimulated with 
anti-CD28/CD3 mAbs (9.3/UCHT-1) used at 10pg/ml for 5 minutes. Cell lysates were resolved 
by SDS-PAGE, transferred onto nitrocellulose and immuno-blotted with an anti-Ser-473 phospho- 
PKB antibody. Equal loading was verified by stripping and re-probing with anti-PKB antibody.
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Spearman’s rank correlation coefficient (rs) between basal PI(3,4,5)P3 and 
phospho-PKB/ total-PKB in T lymphocytes
Data presented so far in this study with leukemic T cell lines and T lymphoblasts 
suggests a positive correlation between basal PI(3,4,5)P3 levels and the basal 
levels of phospho-PKB measured via Western blotting. Basal levels of 
PI(3,4,5)P3 and phospho-PKB may be dependent on the expression of the 
inositol phosphatases SHIP and PTEN. It was decided to investigate if there 
was a positive relationship between levels of basal Pl(3,4,5)P3 (variable X) and 
phospho-PKB/ total-PKB (variable y) in the various T cell lines studied using the 
Spearman’s rank correlation coefficient (rs) statistical test. This coefficient, like 
other statistical methods based on ranks, does not depend on assumptions 
about normal distributions. A resultant rs value between the variables x and y of 
+1 corresponds to a perfect correlation, a value of 0 represents to no correlation 
and a value of -1 corresponds to perfect negative correlation.
The test involves scoring a rank for the variables x and y  for each T cell line (the 
number of cell lines represent n). Thus the highest Pl(3,4,5)P3 and phospho- 
PKB/ total PKB levels between cell lines scores 1, second highest scores 2 and 
so on forth (table 13). The difference between ranks x and y are then 
determined giving the value c/#-. Each individual cf, value is then squared and 
used to calculate rsvia the following equation:
The resultant rs value can then be compared with published critical p values 
(appendix 4) and thus determine if there is a significant correlation between the 
variables.
r s = 1 -















Jurkat 4670 1.02 1 1 0 0
CEM 2500 0.88 2 2 0 0
MOLT-4 2150 0.51 3 3 0 0
HUT 78 289 0.17 5 5 0 0
T-lymphoblast 1110 0.43 4 4 0 0
I  (d,)2 = o
Table 13: Spearman’s rank correlation coefficient between basal levels of PI(3,4,5)P3 and 
phospho-PKB/ total-PKB in T lymphocytes. Scored data for the variables is ranked as 
appropriate and the difference between the ranked variables is squared (d,2) the sum of which is 
used to equate the Spearman’s coefficient (rs).
The rs value, calculated from the equation shown previously, derived from data 
in table 13 is exactly 1, p value = 0.05, suggesting a significant positive 
correlation between basal Pl(3,4,5)P3 levels and basal phospho-PKB levels. 
Thus high basal PI(3,4,5)P3 generates higher levels of phospho-PKB. This 
correlation also supports the crucial role for PTEN and SHIP expression in the 
metabolism of basal levels of PI(3,4,5)P3 and its vital role for regulating PKB 
phosphorylation and activation in T lymphocytes. However this correlation does 
depend on the cell lines having equivalent phosphoinositide pools and PKB 
protein expression. It is unlikely that is indeed the case, so the result of the 
Spearman’s analysis, although of considerable interest, should be viewed with a 
degree of caution.
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Comparison of basal phospho-PKB in leukemic T cell lines
Figure 40 compares basal phospho-PKB levels of different leukemic cell lines 
(107 cells per point). Again Jurkat cells revealed higher basal levels of phospho- 
PKB, at the cell equivalent level, compared to the other cell lines tested with 
HUT 78 again having undetectable basal levels of phospho-PKB. The doublet 
bands detected, which cannot be readily explained, may be as a result of the 
detection of various PKB isoforms. This doublet is sometimes seen on some 
other western blots using phospho/pan-PKB antibodies (see figure 31-Jurkat 
phospho-PKB western).
However it is accepted that we cannot directly compare phospho-PKB levels 
between the different cells types studied. For example cells may have varying 
levels of PKB protein expression that may contribute to the data observed. 
Another way to overcome this problem would be to load equal amounts of 
protein (rather than using whole cell equivalents) onto the gel from lysates of 
each of the cell lines tested. Unfortunately due to time constraints this was not 
achieved. However it becomes increasingly apparent that there is an intimate 
pattern between inositol phosphatase expression, D-3 phosphoinositide profiles 
and the relative activation status of PI(3,4,5)P3-driven effector proteins 
including PKB.
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Figure 40: Comparison of basal levels of phospho-PKB in leukemic cell lines. Cell extracts (107 
cells per point) were lysed, resolved by SDS-PAGE and transferred onto nitrocellulose and 
immuno-blotted with a phospho-PKB polyclonal antibody as described in Materials and  
Methods. Equal loading was verified by stripping and reprobing with an anti-PKB mAb. Results 
are from a single experiment representative of 2 others.
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Phosphorylation Status of PKB and PKB Effectors in Leukemic Cell Lines
and T-Lymphoblasts.
It has been shown that T cell lines studied have different levels of basal and 
stimulated D-3 phosphoinositides. This appears to determine basal levels of 
phospho-PKB in these cells. Another way to measure the activation status of 
PKB is to measure the phosphorylation state of its downstream effectors. A 
well-characterised downstream target of PKB is the multifunctional serine 
threonine kinase, glycogen synthase kinase 3 (GSK3). PKB is known to 
phosphorylate and inactivate GSK3 in a PI 3-K dependent manner (Cross et al 
1995). Using phospho-specific antibodies to GSK3 we therefore are able to 
monitor the basal in vivo activity of PKB in the T cell lines studied.
It can be seen from figure 41 that Jurkat cells show high constitutive levels of 
phospho-GSK3 in accordance with its high phospho-PKB levels. Likewise, 
phospho-GSK3 levels are also high in MOLT-4 and CEM cells but not to the 
extent as those seen in Jurkat cells. In contrast, HUT 78 cells have lower levels 
of phospho-GSK-3 perhaps reflecting the low levels of phospho-PKB seen in 
these cells. T-lymphoblasts also have detectable levels of phospho-GSK3 but 
again not to the extent of Jurkat cells but interestingly more than MOLT4 and 
CEM cells. The elevated levels of phospho-GSK3 seen in T-lymphoblasts are 
not easily explained and may generated as a by-product of the SEB/IL-2 
stimulation/maintenance cell culture protocol. Alternatively other poorly 
characterised signalling pathways may couple to GSK3. The doublet bands 
seen in the blot most certainly represent GSK3 isoforms (GSK3a and GSKp) 
with GSKa being the slightly larger isoform. Equal loading was verified by 
stripping and reprobing with anti-GSK3 mAb. The conclusions drawn from 
phospho-PKB data shown in figure 40 suggests that basal levels of active 
phospho-PKB may regulate the amount of phospho-GSK3 in the cell.
Results 106
























----- ------- ■ ^
* • N • 1
Phospho-GSK3
GSK3
Figure 41: Comparison of basal levels of phospho-GSK3 in leukemic cell lines. Cell extracts 
(107 cells per point) were lysed, resolved by SDS-PAGE and transferred onto nitrocellulose and 
immuno-blotted with a phospho-GSK3 antibody as described in Materials and Methods. Equal 
loading was verified by stripping and reprobing with an anti-GSK3 mAb. Results are from a 
single experiment representative of 2 others.
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Summary
• All T cell lines and T-lymphoblasts contained mRNA for SHIP and PTEN 
(figure 25)
• Jurkat cells lack both SHIP and PTEN at the protein level. Interestingly 
MOLT-4 and CEM cells express SHIP but not PTEN whilst the cell line HUT 
78 and T-lymphoblasts expressed both SHIP and PTEN phosphatases at 
the protein level (figure 26).
• Jurkat cells contained considerable basal levels of PI(3,4,5)P3 with relatively 
low basal levels of PI(3,4)P2. This is reflected in a high basal Pl(3,4,5)P3: 
Pl(3,4)P2 ratio of 27. Upon CD28 stimulation this ratio increased to 152. 
These marked increases upon stimulation may be in part due to the lack of 
SHIP/PTEN expression (figure 30).
• CEM and MOLT-4 (SHIP+/PTEN ) cell lines had basal Pl(3,4,5)P3: PI(3,4)P2 
ratios of 1.3 and 3.5 respectively. This reflects the increased levels of the 
SHIP metabolite Pl(3,4)P2 present in the phosphoinositide pool and differs 
markedly from the situation observed in Jurkats. Upon CD28 stimulation a 
modest increase in the Pl(3,4,5)P3: Pl(3,4)P2 ratio was observed (CEM = 
6.5, MOLT-4 = 4.2) again much lower than Jurkat and perhaps reflecting a 
functional role for SHIP in PI(3,4,5)P3 dephosphorylation to Pl(3,4)P2 in CEM 
and MOLT-4 cells (figure 32 and 34).
• HUT 78 cells had lower, but still detectable, measurable basal levels of 
Pl(3,4,5)P3 and undetectable basal levels of Pl(3,4)P2 (figure 36). Upon 
CD28 stimulation D-3 phosphoinositides did increase exhibiting a 
Pl(3,4,5)P3: PI(3,4)P2 ratio of 30 perhaps reflecting the relative low levels of 
PI(3,4)P2 in HUT 78 cells compared to CEM and MOLT-4.
• T-blasts which express both SHIP and PTEN had measurable basal levels 
of both Pl(3,4,5)P3 and Pl(3,4)P2 (ratio 11). D-3 phosphoinositides did
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increase upon CD28 stimulation but the PI(3,4,5)P3: Pl(3,4)P2 ratio stayed
relatively constant at 10 (figure 38).
• Phospho-PKB levels in Jurkat cells were high in cell lysates and did not 
detectably increase upon cell stimulation, perhaps suggesting saturation of 
PI 3-K signalling in this cell line. A slow clearance (over 60 minutes) of 
phospho-PKB levels was also observed upon treatment with LY 294002 
which may reflect slow metabolism of P!(3,4,5)P3 due to lack of SHIP and 
PTEN (figure 31).
• CEM and MOLT-4 cells also exhibited basal levels of phospho-PKB and 
which were only modestly increased upon cellular stimulation. Treatment of 
LY294002 cleared phospho-PKB levels but at a more rapid rate than that 
observed in Jurkat cells (figures 33 and 35).
• HUT 78 cells, which express both SHIP and PTEN contained no detectable 
phospho-PKB under basal conditions (figure 37). Small increases in 
phospho-PKB levels could be observed upon stimulation although this may 
be due, at least in part, to low CD3/CD28 receptor expression.
• T-blasts were shown to contain basal phospho-PKB levels, rapidly cleared 
upon addition of LY294002. Cell stimulation elicited clear increases in 
cellular levels of phospho-PKB (figure 39).
• Spearman’s rank correlation revealed a significant correlation (p value = 
0.05) between basal PI(3,4,5)P3 levels and basal phospho-PKB levels in the 
T cell lines studied.
• Comparison of phospho-PKB and phospho-GSK3 (a downstream target for 
PKB), between the T cell lines tested revealed high phospho basal levels in 
Jurkat cells. CEM and MOLT-4 cells exhibited slightly lower levels of 
phospho-PKB/GSK3 with HUT 78 showing almost undetectable levels of 
phospho-PKB/GSK3.
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Regulation of SHIP and PTEN by CD28 in T cells 
Background
Analysis of the structure of SHIP (figure 12) reveals several identifiable motifs 
that can participate in multiple protein-protein interactions. This suggests that 
SHIP has diverse signalling capabilities and may not function purely as an 
inositol phosphatase. A major biochemical event following CD28 ligation is the 
recruitment and activation of PI 3-K resulting in the accumulation of D-3 
phosphoinositides (Ward et al 1995). This section will investigate the regulation 
of the inositol phosphatases SHIP and PTEN by various receptors expressed 
on different T cell lines with particular emphasis on the co-stimulatory receptor 
CD28.
Expression of Surface Antigens and SHIP and PTEN Proteins in Murine 
Hybridoma T Cells
Murine hybridoma T cells (clone DC.27 a kind gift from D. Olive, Marseilles 
INSERM France), stably transfected with high surface levels of the human 
CD28 receptor were suitable cells to study CD28 signal transduction. Flow 
cytometry revealed that CD28 was expressed on the cell surface at high levels 
(figure 41). Murine cells, stably transfected with a site-mutated human CD28 
(AYF 173/200) which is unable to recruit PI 3-K (Pages et al 1996) were also 
used to study CD28 regulation of SHIP. These cell lines enables the role of the 
YXXM motif of human CD28 in the regulation of SHIP to be determined. FACS 
analysis also revealed high levels of this CD28-mutant receptor on the cell 
surface (figure 41). Cell lysates from DC.27 cells were shown to express high 
levels of SHIP as detected from Western blotting using an anti-SHIP Ab (figure 
42). Jurkat lysates on the same gel revealed no detectable levels of SHIP as 
previously confirmed from earlier experiments during this study (figure26).
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SHIP is Tyrosine Phosphorylated in Response to CD28 Stimulation in
Murine Hybridoma Cells
Ligation of hCD28 with the mAb 9.3 resulted in rapid tyrosine phosphorylation of 
SHIP by 1 minute (figure 43). Phosphorylation of SHIP was sustained for up to 
10 minutes following stimulation. The observed tyrosine phosphorylation was 
specific to the receptor CD28 as an isotype !gG2a control had no effect on 
tyrosine phosphorylation of SHIP. This observation also suggests, albeit 
indirectly, that any possible FcyRllb receptors present on DC.27 cells are not 
responsible for the observed tyrosine phosphorylation of SHIP. Multiple bands 
of SHIP are seen in the reprobe which is most likely to be indicative of the 
presence of C-terminal-truncated versions of SHIP i.e. p135/p155 SHIP which 
can be observed when using a SHIP polyclonal Ab recognising an N-terminal 
epitope of SHIP (Appendix 1).
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Figure 41: Expression of transfected (wild type and AYF 173/200) human 
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Figure 41: Expression of transfected (wild type and AYF 173/200) human CD28 on DC.27 
murine hybridoma cells. 1X105 DC.27 cells were analysed for CD28 expression using anti-CD28 
9.3 mAb (green bar) against an isotype control lgG2a (blue bar). Cells were stained with an 
FITC-conjugated goat anti-mouse secondary Ab and analysed on a Becton Dickinson FACS 
vantage as described in Materials and Methods. Results are from a single experiment 
representative of at least 3 others.
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Figure 42: Expression of SHIP in DC.27 murine hybridoma cells
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Figure 42: Expression of SHIP DC.27 murine hybridoma cells. Jurkat and DC.27 cells were 
prepared at the above stated cell equivalents, lysed and proteins precipitated by acetone 
precipitation as stated in Materials and Methods. Proteins were resolved by SDS-PAGE and 
transferred to nitrocellulose and immunoblotted with a SHIP mAb. Results are from a single 
experiment representative of 3 others.
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Figure 43: SHIP is tyrosine phosphorylated in response to CD28 ligation in
murine DC.27 T cells.
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Figure 43: SHIP is tyrosine phosphorylated in response to CD28 ligation in DC.27 cells. 107 
DC.27 cells were aliquoted and stimulated with the anti-CD28 mAb, 9.3 or isotype matched 
control lgG2a at 1 pg/ml for the indicated time. Cells were lysed and SHIP was 
immunoprecipitated using an anti-SHIP mAb. Immunoprecipitates were resolved by SDS-PAGE 
and transferred to nitrocellulose and immunoblotted with an anti-phosphotyrosine antibody 
4G10. Blots were stripped and immunoblotted with anti-SHIP mAb to verify equal loading. 
Results are from a single experiment representative of 3 independent experiments.
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SHIP is Tyrosine Phoshorylated by the CD28 Ligands B7.1 and B7.2 in
DC.27 Murine Hybridoma T cells.
Co-sedimentation of wild type expressing hCD28 DC.27 with CHO-B7.1+ cells 
also resulted in a rapid tyrosine phosphorylation of SHIP (figure 44). It has been 
demonstrated previously that CHO cells do not express SHIP, hence the source 
of phosphorylated SHIP in these experiments emanates from DC.27 murine 
hybridoma T cells and not from CHO cells (Edmunds et al 1999). Ligation of 
CD28 with it’s natural ligand B7.1 showed similarities to that observed with the 
anti-CD28 mAb (9.3) in that it induced rapid tyrosine phosphorylation of SHIP by 
1 minute which could be sustained for up to 10 minutes. Ligation of CD28 with 
CHO-B7.2+ (kind gift from D. Sansom, Birmingham, UK) cells also induced rapid 
and sustained tyrosine phosphorylation of SHIP (figure 44) with similar kinetics 
to that observed for CHO-B7.1+ cells. However, it should be noted that murine 
CD28 might also ligate with CHO-B7.1/2+ and contribute to the effects 
observed. Previous work however has suggested that mCD28 surface levels 
are approximately 50 fold-less than transfected hCD28 levels (C. Edmunds 
personal communication). Unfortunately lack of a suitable staining antibody 
meant that mCD28 levels couldn’t be determined during the course of this 
study. Nonetheless, these results strongly suggest that SHIP is a biochemical 
target of CD28-activated PTKs.
SHIP is Tyrosine Phosphorylated in Response to CD3 Ligation in DC.27 
Murine Hybridoma T cells.
Stimulation of the TCR is known to induce the tyrosine phosphorylation of SHIP 
(Lamkin et al 1997). Therefore the tyrosine phosphorylation of SHIP in response 
to stimulation of CD28 and CD3 receptors alone, or in combination, was 
investigated. Ligation of murine TCR with the anti-CD3 mAb, 2C11 induced the 
rapid and sustained tyrosine phosphorylation of SHIP to a similar extent as 
CD28 ligation (figure 45). The multiple tyrosine-phosphorylated bands seen on 
the blots are most likely the truncated isoforms of SHIP. Ligation of both the 
CD28 and CD3 receptors together, stimulated further increased levels of 
tyrosine phosphorylated SHIP, suggesting the existence of positive interaction 
between the signalling pathways (figure 45).
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Figure 44: SHIP is Tyrosine Phoshorylated by the natural CD28 Ligands 
B7.1 and B7.2 in DC.27 Murine Hybridoma T cells.
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Figure 44: SHIP is tyrosine phosphorylated by the CD28 Ligands B7.1 and B7.2 in DC.27 
Murine Hybridoma T cells. 107 DC.27 cells were aliquoted left unstimulated as a control (CTL) 
or stimulated with CHO-B7.1+ or CHO-B7.2+ (at a ratio of 3 DC.27 cells: 1 CHO-B7.1/2+ cell) for 
the times indicated. Cells were lysed and lysates immunoprecipitated with anti-SHIP polyclonal 
Ab. Immunoprecipitates were resolved by SDS-PAGE and transferred to nitrocellulose and 
immunoblotted with an anti-phosphotyrosine antibody 4G10. Blots were stripped and 
immunoblotted with anti-SHIP mAb to verify equal loading. Results are from a single experiment 
representative of 2 others.
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Figure 45: SHIP is Tyrosine Phosphorylated in Response to CD3 Ligation
in DC.27 Murine Hybridoma T cells.
9.3 mAb 2C11 mAb 9.3/2C11 mAb
C 5' 10' C 5' 10' C 5' 10’
I P. SHIP 
Blot: 4G10
145




Figure 45: SHIP is Tyrosine Phosphorylated in Response to CD3 Ligation in DC.27 Murine 
Hybridoma T cells. 107 DC.27 cells were aliquoted left unstimulated as a control (CTL) or 
stimulated with 5 pg/ml anti-CD28 mAb (9.3) or 5 pg/ml anti-CD3 mAb (2C11) alone or in 
combination. Cells were lysed and SHIP was immunoprecipitated using an anti-SHIP polyclonal 
Ab. Immunoprecipitates were resolved by SDS-PAGE and transferred to nitrocellulose and 
immunoblotted with an anti-phosphotyrosine antibody 4G10. Blots were stripped and 
immunoblotted with anti-SHIP mAb to verify equal loading. Multiple bands seen on the blot are 
likely to represent the truncated isoforms of SHIP i.e. p135/p145/p155 isoforms of SHIP. 
Results are from a single experiment representative of 3 independent experiments.
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CD28 coupling to PI 3-K is not required for SHIP tyrosine phosphorylation
in DC.27 murine hybridoma T cells.
Experiments performed by Edmunds et al shows that in unstimulated cells SHIP 
lies within the cytoplasm, but that it rapidly migrates to the plasma membrane 
following CD28 stimulation (Edmunds et al 1999). It was also shown that no 
detectable amounts of SHIP could couple to CD28 following receptor 
stimulation via co-immunoprecipitation studies. One possible mechanism of 
targeting SHIP to the plasma membrane following CD28 ligation is via the 
interaction of SHIP or a PH-domain containing co-associating protein with D-3 
phosphoinositides formed in response to CD28 activation, thereby allowing its 
tyrosine phosphorylation by CD28-activated PTK.
DC.27 murine hybridoma T cells expressing stably transfected wild type human 
CD28 and AYF 173/200 mutant (figure 41), previously shown to abrogate PI 3-K 
recruitment (Pages et al 1996), were used to assess the ability of CD28 to 
tyrosine phosphorylate SHIP following receptor ligation. Mutation of the YXXM 
PI 3-K binding motif in CD28 did not effect its ability to tyrosine phosphorylate 
SHIP following stimulation with anti-CD28 mAb when compared with wild type 
CD28 (figure 46): in both cases up to 50% increases in phospho-SHIP levels 
being observed after 10 minutes CD28 stimulation. Equal loading was verified 
by stripping and reprobing with SHIP polyclonal Ab. This suggests therefore, 
that SHIP or a SHIP-associated protein is not dependent on the generation of 
Pl(3,4,5)P3 by PI 3-K for its tyrosine phosphorylation SHIP. It also suggests, 
albeit indirectly, that SHIP is unlikely to be a target for D-3 phosphoinositide 
dependent tyrosine kinases. This hypothesis could have been tested further by 
observing the effect of pre-treatment of DC.27 cells with pharmacological 
inhibitors of PI 3-K (including wortmannin and LY 294002) prior to CD28 
stimulation and the subsequent effect on the tyrosine phosphorylation of SHIP. 
Unfortunately these experiments were not conducted in this study due to time 
constraints.
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Figure 46: CD28 coupling to PI 3-kinase is not required for SHIP tyrosine 
phosphorylation in DC.27 murine hybridoma T cells.
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Figure 46: CD28 coupling to PI 3-kinase is not required for SHIP tyrosine phosphorylation. 107 
DC.27 cells expressing wild type (WT) or AY/F 173/200 hCD28+ were either left unstimulated as 
a control (CTL) or stimulated with anti-CD28 mAb 9.3 (1 pg/ml) for the times indicated. Cells 
were lysed and lysates immunoprecipitated with an anti-SHIP polyclonal Ab. 
Immunoprecipitates were resolved by SDS-PAGE and transferred to nitrocellulose and 
immunoblotted with an anti-phosphotyrosine antibody 4G10. Bands were quantified by 
densitometry and expressed as a % of control. Blots were stripped and immunoblotted with anti- 
SHIP polyclonal Ab to verify equal loading. Results are from a single experiment representative 
of 3 independent experiments.
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SHIP is tyrosine phosphorylated in response to CD28, CD2, CD3 and IL-2
receptor stimulation in human T-lymphoblasts.
The evidence presented thus far suggests that SHIP is downstream target 
following CD28/CD3 stimulation in murine hybridoma T cells. It was deemed 
necessary to assess such signal transduction events of SHIP tyrosine 
phosphorylation in IL-2-treated human T-lymphoblasts. Human T cells, derived 
from peripheral blood of healthy volunteers, represent a more physiologically 
relevant cell model to monitor signal transduction and can potentially overcome 
some of the limitations of leukemic T cell lines (Astoul et al 2001).
Stimulation of T-lymphoblasts with anti-CD28 (9.3), anti-CD3 (UCHT-1), anti- 
CD2 (6F103 and 3C15- note two antibodies are required to stimulate the CD2 
receptor-mediated signal transduction) mAbs and with recombinant human IL-2 
resulted in tyrosine phosphorylation of SHIP as seen in figure 47 which is 
representative of two separate experiments. Approximate equal loading was 
verified by stripping and probing with anti-SHIP in this case. This data suggests 
that multiple receptors present on human T cells may potentially utilise SHIP as 
a biochemical target and therefore supports a role for SHIP in T-lymphocyte 
signalling. SHIP is also known to be tyrosine phosphorylated in response to a 
variety of cytokines and growth factors (Liu et al 1994) but this is the first 
evidence that SHIP is a downstream target for the CD2 and IL-2 receptors in 
human T lymphocytes. Closer analysis of figure 47 does reveal inconsistencies 
in the ability of receptors to tyrosine phosphorylate SHIP once stimulated. For 
example the CD28 receptor, once stimulated with Ab, in the top panel gives 
only modest phosphorylation of SHIP whilst a clear increase is seen in the 
bottom panel. These discrepancies, which are not readily explicable, represent 
experiments from different donors and a multitude of factors may responsible 
including experimental error, variation of receptor expression profiles between 
donors etc. As a result the data should be interpreted with a degree of caution.
Results 120
Figure 47: SHIP is tyrosine phosphorylated in response to CD28, CD2,
CD3 and IL-2 receptor stim ulation in human T-lymphoblasts.
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Figure 47: SHIP is a tyrosine phosphorylated in response to CD28, CD2, CD3 and IL-2 
receptor stimulation in human T-lymphoblasts. 107 cells of human SEB-activated T- 
lymphoblasts were washed and aliquoted. Cells were left unstimulated as a negative control 
(CTL) or were stimulated at 10 pg/ml with anti-CD28 mAb (9.3), anti-CD3 mAb (UCHT-1), anti- 
CD2 mAbs (6F103 and 3C15) and human recombinant IL-2 at 20ng/ml. Cells were lysed and 
SHIP was immunoprecipitated using an anti-SHIP mAb. Immunoprecipitates were resolved by 
SDS-PAGE and transferred to nitrocellulose and immunoblotted with an anti-phosphotyrosine 
antibody 4G10. Note the strip and reprobe for SHIP did not work in top panel (figure A) but did 
in the second experiment (figure B). This data represents two independent experiments.
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SHIP is tyrosine phosphorylated in the Leukemic cell lines MOLT-4 and
CEM following CD28 and CD3 ligation.
As described in the earlier sections, SHIP is expressed at the protein level in 
the leukemic cell lines MOLT-4 and CEM but interestingly not in Jurkat cells. 
Experiments were performed to establish if SHIP was a biochemical target 
downstream from the CD28 and CDS receptors in these leukemic cel! lines. 
Figures 48a/b shows that SHIP is able to be immunoprecipitated from all of 
these cell lines (apart from Jurkat). In MOLT-4 and CEM cells SHIP is clearly 
tyrosine phosphorylated following CD28 stimulation but only modestly, if at all, 
when CD3 is stimulated. This data suggests that SHIP is a biochemical target in 
MOLT-4 and CEM cells and may partly explain the marked increase in 
Pl(3,4)P2, a SHIP metabolite of Pl(3,4,5)P3, observed following CD28 ligation in 
these cells (figures 32/34). The ability of these cells to generate signals to SHIP 
is ultimately determined by surface-expression of the receptor(s) in question. 
Therefore the weak cell surface expression of CD3/28 receptors on HUT 78 
cells meant that these cells were not examined for SHIP tyrosine 
phosphorylation following stimulation with anti-CD3/CD28 Abs.
Results 122
Figure 48a: SHIP is tyrosine phosphorylated in the Leukemic cell line CEM
follow ing cellular stim ulation
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Figure 48a: SHIP is tyrosine phosphorylated in the cell line CEM following cell stimulation. 107 
CEM cells were aliquoted and left either unstimulated as a control (CTL) or stimulated with 10 
pg/ml of anti-CD28 mAb (9.3) or anti-CD3 mAb (UCHT-1). Cells were lysed and SHIP was 
immunoprecipitated using an anti-SHIP mAb. Immunoprecipitates were resolved by SDS-PAGE 
and transferred to nitrocellulose and immunoblotted with an anti-phosphotyrosine antibody 
4G10. Blots were stripped and immunoblotted with anti-SHIP mAb to verify equal loading. Data 
was quantified by densitometry and expressed as a percentage of control (bottom panel). 
Results are from a single experiment representative of 2 others.
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Figure 48b: SHIP is tyrosine phosphorylated in the Leukemic cell line
MOLT-4 follow ing cellular stim ulation
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Figure 48b: SHIP is tyrosine phosphorylated in the cell line MOLT-4 following cell stimulation. 
107 MOLT-4 cells were aliquoted and left either unstimulated as a control (CTL) or stimulated 
with 10 pg/ml of anti-CD28 mAb (9.3) or anti-CD3 mAb (UCHT-1). Cells were lysed and SHIP 
was immunoprecipitated using an anti-SHIP mAb. Immunoprecipitates were resolved by SDS- 
PAGE and transferred to nitrocellulose and immunoblotted with an anti-phosphotyrosine 
antibody 4G10. Blots were stripped and immunoblotted with anti-SHIP mAb to verify equal 
loading. Data was quantified by densitometry and expressed as a percentage of control (bottom 
panel). Results are from a single experiment representative of 2 others.
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SHIP Immunoprecipitates derived from T Leukemic cells and T-
lymphoblasts display in vitro phosphatase activity
It is generally regarded that SHIP has constitutive phosphatase activity in 
unstimulated cells and that SHIP function is controlled not by tyrosine 
phosphorylation but rather regulating its cellular localisation (Rohrschneider et 
al 2000). It is unknown if SHIP derived from CEM and MOLT-4 cell lysates is 
constitutively active and therefore SHIP immunoprecipitates from CD28- 
stimulated and non-stimulated cells were assayed for in vitro 5’-phosphatase 
activity against 3Hinositol-tetrakisphosphate (lns(1,3,4,5)P4-or IP4). For all the 
cell lines tested, SHIP immunoprecipitates were found to be constitutively active 
towards the IP4 substrate as measured by HPLC analysis of the substrates 
formed (table 14). It should be noted that data obtained is from a single attempt 
and therefore should be viewed as preliminary data. These experiments would 
need to be repeated to confirm the reported observations and we could also 
ascertain if there is a statistically significant difference between phosphatase 
activity derived from CD28-stimulated-SHIP I.Ps and basal-SHIP I Ps, but 
unfortunately, due to time constraints, this was not determined. However, the 
data is consistent with the idea that SHIP is constitutively active and is probably 
regulated controlling access to its substrates (i.e. by membrane recruitment) 
(Carver et al 2000).
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Table 14: In vitro phosphatase activity of SHIP immunoprecipitates. T-blasts, MOLT-4, and 
CEM were left unstimulated (CTL) or stimulated with anti-CD28 mAb 9.3 (1 pg/ml). Cells were 
lysed and subjected to immunoprecipitation with the an anti-SHIP mAb. The 5-phosphatase 
activity was determined by the in vitro hydrolysis of 3H lns(1,3,4,5)P4 to 3H lns(1,3,4)P3 as 
described in Materials and Methods. Data is from a single experiment.
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SHIP co-associates with in vitro protein kinase activity following CD28
ligation
SHIP has been shown to be a target for CD28 activated PTK which may 
regulate its cellular localisation and association with other proteins. SHIP 
immunoprecipitates from DC.27 cells were assayed for in vitro protein kinase 
activity using 32P yATP as a substrate. This will reveal whether there is kinase 
activity associated with SHIP I.Ps and if this is altered following CD28 
stimulation. SHIP was found to rapidly (within 1 minute) co-precipitate with in 
vitro protein kinase activity following CD28 stimulation with CHO-B7.1+ (figure 
49).
In vitro kinase activity appears to co-associate with SHIP under basal conditions 
and the level of kinase activity increased following CD28 ligation. Several 
phospho-proteins of varying densities, appear to co-associate with SHIP with 
apparent molecular weights of 145-150 kDa (presumably SHIP), 100 kDa, 70 
kDa, 60 kDa, and approximately 40 kDa (figure 49). The identity of these 
proteins are currently unknown, as is whether the phospho-proteins are 
serine/threonine or tyrosine phosphorylated (the assay does not discriminate 
between PTK and serine/threonine protein kinases). To distinguish between 
these possibilities, future experiments would include appropriate inhibitors (e.g. 
PKC and MAPK-inhibitors) in order to determine the nature in vitro kinase 
activity associating with SHIP I.Ps. It would also be of importance to determine 
whether a similar spectrum of phosphoproteins co-precipitates with SHIP in 
MOLT-4/CEM/T-blast cells. It is likely that some of these SHIP co-associating 
proteins may potentially regulate the tyrosine phosphorylation, phosphatase 
activity and/or cellular redistribution of SHIP and SHIP-associating proteins 
following CD28 stimulation.
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Figure 49: SHIP co-associates with in vitro protein kinase activity 
following CD28 ligation in DC.27 cells.
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Figure 49: SHIP co-associates with In Vitro protein kinase activity. 2X107 DC.27 murine 
hybridoma T cells expressing wild type hCD28+ were stimulated with CHO-B7.1+ cells at a ratio 
of 3 DC.27 T cells: 1 CHO-B7.1* cells as described in Materials and Methods. Cells were lysed 
and subjected to immunoprecipitation with anti-SHIP mAb. Immunoprecipitates were washed 
and reconstituted in kinase buffer with 1 pCurie of 32P yATP for 20 minutes. Immunoprecipitated 
proteins were resolved on a 7%-15% gradient gel and incorporated 32P was assessed by 
autoradiography. The arrows show distinct phospho-proteins, which co-immunoprecipitate with 
SHIP. Data are from a single experiment representative of three others.
Results 127
CD28 ligation induces the association of the adapter protein p62dok with
SHIP
SHIP was originally identified as being able to bind a multitude of tyrosine 
phospho-proteins. In B cells, one of these has been identified recently as the 
PH-domain containing adapter protein p62dok (Tamir et al 2001). This rasGAP 
associated protein is known to be tyrosine phosphorylated following CD28, but 
interestingly not CD3, receptor ligation (Nunes et al 1996). These data, coupled 
with the observation that a faint 32P phosphoprotein, of approximately 60-65 
kDa, co-associates with SHIP in the in vitro kinase assay, suggest p62dok as a 
good candidate protein which may interact with SHIP downstream from CD28 
signalling in T cells. Subsequent experiments revealed that SHIP does indeed 
inducibly immunoprecipitate with p62dok following CD28 stimulation of DC.27 
cells (figures 50/51).
Figure 51 shows p62dok is associated with SHIP under basal conditions and 
which increases upon CD28 stimulation. SHIP may also associate, albeit at 
much lower levels, with p62dok I.Ps (figure 52). Although the overall quality of 
the blot is poor, SHIP can be seen to recruit to p62dok with maximal co­
association between the two proteins occurring after 5 minutes post-stimulation 
and was observed to be transient in nature. Approximate equal loading was 
confirmed by stripping the blot and reprobing with the relevant antibodies.
It is accepted that immunoprecipitation of whole cell lysates does not prove that 
these associations occur in vivo. Other experiments would need to be 
performed to verify that this is indeed the case. These could include trying to 
extract p62dok protein (from stimulated SHIP I.Ps) from SDS-PAGE gels and 
performing partial tryptic digests to attempt to get some protein sequence data 
to verify the existence of p62dok. Alternatively an immunofluorescence approach, 
where SHIP and p62dok are stained with different secondary conjugated 
antibodies, could provide evidence for co-localisation upon cellular stimulation 
in intact cells rather than cell lysates.
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Ligation of CD28 and CD3 receptors induces the association of SHIP with
the protein tyrosine phosphatase SHP-2 in DC.27 cells
SHIP has been widely documented to bind the protein tyrosine phosphatase 
SHP-2 following stimulation with cytokines and various growth factors (Sattler et 
al 1997). SHIP immunoprecipitates were shown to inducibly associate with 
SHP-2 following stimulation with anti-CD3/anti-CD28 mAb in DC.27 murine 
hybridoma T cells (figure 53). SHP-2 is detectable in basal/resting SHIP 
immunoprecipitates but levels are in general low. Upon CD28 stimulation a 
rapid association (< 1 minute) between SHIP and SHP-2 was seen which was 
sustained for 10 minutes. Equal loading was confirmed by stripping and 
reprobing the blots with an anti-SHIP polyclonal Ab that recognises C-terminal 
truncations of SHIP (i.e. p135/p145 SHIP). This data, albeit encouraging, was 
representative of a single experiment in a hybridoma T cell line and therefore 
should be viewed as preliminary and interpreted with caution. Results from 
similar experiments using T-lymphoblasts and DC.27 cells would be needed to 
confirm the possible association between SHIP and SHP-2.
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Figure 51: SHIP co-associates with p62dok following CD28 ligation. 2X107 per point DC.27 T 
cells expressing wild type hCD28+ were left unstimulated as a control (CTL) or stimulated with 
anti-CD28 mAb 9.3 at 1 pg/ml for the times indicated. Cells were lysed and pre-cleared lysates 
were subjected to immunoprecipitation with anti-SHIP mAb. Immunoprecipitates were resolved 
by SDS-PAGE and transferred to nitrocellulose and immunoblotted with anti-p62dok mAb. A 
lysate was included on the gel to verify if western blotting was successful. Blots were stripped 
and reprobed with anti-SHIP mAb to verify equal loading. Data was quantified by densitometry 
and expressed as a percentage of control (bottom panel). Data is from a single experiment 
representative of 3 others.
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Figure 52: SHIP co-associates
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Figure 52: SHIP co-associates with CD28-stimulated p62dok immunoprecipitates. 207 per point 
DC.27 T cells expressing wild type hCD28+ were stimulated with anti-CD28 mAb (9.3) at 1 
pg/ml for the times indicated. Cells were lysed and pre-cleared lysates were subjected to 
immunoprecipitation with anti-p62dok mAb. Immunoprecipitates were resolved by SDS-PAGE 
and transferred to nitrocellulose and immunoblotted with anti-SHIP Ab. Blots were stripped and 
reprobed with anti-p62dok mAb to verify approximate equal loading. Data was quantified by 
densitometry and expressed as a percentage of control (bottom panel). Data presented is from 
a single experiment representative of 2 others.
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Figure 53: Ligation of CD28 and CD3 receptors induces the association of



















Figure 53: SHIP co-associates with the protein tyrosine phosphatase SHP-2 following 
CD28/CD3 stimulation in DC.27 murine hybridoma T cells. 2x107 per point DC.27 T cells 
expressing wild type hCD28+ were either left unstimulated (CTL) or stimulated with anti-CD28 
mAb 9.3 at 1 pg/ml for the times indicated. Cells were lysed and pre-cleared lysates were 
subjected to immunoprecipitation with anti-SHIP mAb. Immunoprecipitates were resolved by 
SDS-PAGE and transferred to nitrocellulose and immunoblotted with anti-SHP-2 mAb. Blots 
were stripped and reprobed with anti-SHIP (which recognises c-terminal truncated isoforms of 
SHIP) polyclonal Ab to verify equal loading. Data is from a single representative experiment.
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SHIP does not co-associate with the adapter protein Grb-2 following CD28
stimulation in murine DC.27 hybridoma T cells.
The Grb-2/Sos regulatory complex is reported to bind to both CD28 and CD3 T 
cell receptors (Schneider et al 1995). The possibility of SHIP binding to Grb-2 
would provide a mechanism for coupling SHIP to CD28, thereby allowing it’s 
tyrosine phosphorylation by CD3/CD28-activated-PTK. Western blot analysis of 
SHIP immunoprecipitates from DC.27 cells stimulated with CHO-B7.1+ could 
not identify any recruitment of Grb-2 over a 10 minute stimulation period (figure 
54). Grb-2 is clearly visible in the CHO and DC.27 lysate controls and the 
subsequent strip and reprobe confirmed the presence of SHIP in the I.Ps 
derived from DC.27, but importantly not CHO, lysate.
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Figure 54: SHIP does not detectably co-associate w ith the adapter protein










. .r- •r- SC











Figure 54: SHIP does not detectably co-associate with the adapter protein Grb-2 following 
CD28 stimulation. 2x107 DC.27 cells stably expressing hCD28 were aliquoted and left 
unstimulated (CTL) as a control or stimulated with CHO-B7.1* cells at a ratio of 3 T cells: 1CHO- 
B7.1+ cell. Cells were lysed and pre-cleared lysates were subjected to immunoprecipitation with 
anti-SHIP mAb. Immunoprecipitates were resolved by SDS-PAGE and transferred to 
nitrocellulose and immunoblotted with anti-Grb2 polyclonal Ab. A CHO lysate was added to 
verify no SHIP is expressed in these cells. Blots were stripped and reprobed with anti-SHIP 
mAb to verify equal loading. Data is from a single experiment representative of 2 others.
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SHIP may co-associates with the adapter protein GRID following CD28
stimulation in DC.27 T cells
GRID is another adapter protein that is capable of binding to the tyrosine 
phosphorylated YXXM motif within the cytoplasmic tail of CD28 (Ellis et al 
2000). GRID thus competes with PI 3-K for the same binding sites on CD28, 
and mutation of tyrosine residues 173/200 of CD28 abrogates these protein 
interactions (Ellis et al 2000). SHIP is known from in vitro kinase assays (figure 
49) to potentially bind to phospho-proteins of approximately 44 kDa, the 
molecular weight of GRID. Therefore the capability of GRID to associate with 
SHIP following CD28 ligation was assessed.
Analysis of CD28-stimulated SHIP immunoprecipitates reveals that SHIP is able 
to recruit GRID in DC.27 expressing hCD28+ cells (figure 55). These protein 
interactions are first detected at around 10 minutes and are maximal at 30 
minutes post-CD28 ligation. It is interesting to note that SHIP association with 
p62dok is rapid and transient in nature whereas SHIP interaction with GRID 
occurs much later following stimulation. As reported previously (Ellis et al 2000), 
GRID, but not SHIP, was shown to associate with CD28 following receptor 
ligation at 5 minutes (figure 55). Equal loading was verified by stripping and 
reprobing with SHIP mAb.
This data alone, albeit encouraging, does not prove that an association between 
SHIP and GRID occurs in vivo. As discussed previously for the association 
between SHIP and p62dok, this would require similar additional experiments, 
which unfortunately were not performed due to time constraints.
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F igure 55: SHIP associates with the adapter protein GRID following CD28 stimulation. 2x107 
DC.27 cells stably expressing hCD28 were aliquoted and left unstimulated (CTL) as a control or 
stimulated with CHO-B7.1* cells at a ratio of 3 T cells: 1CHO-B7.1+ cell. In addition a lysate was 
added to verify the efficiency of western blotting and also the recruitment of GRID to CD28 i.ps 
as previously reported (Ellis et a l 2000). Cells were lysed and pre-cleared lysates were 
subjected to immunoprecipitation with anti-SHIP and anti-CD28 mAbs. Immunoprecipitates and 
lysates were resolved by SDS-PAGE and transferred to nitrocellulose and immunoblotted with 
anti-GRID polyclonal Ab. Blots were stripped and reprobed with anti-SHIP mAb to verify 
approximate equal loading. Data is from a single experiment representative of 2 others.
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PTEN co-associates with in vitro protein kinase activity following CD28
ligation with B7.1 in DC.27 T cells
PTEN is a crucial regulator of D-3 phosphoinositides and directly antagonises 
PI 3-K signalling. The role of this phosphatase and its coupling to signalling 
complexes in T-lymphocytes is unclear. Unlike SHIP, PTEN does not become 
inducibly tyrosine phosphorylated and is thought to reside at the plasma 
membrane in resting unstimulated cells (Cantley et al 1999). Evidence 
described thus far in this study has revealed that PTEN is not expressed in 
Jurkat, CEM and MOLT-4 T cell lines, and that this lack of expression may have 
consequences for D-3 phosphoinositide turnover and for the regulation of key PI 
3-K dependent signalling enzymes including PKB. It is as yet unclear if CD28 
can signal to PTEN, inducing protein-protein associations and/or regulating its 
phosphatase activity. The C-terminus of PTEN contains a cluster of 
serine/threonine residues of which some can be phosphorylated. Mutations of 
these residues reduced the steady-state levels of PTEN and its half-life 
(Vazquez et al 2000) suggesting that phosphorylation of PTEN may mediate the 
regulation of PTEN. With the knowledge that SHIP can co-associate with in vitro 
kinase activity, PTEN immunoprecipitates from non-stimulated and CD28- 
stimulated DC.27 T cells was assayed for in vitro kinase activity.
PTEN immunoprecipitates, derived from DC.27 cells, were found to be 
associated with kinase activity stimulation with the B7.1 ligand (figure 56). In 
contrast, in vitro kinase activity was found to be virtually absent from PTEN i.ps 
from resting unstimulated DC.27 cells. Following CHO-B7.1+ stimulation, 
induced kinase activity could be detected at 1 minute post-stimulation. This 
activity was maximal at 5 minutes and sustained for 10 minutes. Prominent 32P 
phosphoproteins at molecular weights of 150 kDa, 85 kDa, 72 kDa, 56 kDa and 
40 kDa were revealed to co-associate with PTEN following CD28 ligation. The 
identity of these co-associating proteins is not known although [32p]56 kDa could 
be PTEN itself. Interestingly, the labelled protein band at 150 kDa shares a 
similar molecular weight to SHIP (145 kDa). The possible identification of these 
potential unknown co-assocoating proteins may yield interesting clues to how 
CD28 signals to and/or possibly regulates PTEN. The p85 immunoprecipitate,
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was used as a positive control for the assay, gave identifiable phosphoprotein 
bands of 85 and 110 kDa, representing the adapter and catalytic subunits of PI 
3-K respectively as a result of autophosphorylation (figure 56).
Again it’s unclear if the in vitro kinase activity observed in CD28-stimulated 
PTEN immunoprecipitates is through serine/threonine and/or tyrosine kinases 
due to the limitations of the assay. If these experiments were to be repeated 
inhibitors, e.g. those which block tyrosine kinase activity (herbimycin) or PKC 
inhibitors, could be included in the assay and may aid identification of the class 
of kinase possibly associating with PTEN. The data presented here is 
insufficient to prove that CD28 signals to PTEN and other experiments are 
required to prove this hypothesis. These might include assaying 
unstimulated/CD28-stimulated PTEN immunoprecipitates for in vitro lipid kinase 
activity towards a phosphatidylinositol substrate, and assessing the 
phosphatase activity of unstimulated/CD28-stimulated PTEN 
immunoprecipitates activity against lns(1,3,4,5)P4 (IP4). This would reveal 
whether or not PI 3-K is recruited to PTEN in a CD28-dependent manner and 
whether if ligation of CD28 can upregulate, or indeed downregulate, PTENs 
dephosphorylation of IP4 in vitro.
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Figure 56: PTEN co-associates w ith  in vitro protein kinase activity
fo llow ing CD28 ligation w ith B7.1 in DC.27 T cells.
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Figure 56: PTEN co-associates with in vitro protein kinase activity following CD28 ligation with 
B7.1 in DC.27 murine T cells. 2X107 DC.27 cells stably expressing hCD28 were aliquoted and 
left unstimulated as a control or stimulated with CHO-B7.1* cells at a ratio of 3 T cells: 1CHO- 
B7.1+ cell. Cells were lysed and pre-cleared lysates were subjected to immunoprecipitation with 
anti-PTEN mAb or p85 mAb (used as a positive control for the assay). Immunoprecipitates were 
washed and reconstituted in kinase buffer with 1 pCurie of 32P yATP for 20 minutes as 
described in materials and methods. Immunoprecipitated proteins were resolved on a 7%-15% 
gradient gel and incorporated 32P was assessed by autoradiography. Prominent unidentified 
‘hot’ phospho-proteins, of varying molecular weight, co-immunoprecipitating with PTEN is 
shown in arrows. Data are from a single experiment representative of three others.
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Summary of results
• SHIP is tyrosine phosphorylated following stimulation with anti-CD28 9.3
mAb and the natural ligands CHO-B7.1+ and CHO-B7.2+ in DC.27
hybridoma T cells.
• SHIP is tyrosine phosphorylated following stimulation of CD2 and CD3 and 
by human-recombinant lnterlukin-2 in DC.27 T cells and T-lymphoblasts. 
Stimulation of CD28 and CD3 receptors with appropriate antibodies in 
combination enhanced tyrosine phosphorylation of SHIP when compared 
with either antibody alone.
• SHIP expressed in the leukemic cell lines MOLT-4 and CEM can also be 
tyrosine phosphorylated upon CD28 and CD3 stimulation.
• SHIP Immunoprecipitates derived from T Leukemic cells and T-lymphoblasts
were shown to have constitutive in vitro phosphatase activity towards an
lns(1,3,4,5)P4 substrate. Phosphatase activity was not increased upon 
CD28 ligation.
• CD28 coupling to PI 3-K is not required for SHIP tyrosine phosphorylation as 
revealed by using CD28 mutants which are unable to bind PI 3-K.
• SHIP co-associates with in vitro protein kinase activity following CD28 
ligation and reveals the presence of a variety of phosphoproteins, the 
identities of which are unknown.
• CD28 stimulation may induce the association of SHIP with the adapters 
p62dok and GRID. The association between SHIP and p62dok was rapid 
whereas that between SHIP and GRID was delayed. Further experiments 
will be needed to confirm the observed in vitro associations also occur in 
vivo. Grb-2, another adapter important for relaying mitogenic signals, was 
found not to associate with SHIP following CD28 ligation.
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• PTEN, like SHIP, immunoprecipitates with in vitro kinase activity following 
CD28 stimulation. A variety of unknown phosphoproteins identified that 
appeared to co-associate with PTEN in a ligand dependent manner and 
whose function remains to be determined.
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Discussion
Expression of the inositol phosphatases SHIP and PTEN in leukemic T cell 
lines and T-lymphoblasts.
Both SHIP and PTEN are proposed to play important regulatory roles in PI 3-K 
signalling in haemopoietic ceils. The importance of these phosphatases is 
further highlighted in mice knockouts where PTEN'7' die in utero (Di Cristofano 
et al 1998) and SHIP"7' exhibit various lymphoproliferative disorders (Helgason 
et al 1998). Many leukemic cell lines are defective in key enzymes, including 
PTEN, which control cell cycle progression. The T-leukemic cell line Jurkat, a 
widely used cell model for T cell biology, lacks the phosphatase PTEN resulting 
in constitutive activation of PI 3-K mediated signal transduction pathways 
(Astoul et al 2001). This observation has raised questions as to the suitability of 
such cell lines as models for signal transduction research. This study described 
the expression of SHIP and PTEN at the mRNA and protein level in a variety of 
commonly used leukemic cell lines namely Jurkat, CEM, MOLT-4 and HUT 78 
as well as from SEB-activated-T-lymphoblasts derived from healthy volunteers. 
An attempt was also made at establishing the effect of differential SHIP/PTEN 
expression on basal and stimulated D-3 phosphoinositide lipid profiles and the 
effect, if any, on PI 3-K-dependent downstream signalling cascades.
Using RT-PCR it was found that all the cell lines examined expressed SHIP and 
PTEN mRNA. However this data conflicted with that on protein expression of 
these same phosphatases obtained by western blotting. Jurkat cells lacked both 
SHIP and PTEN phosphatases, which is consistent with previous published 
work (Shan et al 2000 and Edmunds et al 1999). In Jurkat cells, several 
mutations causing premature stop codons have been described which result in 
truncated proteins that are highly unstable and hence rapidly degraded (Sakai 
et al 1998). The data presented here represents the first description of 
SHIP/PTEN phosphatase expression in other commonly used T-leukemic cell 
lines. MOLT-4 and CEM cells were shown to lack PTEN but express SHIP. It 
could still be argued that Jurkat, MOLT-4 and CEM cells still express the 
phosphatases in question, but below the limit of detection for Western blotting.
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In contrast, HUT 78 cells and T-lymphoblasts expressed both SHIP and PTEN 
together. The expression of other relevant inositol phosphatases such as SHIP2 
was not investigated in this study primarily due to the lack of suitable antibodies. 
The phosphatase SHIP 2 has been reported to be co-expressed with SHIP in T 
lymphocytes (Bruyns et al 1999), however it is presently undetermined if SHIP2 
is expressed at detectable levels, if at all, in the leukemic cell lines used in this 
study. It is thus possible that the expression of SHIP 2 might be able to 
compensate to some extent for the loss of SHIP in Jurkat cells. However, the 
observed D-3 phosphoinositide profiles in Jurkat (discussed later) suggest that 
this is unlikely to be the case.
D-3 Phosphoinositde profiles in Leukemic T cell lines and T-lymphoblasts 
and consequences on downstream PI 3-K-driven signalling cascades .
Measurement of D-3 phosphoinositide levels as achieved by in vivo 32P labelling 
revealed that radiolabelled-Jurkat cells had high basal levels of the PI 3-K 
product PI(3,4,5)P3 when compared with the other cell lines used in this study; 
an observation consistent the findings of Ward et al (1995). Despite the fact that 
Jurkat PI(3,4,5)P3 levels can increase 10-fold following CD28 stimulation, it is 
becoming increasingly accepted that Jurkat cells have constitutively active PI 3- 
K signalling (Astoul et al 2001). Unstimulated Jurkat cells revealed considerable 
levels of phospho-PKB that did not increase detectably upon stimulation. This 
observation was mirrored by phospho-GSK3 levels, a downstream effector of 
PKB, which were also high in unstimulated Jurkat cells. Interestingly, the high 
levels of PI(3,4,5)P3and phospho-PKB could be abolished by pre-treatment with 
the PI 3-K inhibitor, LY 294002, which supports the notion that phospho-PKB 
levels are intimately linked to Pl(3,4,5)P3 levels. However complete abrogation 
of basal phospho-PKB levels in Jurkat cells required pre-treatment with LY 
294002 for up to 2 hours reflecting the high basal levels of phospho-PKB in 
these cells and the slow metabolism of phosphoinositides resulting from the 
lack of expression of SHIP and PTEN. Detectable levels of Pl(3,4,)P2, a 
bioactive second messenger in it’s own right, were observed in Jurkat cells, but 
were very low when compared with those of Pl(3,4,5)P3. This is reflected in a 
ratio of the two lipids. Jurkat cells had an unstimulated PI(3,4,5)P3: Pl(3,4,)P2 
ratio of 27 which increased considerably to 152 upon CD28 stimulation.
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The lack of expression of SHIP in Jurkat which generates PI(3,4,)P2 via
dephosphorylation of PI(3,4,5)P3, may explain the relatively low levels of
PI(3,4,)P2 observed in both unstimulated and CD3/28-stimulated Jurkat cells.
The MOLT-4 and CEM leukemic cell lines (SHIP+/PTEN') had a different 
phosphoinositide profile to Jurkats. Basal Pl(3,4,5)P3 levels were considerable 
in MOLT-4 and CEM cells, but they were not as high as that observed in Jurkat 
cells. Stimulation of the CD28 receptor by CHO-B7.1+ resulted in the rapid and 
sustained accumulation of Pl(3,4,5)P3, indicating that the CD28 receptor 
functionally couples to PI 3-K in these cell lines, as observed in other cell 
models (Ward et al 1992). Although it is not valid to compare directly 
phosphoinositide levels between different cell lines, this approach does allow a 
comparison to be made of phosphoinositide profiles and relative Pl(3,4,5)P3: 
PI(3,4,)P2 ratios obtained from the different cell types.
MOLT-4 and CEM cells exhibit substantial basal levels of Pl(3,4)P2, the 
metabolic product of SHIP, which increases markedly upon CD28 ligation with 
CHO-B7.1+. The higher levels of Pl(3,4,)P2 in these cells are highlighted in 
substantially lower basal Pl(3,4,5)P3: Pl(3,4 ,)Pz ratios (CEM 1.3, MOLT-4 3.5) 
when compared with that of Jurkat. These observations are consistent with the 
lack of PTEN but presence of SHIP, which drives the unopposed catalytic shunt 
of Pl(3,4,5)P3 to Pl(3,4)P2. Considerable levels of basal phospho-PKB were 
observed in CEM and MOLT-4 cells that may, again reflect the considerable 
levels of basal D-3 phosphoinositides. As with Jurkat cells, LY 294002 could 
abolish basal phospho-PKB levels in MOLT-4 and CEM cells over time. In 
contrast to the apparent saturated nature of PI 3-K signalling observed in Jurkat 
cells, stimulation of CD28/CD3 in CEM and MOLT-4 cells did result in the 
increased phosphorylation status of PKB, albeit modestly, above basal levels.
There are several recently identified proteins which contain PH domains which 
bind specifically with high affinity towards Pl(3,4)P2 but not Pl(3,4,5)P3; the 
adapters DAPP and TAPP (Dowler et al 2001). The fact that MOLT-4 and CEM 
cells contain considerable basal levels of PI(3,4)F2, which increases upon 
cellular stimulation, indicates that these cell lines are a more suitable surrogate
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T cells model in which to assess the function of novel Pl(3,4)P2-dependent 
signalling cascades and also the unknown functional role of the novel 
PI(3,4)P2-interacting adapter proteins, including the recently identified proteins 
TAPP/DAPP.
The T-helper like leukemic cell line HUT 78 and T-lymphoblasts were positive 
for SHIP and PTEN at both mRNA and protein level. Both cell lines had lower 
levels of basal PI(3,4,5)P3/cell when compared with Jurkat cells. In particular the 
HUT78 cell line had very low levels of D-3 phosphoinositides, which only 
moderately increased upon anti-CD3 mAb and CHO-B7.1+ stimulation. 
Subsequent FACS analysis, however, revealed that they expressed relatively 
low levels of CD28/CD3 (< 10% when compared with isotype matched controls). 
PI(3,4)P2 levels in HUT 78 cells could hardly be detected upon in vivo lipid 
labelling. This may be attributed to the expression of both SHIP and PTEN, but 
could equally be explained by the cells having a naturally lower 
phosphoinositide pool compared to the other cell lines studied. As a result of the 
low phosphoinositides measured in the HUT 78 cell line, basal phospho- 
PKB/GSK3 levels were, predictably, absent indicating the importance of 
Pl(3,4,5)P3 in maintaining phospho-PKB levels.
T-lymphoblasts that also express SHIP and PTEN had D-3 phosphoinositide 
levels and basal/stimulated PI(3,4,5)P3: Pl(3,4,)P2 ratios dissimilar to those 
observed in HUT 78 (T-blast 10, HUT 78 30). Basal levels of Pl(3,4,5)P3 in T 
lymphoblasts increased rapidly upon stimulation with anti-CD3 mAb, IL-2 (20 
ng/ml) and with CHO-B7.1+. Phospho-PKB could also be observed in 
unstimulated T-lymphoblasts and the amount seen increased upon CD28 
stimulation. The possible roles of SHIP and PTEN in determining the D-3 
phosphoinositide profile of the different cell types studied are summarised 
further in figure 57.
The Spearman’s rank correlation test was applied to see if there was a positive 
association between basal levels of PI(3,4,5)P3 and phospho-PKB levels 
(expressed as a ratio of total PKB) in the cell types studied. The observed 
correlation was statistically significant (p = 0.05) suggesting that higher basal 
levels of PI(3,4,5)P3 contribute to higher relative levels of phospho-PKB: total
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PKB ratios, at least in T lymphocytes. The result of the analysis therefore 
indirectly reveals the support of a crucial role for PTEN and SHIP in the 
metabolism of PI(3,4,5)P3 metabolism and, thereby, in the regulation of the 
phosphorylation status, and hence, activity of PKB.
There is some controversy as to whether PI(3,4,5)P3 or Pl(3,4)P2 is the critical 
second messenger that mediates the membrane recruitment of PKB and its 
associated kinases in vivo. Whilst the PH domain has been reported to have 
dual specificity, recent in vitro data suggests that Pl(3,4,)P2 binds PKB with a 
has a higher affinity than PI(3,4,5)P3 (Franke et al 1997). More recently, studies 
using SHIP knockout mice have revealed that Pl(3,4)P2 is essential for the 
phosphorylation and activation of PKB Ser473 (Scheid et al 2002). In contrast, 
the data presented here suggest that Pl(3,4,5)P3 is a critical regulator of PKB 
activation (as seen with high basal Pl(3,4,5)P3 levels and saturated PKB 
signalling in Jurkat cells). However the possibility of PKB binding to the low 
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Figure 57: Effect of SHIP/PTEN expression on D-3 phosphoinositide levels in T-leukemic cell 
lines. Jurkat cells, which express neither SHIP or PTEN, exhibit high basal levels of PI(3,4,5)P3 
relative to PI(3,4)P2 perhaps, in part, due to the lack of SHIP. Jurkats are thus inefficient in 
metabolising PI(3,4,5)P3 and have high basal levels of phospho-PKB. CEM/MOLT-4 cell lines 
express SHIP but not PTEN and are therefore able to shunt PI(3,4,5)P3 towards PI(3,4,)P2 
reflected in a low PI(3,4,5)P3: PI(3,4)P2 ratio. HUT 78 cells express both SHIP and PTEN and, 
according to this model, should be able to rapidly metabolise Pl(3,4,5)P3 more efficiently than 
the other leukemic cell lines, hence the lower observed level of basal D-3 phosphoinositides. 
The relative strength of the arrows estimates the relative production of D-3 phosphoinositide 
observed in each of the T leukemic cell lines.
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Regulation of SHIP and PTEN by T cell surface receptors
The 5’ phosphatase SHIP has previously been reported to be a downstream 
target for both CD3 (Liu et al 1997) and CD28 receptors (Edmunds et al 1999). 
Originally identified as 145 kDa tyrosine phosphoprotein in appropriately 
stimulated T cell lysates (Damen et al 1993). SHIP is now recognised as a 
constitutively active cytosolic phosphatase that moves to the plasma membrane 
following cellular stimulation (Rohrschneider et al 2001). In B cells and other cell 
types, SHIP is able to translocate to the plasma membrane via a direct 
interaction with cell surface receptors containing tyrosine phosphorylated ITIMs 
(e.g. the FcyRllb receptor), thus placing it into proximity to its substrates 
(Bolland et al 1998). The precise molecular mechanisms responsible for the 
subcellular translocation of SHIP to the plasma membrane in T cells remain to 
be determined. SHIPs translocation from the cytoplasm to the plasma 
membrane in response to CD28 ligation has been observed in murine 
hybridoma T cells (Edmunds et al 1999). However, CD28 has no ITIMs or other 
recognisable motifs, that would allow its interaction with SHIP and the lack 
detectable association between SHIP and CD28 has been confirmed by 
western blotting of CD28 I.Ps (Edmunds et al 1999). The question therefore 
arises: how does CD28 signal to SHIP?
In this investigation it was shown that ligation of CD28 with mAb or B7 ligands 
and CD3 with mAb can lead to the tyrosine phosphorylation of SHIP in a variety 
of leukemic T cell lines (excluding Jurkat cells which do not express SHIP), 
murine hybridoma T cells and in human T-lymphoblasts. Co-ligation of CD28 
and CD3 in murine hybridoma T cells resulted in increased tyrosine 
phosphorylation of SHIP compared to ligation of with either receptor alone. 
CD28-induced tyrosine phosphorylation of SHIP was independent of PI 3-K 
recruitment to the receptor. This suggests that a PI 3-K-dependent PTK is 
probably not responsible for the tyrosine phosphorylation of SHIP observed 
following CD28 stimulation and secondly, the that the formation of D-3 
phosphoinositides are not essential for SHIP phosphorylation.
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Also presented here is the first known evidence for the tyrosine phosphorylation 
of SHIP following CD2 and IL-2 receptor stimulation in T-lymphoblasts. The T 
cell receptors CD3, CD28 and CD2 are all known to cluster in the mature 
immunological synapse (IS) formed with antigen presenting cells. It is thus 
reasonable to hypothesise that co-engagement of these receptors by their 
physiological ligands present on APC would result in high local levels of tyrosine 
phosphorylated SHIP. This in turn would produce significant local levels of 
Pl(3,4)P2 within the vicinity of the IS. The potential increased accumulation of 
Pl(3,4)P2 in the IS may be sufficient to initiate PI(3,4)P2-dependent signalling 
cascades, involving adapter proteins with PH domains specific for PI(3,4)P2 
such as DAPP-1 and TAPP (figures 58/59). Consistent with this possibility, 
additive tyrosine phosphorylation of SHIP using soluble anti-CD28 and CD3 
signalling mAbs has been shown to occur in murine hybridoma T cells. SHIP 
therefore has the potential to increase the diversity of PI 3-K signalling via 
mediating the shunt from PI(3,4,5)P3 to PI(3,4)P2-driven signalling pathways 
(figure 54). SHIP, therefore has the potential to negatively regulate PI(3,4,5)P3 
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Figure 58: Proposed role for SHIP in the mature IS. Multiple engagement of clustered T cell 
molecules by their cognate ligands on the APC initiates cell signalling, including the tyrosine 
phosphorylation of SHIP and the local accumulation of PI(3,4)P2. Specific PH-domain containing 
adapter proteins including the recently identified TAPP and DAPP and other as yet 
uncharacterised signalling proteins, have the potential to initiate poorly characterised PI(3,4)P2- 
dependent signalling cascades.
SHIP co-associating proteins in T cells.
SHIP contains multiple domains capable of mediating a plethora of protein- 
protein interactions and was originally identified through its capacity to bind to 
She following cytokine stimulation (Damen et al 1996). SHIP, a target for CD28- 
activated PTKs, has been shown to co-immunoprecipitate with several tyrosine- 
phosphorylated proteins with predicted molecular masses of 62 and 100 kDa 
(Edmunds et al 1999). Data presented here suggests that the multi-functional 
adapter protein p62dok bind to SHIP immunoprecipitates in T cells following 
stimulation with anti-CD28 mAb. This particular adapter is known to be a 
downstream target for CD28-activated-PTK but not TCR-activated-PTK (Nunes 
et al 1996). SHIP was also found to associate in the reverse, p62 
immunoprecipitates further supporting an association between these two
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proteins. Similar associations have been reported to occur in B cells (Tamir et al 
2000), and it has been postulated that p62dok and SHIP are key mediators of 
FcyRllb signalling in B cells (Ott et al 2002). SHIP binding to p62dok may provide 
a mechanism for SHIP’S translocation from the cytosol to the plasma membrane 
following CD28 stimulation, as p62dok contains a PH domain. However the fact 
that SHIP can still be tyrosine phosphorylated through stimulation of a CD28 
mutant unable to recruit PI 3-K suggests that the formation of D-3 
phosphoinositides and therefore the requirement for PH-domain containing 
adapter proteins, is not required for the translocation of SHIP. Another 
interesting observation regarding p62dok association with SHIP is that it is also 
known to associate with RasGAP proteins. These function to suppress active 
Ras GTP levels and therefore negatively regulate the mitogenic MAPK/Erk 
pathways (Tamir et al 2000). SHIP/p62dok regulation of Erk may contribute to 
CD28 signalling although further investigation is needed to confirm or refute this 
hypothesis. Other indirect evidence for SHIPs association with p62dok comes 
from the in vitro kinase assays. These showed that following CD28 stimulation, 
immunoprecipitation with anti-SHIP mAb revealed the presence of a 32-P 
labelled p62 phosphoprotein, which may be p62dok.
SHIP has been shown to bind to the adapter protein Grb2 in B cells (Harmer et 
al 1999) and has been postulated to negatively regulate the MAPK/Erk cascade 
through its ability to sequester regulatory adapter proteins (Tridandapani et al 
1997). In this study, no evidence was obtained to suggest an interaction of 
SHIP and Grb2 in T cells following CD28 stimulation. The recently identified 44 
kDa adapter protein GRID was shown to associate with SHIP 
immunoprecipitates following CD28 stimulation. GRID, along with PI 3-K, is able 
to interact with CD28 at the 173YXXM-consensus motif within the cytoplasmic tail 
and potentially regulate uncharacterised mitogenic signalling cascades (Ellis et 
al 2000). The data presented here is the first to provide evidence for an 
interaction between SHIP and GRID, although the mechanism and functional 
consequence remains to be determined. SHIP may act to sequester GRID away 
from the CD28 scaffold platform, thereby negatively regulating GRID signalling 
cascades. The mechanism(s) by which SHIP mediates these protein-protein 
interactions remains to be established. The observed associations may be 
direct or indirect, and perhaps mediated by an unidentified adapter protein. In a
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single experiment, SHIP was shown to rapidly and inducibly associate with the 
protein tyrosine phosphatase SHP-2 following cellular stimulation with anti- 
CD28/CD3 mAbs. The observed association was rapid and sustained. 
Interestingly similar observations have been observed in other signalling 
systems, most notably after stimulation with BCR/ABL growth factors (Sattler et 
al 1997). SHIP and SHP-2 are also known to bind to ITIM motifs within the 
FcyRllb receptor and mediate its inhibitory signalling (Sarmay et al 1999). Again 
the molecular nature of the protein interactions described is undefined, but 
SHP-2 may regulate the tyrosine phosphorylation of SHIP and other associated 
proteins, thereby regulating its activity. The protein-protein interactions SHIP 
exhibits following CD28 stimulation and their possible consequences are 
summarised in figure 59.
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Figure 55: SHIP protein-protein interactions following CD28 stimulation in T cells. Ligation of 
CD28 results in the activation of PTK, phosphorylation of the CD28 cytoplasmic tail, recruitment 
of PI 3-K and the formation of D-3phosphoinositides including PI(3,4,5)P3. CD28-activated-PTK 
also phosphorylates SHIP and the adapter p62dok perhaps inducing their association via the 
SH2 domain of SHIP (Tamir et al 2000). The PH domain of p62dok may serve to translocate 
cytoplasmic SHIP to the plasma membrane placing it in proximity to its substrates and resulting 
in the formation of PI(3,4)P2 which may activate other signal transduction pathways. The 
functional significance of SHP-2 and GRID binding to SHIP is uncertain. SHIP may possibly 
negatively regulate GRID function by sequestering it away from the CD28 scaffold, whereas 
SHP-2 may regulate the tyrosine phosphorylation status of SHIP and its binding proteins. The 
molecular nature of the various protein interactions is unclear.
CD28 stimulated-SHIP immunoprecipitates were shown to contain in vitro 
protein kinase activity. This kinase activity was low in unstimulated cells, with a 
marked and sustained increase following CD28 stimulation. Unknown 
phosphoproteins of varying molecular masses, including 62 kDa (p62dok?), 100 
kDa and 145 kDa, presumably SHIP, being observed to co-precipitate with 
SHIP. The 100 kDa 32-P phosphoprotein found to immunoprecipitate with SHIP 
following CD28 stimulation may be Gab2 (Grb2 adapter binding protein 2), the 
molecular weight of which is 97 kDa. Gab2 has been shown to associate with
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SHIP following IL-3 stimulation (Bone et al 2000). The in vitro kinase data 
presented here provides the first evidence that SHIP is able to inducibly 
associate with one or more proteins with kinase activity, although it is not known 
if this kinase(s) are tyrosine or a serine/threonine kinase. It is possible that the 
kinase(s) found to associate with SHIP might be responsible for its tyrosine 
phosphorylation following CD28 stimulation. A candidate tyrosine kinase is 
p56lc\  which has been shown to phosphorylate SHIP in T cells (Lamkin et al 
1997). SHIP also exhibited in vitro 5’ phosphatase activity towards 
lns(1,3,4,5)F4 resulting in the generation of the soluble metabolite lns(1,3,4)P3. 
Evidence is presented to suggest that this phosphatase is constitutively active 
and thus, in agreement with published data, it would seem that the translocation 
of SHIP to the membrane is the key factor regulating its access to substrates 
and hence biological activity (Rohrschneider et al 2000).
CD28 regulation of PTEN
In this investiagtion an attempt has been made to determine if PTEN is a 
downstream target for CD28 following stimulation. PTEN, unlike SHIP, is not a 
target for PTK and contains fewer recognised protein-protein interaction motifs. 
However, PTEN does contain PDZ domains that capable of mediating protein- 
protein interactions. The regulatory mechanisms governing PTEN function are 
poorly defined. Recent evidence, however, has shown that PTEN is under co­
stimulatory control in CD4+ primary T cells. Studies have shown that PTEN is 
upregulated at both mRNA and protein level following stimulation with CD28 
and CD2 and that it controls T cell proliferation (Harris et al 2002). In contrast, 
PTEN expression was high in lymphoma cells but remained CD28 and CD2 
unresponsive (Carsten et al 2002). Interestingly, this CD28 costimulatory 
upregulation of PTEN was not blocked by the PI 3-K inhibitor wortmannin, 
suggesting that upregulation is independent of PI 3-K signalling pathways 
(Carsten et al 2002). Data presented here show that PTEN immunoprecipitates 
contain in vitro protein kinase activity following CD28 stimulation. Furthermore, 
evidence was also obtained for recruitment and phosphorylation of several 
phosphoproteins (ranging in size from 150 - 40 kDa) induced upon CD28 
stimulation, which may be involved in the regulation of PTEN activity. A PTEN 
multimeric protein complex has been described and observed to elute at >600
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kDa in gel filtration columns (Vazquez et al 2001). Thus data described here are 
the first observations to reveal that CD28 can indeed signal to PTEN. The 
identities of the kinase and phosphoproteins immunoprecitating with PTEN 
following CD28 stimulation are unknown and warrant further investigation. Of 
added interest, one of the 32-P labelled phosphoproteins found to inducibly 
associate with PTEN following CD28 stimulation was of 145 kDa, the same 
molecular weight as SHIP. An association between these two phosphatases 
has never been described and unfortunately further analysis (western blotting) 
was not undertaken. It remains to be established whether stimulation of the 
TCR is also able to induce in vitro kinase activity and associating proteins in 
PTEN immunoprecipitates. PTEN has been reported to interact with focal 
adhesion kinase (Tamura et al 1999) and this may be a candidate kinase to co- 
precipitate with PTEN and is responsible for the observed in vitro kinase 
activity.
Unfortunately, in vitro phosphatase assays were not performed on PTEN 
immunoprecipitates for activity on the water soluble lns(1,3,4,5)P4. It would 
have been of interest to determine if PTEN immunoprecipitates from CD28 
stimulated lysates had increased phosphatase activity towards IP4 when 
compared with unstimulated control PTEN immunoprecipitates. It is therefore 
unknown if CD28 and other T cell surface co-stimulatory receptors (such as 
CD3) can increase or decrease the D-3 phosphatase activity of PTEN under in 
vitro conditions. However the in vitro kinase data does suggest a regulatory role 
for CD28 in PTEN function.
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Assessing the role of PPARy agonist on T-lymphocyte proliferation. 
Methods to measure T cell proliferation
Resting T lymphocytes require at least 2 signals to drive clonal expansion. The 
first signal is derived from a specific interaction between the TCR and antigen in 
complex with MHC proteins on the APC. Co-stimulatory receptors such as 
CD28 engaging with their respective B7 ligands provide signal 2. Activation and 
blast formation of T cells in an unphysiological setting can also be achieved by 
using pharmacological tools such as the phorbal ester, phorbal myristol acetate 
(PMA), and ionomycin in combination. A functional consequence of T 
lymphocyte activation is an increase in DNA synthesis, which can be measured, 
albeit indirectly, by assessing the T cells ability to incorporate 3H-thymidine into 
DNA. In recent years therapeutic interest has focused the potential anti­
inflammatory properties of PPARy agonists (for review see Kersten et al 2000). 
This is due to their ability to inhibit the production by monocyte inflammatory 
cytokines (Jiang et al 1998) and also inhibiting the activation of T-lymphocytes 
by blocking production of the T cell cytokine IL-2 (Yang et al 2000). This section 
will describe the effect of various PPARy agonists on the proliferation of resting 
primary T cells and T lymphoblasts.
Proliferation of primary T cells in response to CD3, CD28, CD3/CD28, PMA 
and PMA/CD28 signals.
Freshly purified primary T cells were assessed for their ability to proliferate in 
response stimulation with anti-CD28/CD3 mAb and phorbal ester (PMA) alone 
or in combination. As expected, ligation of the CD3 or CD28 receptors with anti- 
CD3/CD28 mAbs did not result in significant 3H-thymidine incorporation (figure 
60). Addition of both anti-CD3/CD28 antibodies together resulted in a 100-fold 
increase in 3H-thymidine incorporation and in the blast-cell formation (assessed 
microscopically). PMA added alone did not induce significant 3H-thymidine 
incorporation, but did so in the presence of a co-stimulatory signal (anti-CD28 
mAb) resulted in a 95-fold increase in 3H-thymidine incorporation that was 
increased to an extent comparable to that observed with combined anti-
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CD3/CD28 mAb treatment. These findings are consistent with previously 
published work in that naive primary T cells require at least 2 signals for 
proliferation with one emanating from the TCR-CD3 subunit and one from a co­
stimulatory molecule such as CD28.
Figure 53: Proliferation of primary T cells in response to CD3, CD28, 


























Figure 60: Proliferation of primary T cells in response to various mitogenic signals. 1 x 105 
primary T cells/well were aliquoted and stimulated as indicated with anti-CD3 (UCHT-1) and 
anti-CD28 (9.3) mAbs in the combinations described. Alternatively, T cells were stimulated with 
5 ng/ml PMA alone or in combination with anti-CD28 9.3 mAb. Data are the mean ± S.E.M of 
quintuplicate samples from a single experiment representative of at least 3 others.
Results 157
T cell proliferation studies: Effect of Peroxisome Proliferator-Activated
Receptor (PPAR) y agonists.
The PPAR family of receptors (a,(3 and y) are transcription factors and members 
of the nuclear receptor superfamily. The prostaglandin, 15-deoxy-A12,14 
prostaglandin J2 (PGJ2), a derivative of PGE2 and therefore downstream of 
cyclooxgenase-2 (COX2), is a natural ligand for PPARy. PPARy was initially 
implicated in the regulation of genes involved in lipid metabolism and adipocyte 
differentiation (Issemann et al 1990). The PPARy ligand troglitazone, a 
thiazolidinedione compound formerly used to treat type II diabetes but was 
withdrawn due to toxic side effects. The studies of Yang et al looked at the 
ability of various PPARy ligands to inhibit T lymphocytes stimulated with the 
pharmacological agents PMA and the mitogenic lectin phytoheamagglutinin 
(PHA). In this investigation I have sought to assess the role of PPARy ligands in 
inhibiting CD3/CD28, IL-2 and PMA/lonomycin-mediated proliferation of primary 
naive T cells as well as SEB-activated T-lymphoblasts.
The PPARy receptor is expressed at the protein level in SEB-activated T- 
lymphoblasts and T cell leukemic cell lines.
It has been published previously that mRNA for PPARy is expressed in 
peripheral blood T-lymphocytes (Greene et al 1995). Cell-equivalent lysates 
were prepared from T-lymphoblasts and the T cell leukemic cell lines Jurkat, 
CEM, MOLT-4 and HUT 78 and immunoblotted for PPARy using an anti-PPARy 
mAb which reacts with exclusively to the PPARyl isoform (figure 61). PPARy 
protein could be detected in the above cell lysates as revealed by Western 
blotting although expression was reduced in the MOLT-4 leukemic cell line. 
Rather than check protein expression levels of PPARy using cell equivalents, an 
alternative approach would be to load equal amounts of protein from the 
different cell lines (via Bradford assay for determining protein concentration). 
This would help verify if the reduced levels of PPARy observed in MOLT-4 cells 
compared to the other cell lines is real.
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Figure 61: The PPARy receptor is expressed at the protein level in SEB- 




Figure 61: Expression of PPARy in T cell lines. 107 of each cell line were washed, aliquoted and 
lysed in lysis buffer. The resultant cell lysates were acetone precipitated and the precipitated 
proteins boiled in lamelli sample buffer. Proteins were resolved by SDS-PAGE and transferred 
onto nitrocellulose and immunoblotted with an anti-PPARy (which reacts with the PPARy-1 
isoform) mAb as described in Materials and Methods. Results are from a single experiment 
representative of two others.
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The PPARy ligands troglitazone and 15dPGJ2 but not ciglitazone inhibit
CD3/CD28 co-stimulation in primary T cells.
Transformation of purified, resting T lymphocytes could be achieved by the 
addition of anti-CD3/CD28 mAbs (1 pg/ml) covalently bound to M-450 
dynabeads or by treatment with PMA/ionomycin (5 ng/ml and 1 pM 
respectively). Primary T cell proliferation could be potently inhibited by pre­
treatment with the naturally occurring PPARy ligand 15dPGJ2 (figure 62). 
Inhibitors used were added before stimulating cells and were present for the 
remainder of the proliferation assay. The thiazolidinedione, troglitazone was 
able to inhibit CD3/28 co-stimulation at higher doses (30 pM) but interestingly 
had no effect on PMA/lonomycin stimulation. In contrast, and consistent with 
previous findings (Yang et al 2000), ciglitazone, which is structurally related to 
troglitazone, had no inhibitory effects, on primary T cell proliferation stimulated 
with CD3/CD28 or PMA/lonomycin (figure 62).
Of the PPARy agonists examined, 15dPGJ2 appeared to be the most potent 
with an almost complete abrogation of 3H-thymidine incorporation observed at 
10 pM. The IC50 for inhibition of CD3/CD28 co-stimulation by 15dPGJ2 and 
troglitazone was 0.8 pM and 5 pM respectively (figure 63a). The estimated IC50 
for 15dPGJ2-mediated inhibition of PMA/lonomycin stimulation of primary T cell 
proliferation was 3 pM, slighter higher than its predicted IC50 for CD3/CD28 
inhibition (figure 63b).
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Figure 62: Effect of PPARy ligands on CD3/CD28 and PMA/lonomycin 
induced primary T cell proliferation.
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Figure 62: Effect of PPARy ligands on CD3/CD28 and PMA/lonomycin induced primary T cell proliferation. 
105 primary T cells were aliquoted and pre-treated for 30 minutes with the PPARy ligands as indicated 
(Inhibitors were present with cells for remainder of assay). Cells were stimulated with either 1 gg anti- 
CD3/CD28 bound to M-450 dynabeads at a ratio of 1 bead to 1 cell or with 5 ng/ml PMA and 1 gM 
lonomycin as described in Materials and Methods. Cells were incubated for 48 hours at 37°C and then 
pulsed for a further 12 hours with 1 g curie [3H]-thymidine. Cells were harvested onto filter plates, washed 
and thymidine incorporation was assessed using a scintillation counter. Data are the mean data ± S.E.M 3 
independent experiments. * *  = p value 0.010, *  = p value of 0.005 and represent a significant difference 
compared to appropriate positive control.
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Figure 63a: Percentage inhibition of CD3/CD28-mediated proliferation by 
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F igure 63a/b: Percentage inhibition of CD3/CD28 mediated proliferation by PPARy ligands 
15dPGJ2 (yellow line), troglitazone (purple line) and ciglitazone (blue line) in primary T cells and 
also PMA/ionomycin-mediated proliferation by the PPARy ligand 15dPGJ2 (blue line bottom 
panel). Mean proliferation data generated from figure 63 were used to calculate inhibitory 
effects of PPARy ligands as a percentage of stimulated cells without PPARy ligand (positive 
control). Data are from mean pooled data from 3 independent experiments.
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The PPARy ligands troglitazone and 15dPGJ2 but not ciglitazone inhibit
CD3/CD28 co-stimulation in SEB-activated T-lymphoblasts.
Treatment of T lymphoblasts with the various PPARy ligands tested gave similar 
results to those obtained using primary T cells. Both 15dPGJ2 and troglitazone 
were able to inhibit CD3/CD28 induced [3H]-thymidine incorporation. Again, 
troglitazone was less potent when compared with 15d-PGJ2, only effective at 
inhibiting CD3/CD28 T lymphoblast proliferation at concentrations of >10 pM 
with almost complete inhibition being observed at 100 pM (figure 64). However 
it cannot be ruled out that these high concentrations of troglitazone may been 
toxic and/or pro-apoptotic. The natural PPARy ligand 15d-PGJ2 seemed to be 
more effective at inhibiting proliferation at lower concentrations. Ciglitazone, as 
in the case of primary T cells, was ineffective in inhibiting CD3/CD28 
costimualtion of T-lymphoblasts even at higher concentrations of upto 20 pM 
(figure 64).
The IC50 of 15dPGJ2 and troglitazone in inhibiting CD3/CD28-mediated T- 
lymphoblast proliferation from the data generated in figure 64 was 5 pM and 18 
pM respectively (figure 65). It is apparent that the IC50 for 15dPGJ2 is similar 
(i.e. in low micromolar range) in both primary T cells and T-lymphoblasts. In 
contrast, the IC50 for troglitazone is slightly higher in T-blasts when compared 
with that obtained for primary T cells. It would have been of great interest to see 
if the PPARy ligands used in this study could inhibit PMA/lonomycin-mediated 
proliferation of T-lymphoblasts but unfortunately this was not done due to time 
constraints.
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Figure 6 4 :  The P P A R y  ligands troglitazone and 15d-PGJ2 but not 
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Figure 64: The PPARy ligands troglitazone and 15dPGJ2 but not ciglitazone inhibit CD3/CD28 
co-stimulation in SEB-activated T-lymphoblasts. 105 T lymphoblasts were aliquoted and pre­
treated for 30 minutes with the PPARy ligands as indicated (Inhibitors were present with cells for 
remainder of assay). Cells were stimulated with 1 pg anti-CD3/CD28 bound to M-450 dynabeads 
as described in Materials and Methods. Cells were incubated for 48 hours at 37°C before being 
pulsed overnight with 1 p curie [3H]-thymidine. Cells were harvested onto filter plates, washed 
and thymidine incorporation was assessed using a (3-scintillation counter. Data are the mean 
pooled data ± S.E.M of 3 experiments. .** = p value 0.010, * = p value of 0.005 and represent a 
significant difference compared to appropriate positive control.
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Figure 65: Inhibition of CD3/CD28-mediated proliferation by PPARy ligands 15dPGJ2 (yellow 
line), troglitazone (blue line) and ciglitazone (purle line) in T-lymphoblasts. Mean proliferation 
data generated from figure 65 were used to calculate inhibitory effects of PPARy ligands as a 
percentage of stimulated cells without PPARy ligand (positive control). Data are from pooled 
data from 3 independent experiments.
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Troglitazone and 15dPGJ2 inhibit IL-2 driven proliferation in T- 
lymphoblasts
Transformation of peripheral primary T cells into T lymphoblasts by the 
superantigen SEB induces the surface expression of the IL-2 receptor. 
Engagement of the cytokine IL-2 with its receptor drives T cell proliferation 
(Smith K et al 1990). The ability of the PPARy ligands troglitazone and 15dPGJ2 
to inhibit IL-2 driven T-blast proliferation was investigated in order to determine 
if IL-2 stimulated T cells were sensitive to PPARy-mediated inhibition. 
Subsequent experiments revealed that both PPARy ligands could inhibit IL-2 
(20 ng/ml) mediated-[3H]-thymidine incorporation in SEB-activated T- 
lymphoblasts, with 15dPGJ2, again, being slightly more potent than troglitazone 
(figure 66). Troglitazone significantly inhibited IL-2-mediated proliferation at 
concentrations > 10 pM, with almost complete inhibition at 100 pM. The natural 
PPARy ligand 15dPGJ2, had significant inhibitory effects on T blast proliferation 
at concentrations as low as 1 pM. These experiments involving 15dPGJ2 would 
have benefited with an extended lower range of concentrations of 15dPGJ2 (i.e. 
low nanomolar range) to get a more accurate assessment of inhibition of IL-2 
mediated T-lymphoblast proliferation by this PPARy agonists.
The estimated IC50 values for the inhibition for both 15dPGJ2 and troglitazone 
generated from this data were 0.4 pM and 15 pM respectively (figure 67). The 
effect of ciglitazone on IL-2 dependent proliferation of T-lymphoblasts was 
unfortunately not tested. Estimated IC50 for PPARy ligands on T cell proliferation 
are summarised and tabulated in table 15.
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Figure 66: The PPARy ligands troglitazone and 15dPGJ2 inhibit IL-2-mediated proliferation in 
SEB-activated T-lymphoblasts. 105 T lymphoblasts were aliquoted and pre-treated for 30 
minutes with the PPARy ligands as indicated (Inhibitors were present with cells for remainder of 
assay). Cells were stimulated with IL-2 (20 ng/ml) described in Materials and Methods. Cells 
were incubated for 48 hours at 37°C before being pulsed overnight with 1p curie [3H]-thymidine. 
Cells were harvested onto filter plates, washed and thymidine incorporation was assessed using 
a 3-scintillation counter. Data are the mean pooled data ± S.E.M of 2 other independent 
experiments. ** = p value 0.010, * = p value of 0.005 and represent a significant difference compared to 
appropriate positive control.
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Figure 67: Inhibition of IL-2-mediated proliferation by the PPAR y ligands 
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Figure 67: Inhibition of IL-2-mediated proliferation by the PPARy ligands troglitazone (purple 
bar) and 15dPGJ2 (blue bar) in T-lymphoblasts. Mean proliferation data generated from figures 
66 were used to calculate inhibitory effects of PPARy ligands as a percentage of stimulated cells 
without inhibitor (positive control). Data are the pooled mean data 2 separate experiments.
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Table 15: IC50 values for inhibition of primary T cell/ T-lymphoblast 
proliferation upon pre-treatment with the PPARy agonists








15dPGJ2 4 1 ND 1.5 0.1
TROGLITAZONE NIO 5 ND 23 15
CIGLITAZONE NIO NIO ND NIO ND
Table 14: Estimated IC50 values for inhibition of primary T cell/ T-lymphoblast proliferation upon 
pre-treatment with the PPARy agonists 15dPGJ2, troglitazone and ciglitazone. Abbreviations 
used: NIO= no inhibition observed, ND = undetermined.
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T-lymphoblast CD3/CD28 co-stimulatory proliferation can be inhibited by 
pre-treatment and post-treatment of the PPARy ligands 15dPGJ2 and 
troglitazone.
Cell signalling experiments, involving pharmacological inhibitors, are usually 
performed by pre-treating cells with the appropriate inhibitor for an appropriate 
time before a stimulus is added. In the proliferation studies described thus far, T 
cells have been pre-treated with PPARy ligands for 30 minutes. PPARy-treated 
T cells were then stimulated with CD3/CD28-coated M450-dynabeads, 
PMA/ionomycin or IL-2. The PPARy agonists then remained with the cells for 
the duration of the assay. Additional experiments were designed to determine if 
untreated T-lymphoblasts, which had then been co-stimulated with CD3/CD28- 
coated dynabeads, and therefore actively proliferating, for set time periods were 
resistant to inhibition by 15dPGJ2 and troglitazone when added at later time 
points. It was found that the delayed addition of either PPARy ligands 
(troglitazone or 15dPGJ2) to CD3/CD28 stimulated samples was able to 
significantly inhibit the incorporation of [3H]-thymidine (figure 68).
Troglitazone (10 juM) was able to inhibit T-lymphoblast proliferation to control 
levels even after 48 hours post-CD3/CD28 co-stimulation. However it is 
acknowledged that a toxic effect of troglitazone used at these concentrations on 
T lymphoblasts cannot be ruled out. 15dPGJ2 (10 juM), was able to reduce 
proliferation when added up to 24 hours post-stimulation but was ineffective at 
the 48 hours time point (figure 68). This may be due to the instability of 
15dPGJ2 as once it was reconstituted it was then stored at 4°C for the 
remainder of the time course of the assay. These results may suggest that both 
troglitazone and 15dPGJ2 are able to override and inhibit established 
proliferative co-stimulatory signals in T cells. However the data, albeit 
encouraging, was obtained in a single experiment and must therefore be 
interpreted with caution.
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Figure 68: T-lymphoblast CD3/CD28 mediated-proliferation 
inhibited by pre-treatment or post-treatment of the PPARy 
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Figure 68: Co-stimulatory-mediated proliferation of T-blasts can be inhibited by pre- or post­
treatment with the PPARy ligands 15dPGJ2(10 pM) or troglitazone (10 pM). 105 T lymphoblasts 
were aliquoted and pre-treated or post-treated with the PPARy ligands at the times indicated. 
Cells were stimulated with anti-CD3/CD28 bound to M-450 dynabeads at ratios described in 
Materials and Methods. Cells were incubated for 48 hours at 37°C before being pulsed 
overnight with 1p curie [3H]-thymidine. Cells were harvested onto filter plates, washed and 
thymidine incorporation was assessed using a p-scintillation counter. This data is from a single 
experiment. ** = p value 0.010, * = p value of 0.005 and represent a significant difference compared 
to appropriate positive control.
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The P P A R y  ligand troglitazone doesn’t inhibit proliferation in the leukemic 
cell lines Jurkat, CEM, MOLT-4 and HUT 78.
Western blot analysis of lysates from the above leukemic cell lines reveals the 
expression of P P A R y  protein (figure 6 1 ) .  It was decided to investigate, therefore 
whether, the P P A R y  ligand troglitazone (used at 1 0  j u M )  could inhibit the 
proliferation of these leukemic cell lines in a manner similar to that observed in 
C D 3 / 2 8  stimulated primary T cells/T-lymphoblasts derived from normal 
volunteers (figures 6 2 / 6 4 ) .  Troglitazone had no significant effect on the 
proliferation of these leukemic T cell lines under basal conditions.
This data suggests that leukemic T cells are resistant to the growth-inhibitory 
effects of troglitazone. Further experimentation is confirm or refute this 
possibility. Unfortunately due to time constraints the P P A R y  ligands 1 5 d P G J 2  
and ciglitazone were not tested for their potential inhibitory effect on leukemic T 
cell proliferation.
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Figure 69: The PPARy ligand troglitazone does not inhibit proliferation in 












□ L C M
Control
Troglitazone
Jurkat Molt4 CEM Hut 78
Cell Line
Figure 69: Troglitazone does not inhibit proliferation in the leukemic cell lines Jurkat, CEM, 
MOLT-4 and HUT 78. 105 leukemic cells from each cell line were washed and aliquoted. Cells 
were either left unstimulated (blue bar) or treated with troglitazone at 10 |iM (red bar) and 
incubated for 48 hours before being pulsed with 1p curie of [3H]-thymidine for 14 hours. 
Proliferation was assessed by p-scintillation counting as described in Materials and Methods. 
Data are the mean ± S.E.M of quintuplicate samples from a single experiment representative of 




• Primary T cells proliferate in response to the simultaneous ligation of the 
CD3 and CD28 receptors but not in response to ligation of either receptor 
alone. T cells stimulated with 5 pg/ml PMA and 1jliM ionomycin also 
proliferate. Both results are consistent with the literature.
• The PPARy-1 isoform is expressed in T-lymphoblasts and the leukemic T 
cell lines Jurkat, CEM, MOLT-4 and HUT 78.
• The PPARy agonists troglitazone and 15dPGJ2 inhibit CD3/CD28 
proliferation in primary T cells and T-lymphoblasts with 15dPGJ2 being more 
potent on a molar basis than troglitazone. The structurally related PPARy 
agonist ciglitazone had no observable effect on T cell proliferation.
• PMA/ionomycin stimulated primary T cells were resistant to the inhibitory 
effects of troglitazone but not the prostaglandin 15dPGJ2.
• Troglitazone and 15dPGJ2 are both able to inhibit IL-2 induced proliferation 
of T-lymphoblasts again with 15dPGJ2 showing greater potency (in molar 
terms) in inhibition.
• Preliminary findings suggest that the growth of CD3/28 stimulated T- 
lymphoblasts can be inhibited by addition of troglitazone/15dPGJ2 at 10 pM 
post-stimulation.
• Troglitazone (10 juM), had no detectable significant effect on basal 
proliferation of the leukemic cell lines Jurkat, CEM, MOLT-4 and HUT-78 
despite the apparent expression of PPARy receptor at the protein level.
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Control of T cell proliferation by PPARy agonists
The PPAR proteins are members of the nuclear hormone receptor superfamily 
and all are believed to function as ligand dependent transcription factors. 
Studies have shown that PPARy participates in diverse biological roles including 
differentiation, atherosclerosis and cancer and is therefore of significant clinical 
interest (Sporn et al 2001). Increasing research is being focussed on the role of 
PPARy agonists in the regulation of immune cell function, particularly cells of 
the monocyte/macrophage series, and their clinical potential as anti­
inflammatory agents. Studies have also revealed that specific PPARy agonists 
such as troglitazone and 15dPGJ2 can inhibit activation of human T 
lymphocytes following stimulation with non-physiological ligands such as the 
mitogenic lectin phytoheamaglutin (PHA) and the phorbal ester PMA (Yang et al 
2000) highliging the potential of PPARy agonists as down-regulators of T cell- 
mediated inflammatory diseases. This study investigated the anti-proliferative 
effect of a variety of specific PPARy agonists (15dPGJ2, troglitazone and 
ciglitazone) in human primary T cells and T-lymphoblasts following a more 
physiological stimulus (anti-CD28/CD3 mAbs and IL-2) and compared the 
functional outcome (proliferation) with that obtained using PMA/lonomycin.
In agreement with previous findings, western blotting with anti-PPARy Ab 
revealed the high expression of PPARy protein in human peripheral T 
lymphoblasts and leukemic T cell lines (Yang et al 2000 and Harris et al 2001). 
Visual inspection of blots from T cell lysates revealed lower expression of 
PPARy receptor in MOLT-4 leukemic T cells than was observed in other cell 
lines. 30 minutes pre-treatment with the prostaglandin 15dPGJ2 prior to cellular 
stimulation, was shown to be a potent inhibitor of T cells and T-lymphoblasts 
proliferation in response to stimulation with the following anti-CD28/CD3 mAb (1 
jug/ml), PMA/lonomycin (used at 5 ng/ml and 1 pM respectively) and the T cell 
growth factor IL-2 (20 ng/ml). In agreement with previous reports 15dPGJ2, but 
not troglitazone, was also found to inhibit PMA/lonomycin stimulated T cell 
proliferation (IC5o 100 nM) (Yang e/a/2000). Data obtained using 15dPGJ2 has 
to be interpreted with increasing caution, as this is now known to interact and
Discussion 175
modulate other PPARy-independent pathways, including the NFkB pathway 
(Straus et al 2000). Indeed, a physiological specific and potent ligand of PPARy 
has yet to be identified. The results of recent experiments suggest that 15dPGJ2 
may elicit anti-inflammatory actions and even promote apoptosis of eosinophils 
via PPARy-independent mechanisms (Ward et al 2002) but the effect of addition 
of 15dPGJ2 treatment on T cells was not reported. Other studies have shown 
15dPGJ2 to physically interact with the transcription factor NF-AT and block 
activity of the IL-2 promoter (Yang et al 2000) and chemokine genes (Zhang et 
al 2001), in some cases inducing T cell apoptosis (Harris et al 2002).
The PPARy pathway has been shown recently to impinge on inositol lipid 
metabolism in macrophages, primarily through its ability to upregulate 
expression of PTEN. This results in an inhibition of cell growth in macrophages 
mediated by the degradation of Pl(3,4,5)P3 and abrogation of PI 3-K signalling 
(Patel et al 2001). Interestingly, in the same study it was reported that the 5’- 
phosphatase SHIP-2 was not upregulated, and was therefore unlikely to 
contribute to the observed inhibition of proliferation. It would be of interest to 
determine if PPARy ligands can upregulate SHIP (as opposed to SHIP-2) in 
haematopoietic cells, including T cells, and contribute to D3-phosphoinositide 
metabolism in a manner to that observed with PTEN. The same studie used the 
PPARy-selective ligand rosglitazone that is structurally related to troglitazone 
(Patel et al 2001,). It is not known whether 15dPGJ2 and other PPARy -specific 
agonists (including troglitazone) can upregulate PTEN via a similar mechanism 
in T cells. Recent work has also identified a role for troglitazone and PPARa 
ligands in disrupting PI 3-K dependent endothelial cell migration by targeting 
and inhibiting the phosphorylation of PKB (Goetze et al 2002). It would be of 
considerable interest to know if PPARy ligands could disrupt T cell chemotaxis 
via similar PI 3-K-dependent mechanisms.
The synthetic thiazolidinedione (TZD) compounds troglitazone and ciglitazone 
were also tested for inhibitory effects on T cell proliferation. Ciglitazone had no 
detectable effect on 3H-thymidine incorporation into cultures of primary T cell or
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T lymphoblasts, a result consistent with previous studies (Yang et al 2000). 
There is evidence, however, that ciglitazone, as well as 15dPGJ2, can inhibit 
experimental allergic encephalomyelitis, an experimental model of multiple 
sclerosis, by blocking IL-12 production and Th1 cell differentiation (Natarajan et 
al 2002). Collectively these data suggest that ciglitazone is potentially inactive in 
naive, resting primary T cells but may have an inhibitory effect in differentiated 
(Th1)T cells.
Troglitazone did inhibit CD3/CD28, IL-2 induced T cell proliferation albeit at 
higher concentrations than 15dPGJ2 (IC50 approx. 15 pM), but interestingly had 
no effect on T cells stimulated with the non-physiological ligands 
PMA/lonomycin. In contrast Yang et al observed an inhibitory effect of 
troglitazone on PHA/PMA induced proliferation, also a non-physiological 
stimulus (Yang et al 2000). Reasons for this conflicting evidence are not clear, 
but it may be that the use of lonomycin as a second stimulus renders the T cells 
troglitazone-insensitive. Previous studies have shown a slight potentiation of T 
cell proliferation when using troglitazone at nanomolar concentrations (Yang et 
al 2000). A similar effect of using nano-molar concentrations of troglitazone was 
also seen in this investigation, but the magnitude of decrease was small and not 
statistically significant (figures 62, 64 and 66). Add-back experiments, where 
troglitazone (10 pM) and 15dPGJ2 (10 pM) were added back to actively 
proliferating T-lymphoblasts 24 hours post-CD3/CD28 stimulation revealed 
these PPARG ligands to be equi-potent with regards to anti-proliferative actions. 
Although this is preliminary data, and must therefore be interpreted with caution, 
this observation suggests that certain PPARy ligands can override established 
mitogenic, proliferative cell signals and arrest cell growth or maybe induce toxic 
or apoptotic events. Further experiments need to be performed to eliminate the 
possibility if PPARy agonists are indeed cytotoxic and not pro-apoptotic. These 
could include performing cell-based apoptotic assays including annexin V  
staining of PPARy-treated T cells. It is worthy of note, however, that 15d-PGJ2, 
despite inducing apoptosis in transformed malignant T cells, has been shown 
recently to pre-dispose normal human T cells to apoptosis (Harris et al 2002).
A schematic model of anti-inhibitory action of PPARy ligands on stimulated 
primary T cell/lymphoblasts derived from data generated in this study and other
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Figure 70: Potential role for the PPARy ligands, troglitazone and 15dPGJ2 in inhibiting 
proliferation of T lymphocytes. In a physiological setting, stimulation of T cells via CD3/CD28 
and IL-2 results in the activation of mitogenic intracellular signalling cascades, including the 
activation of PI 3-K. These signals regulate expression of genes, including the IL-2 gene that 
can drive clonal expansion of T cells. Troglitazone and 15dPGJ2 used at low micromolar levels 
can inhibit T cell proliferation following stimulation with IL-2 or with anti-CD3/CD28 mAb. In 
addition 15dPGJ2, but not troglitazone, is able to inhibit T cell proliferation following stimulation 
with the non-physiological ligands PMA/lonomycin. The exact mechanisms of PPARy ligand- 
mediated inhibition are still unclear. Some studies have showed that troglitazone is able to 
inhibit secretion/expression of IL-2 (Yang et al 2000), whereas others have described data 
showing upregulation of PTEN gene in monocytes that can antagonise PI 3-K signalling (Patel 
et a l 2001).
The effect of troglitazone on proliferation (1 0  jliM ), was assessed in the leukemic 
cell lines Jurkat, CEM, MOLT-4 and HUT 78. Interestingly, troglitazone had no
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effect on leukemic T cell proliferation suggesting that unstimulated leukemic 
cells are insensitive to the inhibitory actions of troglitazone, at least at 10 jliM . It 
would have been of interest if troglitazone was able to inhibit proliferation in 
CD3/CD28-stimulated leukemic cells but due to time constraints ,this was 
unfortunately not determined. Analysis of the data revealed that leukemic T 
cells had different growth rates, with Jurkats showing greatest [3H]-thymidine 
incorporation compared to the other T cell lines. Of added importance was the 
fact that troglitazone was shown to be non-toxic to the leukemic T cells, at least 
when observed on the basis of their ability to exclude trypan blue. However, it 
cannot be ruled out that higher concentrations of troglitazone of above 10 pM 
may inhibit leukemic cell proliferation.
Unfortunately, time did not allow for the effect of the more potent 15dPGJ2 on 
leukemic T cell proliferation to be investigated. In a recent report, however, it 
was shown that 15dPGJ2 could inhibit proliferation and indeed induce apoptosis 
in the leukemic cell line Jurkat (Harris et al 2002), highlighting a potential 
therapeutic role for PPARy ligands in T cell leukaemia. However these inhibitory 
events of 15dPGJ2 may be occurring through PPARy-dependent as well as 
PPARy-independent pathways. This study did not address the issue of apoptotic 
effects of the PPARy ligands troglitazone and 15dPGJ2 on primary T cells and 
T-lymphoblasts and would have been of interest to know if treatment of PPARy 




Expression profiles, at both mRNA and protein level, of the key inositol 
phosphatases SHIP and PTEN in a variety of commonly used leukemic T cell 
lines are now better understood. The data presented in this study also provide 
direct evidence that SHIP contributes to PI(3,4,5)P3 metabolism in T 
lymphocytes following CD28 stimulation, producing the metabolite Pl(3,4)P2. 
Jurkat cells, which expressed neither SHIP nor PTEN, exhibited high basal 
levels of Pl(3,4,5)P3, which were increased upon CD28 ligation, and 
comparatively low levels of Pl(3,4)P2, as reflected by a high PI(3,4,5)P3 : 
PI(3,4)P2 ratio. Basal phospho-PKB levels in Jurkat cells appeared to be 
maximal and did not increase further upon cell stimulation. MOLT-4 and CEM 
cells expressed SHIP but not PTEN and had moderate basal levels of both 
Pl(3,4,5)P3 and Pl(3,4)P2, which both increased significantly upon CD28 
ligation. The Pl(3,4,5)P3 : PI(3,4)P2 ratio was much lower in these cell lines 
compared to Jurkat reflecting higher relative levels of Pl(3,4)P2. HUT 78 cells 
expressed both SHIP and PTEN and had much lower levels of D-3 
phosphoinositides which did not increase significantly upon CD28 ligation, 
perhaps due to either poor cell surface expression of CD28/CD3 or their rapid 
metabolism by PTEN and/or SHIP. T-lymphoblasts, which express both 
phosphatases, also had detectable levels of Pl(3,4,5)P3 which increased upon 
CD28 ligation but in a more regulated manner. PI(3,4)P2 basal levels were low 
and did not significantly increase upon cellular stimulation. Accordingly, 
phospho-PKB levels were comparatively low in both HUT 78 cells and T- 
lymphoblasts.
SHIP was shown to be rapidly tyrosine phosphorylated by a multitude of T cell 
surface receptors including, CD28 (upon anti-CD28 mAb and natural CHO- 
B7.1/2+ ligands), CD3, CD2 and IL-2. SHIP may also be able to mediate 
protein-protein interaction with the adapter proteins, p62dok and the newly 
identified GRID. Also, SHIP was found to immunoprecipitate with in vitro kinase 
activity. The identity of the co-associating kinase(s) is unknown but was shown 
to inducibly associate with SHIP following CD28 stimulation, leading to the
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phosphorylation of a number of uncharacterised proteins of different molecular 
weights.
Preliminary evidence was generated that CD28 may be able to signal to PTEN 
through in vitro kinase data. PTEN, like SHIP, was shown to inducibly associate 
with kinase activity following CD28 ligation, revealing several ‘hot’ co­
associating proteins of different molecular weight. The identity of these co­
associating proteins and kinase(s) remains to be discovered and may provide 
clues about the regulation of PTEN activity in T cells.
The effect of PPARy ligands upon primary T cell proliferation, stimulated with 
anti-CD3/CD28, IL-2 or PMA/lonomycin were also assessed in this study. Both 
troglitazone and 15dPGJ2 were shown to have inhibitory properties towards T 
cell proliferation with 15dPGJ2 being the more potent. The precise 
mechanism(s) of this inhibition were not evaluated. Ciglitazone, which is 
structurally related to troglitazone, was found to be ineffective in inhibiting T cell 
proliferation, which is in agreement with the published literature. In addition, 
troglitazone was shown to have no detectable effect on proliferation of leukemic 
T cell lines, the effect of 15dPGJ2 was unfortunately not determined. This data, 
viewed in the context of the published literature, suggests a potential 
therapeutic role for some PPARy ligands in the treatment of certain T cell 
mediated diseases e.g. autoimmune diseases.
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Future Work
Jurkat cells lack expression of both SHIP and PTEN and show signs of 
constitutively active PI 3-K signalling. It would be of interest to investigate what 
the effects, alone or in combination, would be of reintroduction of either SHIP 
and PTEN, perhaps using a Tet-regulated promoter to induce phosphatase 
expression, on D-3 phosphoinositide levels and downstream PI 3-K signalling 
cascades. The expression of PTEN and SHIP in Jurkats should, in theory, 
deplete phospho-PKB levels and may render the cell sensitive to apoptosis. 
Similar experiments could also be conducted in MOLT-4 and CEM cells i.e. 
reintroduction of PTEN. The observation that MOLT-4 and CEM cells exhibit 
high basal levels of the Pl(3,4,5)P3 metabolite, PI(3,4)P2 means that closer 
analysis of Pl(3,4)P2 -dependent signalling cascades should be studied in 
these cell lines. PH-domains of TAPP, a specific Pl(3,4)P2 adapter, coupled to 
green-fluorescent protein (GFP) could allow us to observe the cellular 
translocation of this PH domain in various leukemic cells (i.e. Jurkat versus 
CEM) via confocal microscopy following stimulation of T cell surface receptors.
The exact mechanism of CD28 targeting SHIP and the nature of the protein- 
protein interactions between SHIP and co-associating proteins remains unclear. 
One approach to clarify this quandary would be to construct GST-fusion 
proteins of specific domains of SHIP i.e. SH2 domain of SHIP, and perform 
immunoprecipitation studies in CD28-stimulated T cell lysates. This would help 
decipher the molecular nature of such protein-protein interactions. In addition, it 
would be worth investigating PTENs inducible recruitment into a multimeric 
complex following CD28 ligation further. The other proteins observed 
associating with PTEN are likely to regulate PTEN activity/function and it would 
be of great interest to determine their identity of the co-associating proteins and 
that of the kinase(s) responsible for the in vitro phosphorylations.
The mechanisms of PPARy anti-proliferative effects on primary T cells need to 
evaluated. Interestingly, recent literature has linked PPARy with regulation of PI 
3-K signalling through upregulation of PTEN in monocytes (Patel et al 2001). It
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would be worth investigating if similar PTEN upregulation occurs in T cells 
following treatment with the PPARy ligands troglitazone and 15dPGJ2. Such an 
approach could also assess if SHIP is upregulated via similar mechanisms and 
what the potential biological consequence of such upregulation would be. In 
preliminary experiments, troglitazone (10 ^M) was snot to have any anti- 
inhibitory effect on leukemic T cell lines. These studies need to be reproduced 
and extended to include the more potent, naturally occurring PPARy ligand 






Conical centrifuge tube (15ml) Becton and Dickinson, USA
Conical centrifuge tube (50ml) Becton and Dickinson, USA
Cryovials NUNC, UK
Dialysis tubing NUNC, UK
30ml Pipettes NUNC, UK
10ml Pipettes NUNC, UK
Eppendorf Centrifuge tubes (1.5ml) NUNC, UK
3mm Filter paper Whatmann, UK
Flasks 25cm2 NUNC, UK
Flasks 80cm2 NUNC, UK
Flasks 175cm2 NUNC, UK
Gel loading tips Jinkins, USA
Gilson tips (all sizes) Gilson, UK
HPLC column (SAX partishere) Whatmann, UK
Immunosorbent 96-well plates NUNC, UK
MACS CS column Miltenyl Biotech, UK
Needles 19-gauge ‘butterfly’ Terumo, Belgium
Nitrocellulose BDH, Poole, UK
Pastettes (1ml/ 3ml) NUNC, UK
PCR tubes (thin walled) Promega, Wl, USA
Petri dishes NUNC, UK
Plastic tubes 7mt/30 Sterilin, UK
Plastic pots (60M/150M) Sterilin, UK
Starstad screw-lid centrifuge tubes Starstad, Germany
Stopcocks BDH, Poole, UK
Syringes (all sizes) NUNC, UK
Tissue culture 96-well plates NUNC, UK
TLC Plates Whatmann, Maidstone, Kent
TOP Seal™ Canberra Packard, UK
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Unifilter™ GF/C'^ 96 well filter plates Canberra Packard, UK
Xomat film Kodak, Harrow, UK
Media and Reagents
REAGENT SOURCE
Acetone Fisher scientific, UK
Acrylamide Biorad
Agarose Sigma, Poole, UK
Ammonium Phosphate (NH4)2HP04 Sigma, Poole, UK
Ammonium persulphate (APS) Sigma, Poole, UK
Hapten-antibody cocktail Miltenyl Biotech , UK
Anti-hapten microbeads Miltenyl Biotech , UK
Aprotinin Sigma, Poole, UK
ATP Sigma, Poole, UK
Bovine serum albumin (BSA) Sigma, Poole, UK
Bovine Foetal Calf Serum (FCS) 
(heat inactivated)
Gibco BRL, Paisley, UK
Bromophenol blue Sigma, Poole, UK
|3-glycerol phosphate Sigma, Poole, UK
Chloroform Fisons, Loughborough, UK
Ciglitazone Alexis, Cambridge, UK
Coomoasie blue Sigma, Poole, UK
Deoxynucloside triphosphates:dATP, 
dCTP, dGTP and dTTP
Boehringer Mannheim, Germany
DMEM (with L-glutamine) Gibco BRL, Paisley, UK
DMEM (without L-glutamine) Gibco BRL, Paisley, UK
DMEM (phosphate free) Gibco BRL, Paisley, UK
Dimethyl sulphoxide (DMSO) Sigma, Poole, UK
ECL Amersham, UK
EDTA Sigma, Poole, UK
Ethanol Fisher Scientific, UK
Ethidium bromide Sigma, Poole, UK
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Ethyl Formate Fisher Scientific, UK
Flo-scint IV liquid scintillant Canberra Packard, UK
Folsh lipids Sigma, Poole, UK
Fungizone Gibco, BRL, UK
Glacial Acetic Acid Fisher Scientific, UK
Gluteraldehyde Sigma, Poole, UK
Glycerol Sigma, Poole, UK
Glycine Sigma, Poole, UK
HCI BDH, Poole, UK
Heparin Fisons, Loughborough, UK
HEPES Sigma, Poole, UK
HPLC column (SAX partishere) Whatmann, UK
lnterlukin-2 (human recombinant) Sigma, Poole, UK
Iodine Sigma, Poole, UK
lodoacetamide Sigma, Poole, UK
Lauryl Sulphate (SDS) Sigma, Poole, UK
Leupeptin Sigma, Poole, UK
Lithium chloride Sigma, Poole, UK
Lymphoprep™ (density 1.077) Nycomed, Birmingham, UK
Magnesium Chloride Anachem, Luton, UK
Manganese Chloride BDH, Poole, UK
Marvel Local stores
Methanol Fisher Scientific, UK
Methylamine (25% w/v) Fisher Scientific, UK
Microscint-OTM scintillant Canberra Packard, UK
Molecular Weight Markers Sigma, Poole, UK
M-450 dynabeads couple to 
CD28/CD3
C. June, Naval research institute, 
Bethedsa, USA
NaCI Sigma, Poole, UK
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NaF Sigma, Poole, UK
Nitrocellulose Invitrogen, UK
NP-40 Fisher Scientific, UK
Paraformaldehyde Sigma, Poole, UK
Penicillin/Streptomycin Gibco, BRL, UK
Petroleum ether (Bp 40-60°C) BDH, Poole, UK
15d-PGJ2 Cayman Chemicals, USA
Phenyl Methyl Sullenly Fluoride Sigma, Poole, UK
PBS (without Ca2+ and Mg2+) Gibco, BRL, UK
Phosphatidyl inositol Sigma, Poole, UK
Phosphatidyl serine Sigma, Poole, UK
Phosphoric acid Fisher Scientific, UK
PMA Calbiochem, Nottingham, UK
Potassium Oxalate Sigma, Poole, UK
Propan-1-ol Fisher Scientific, UK
Propan-2-ol Fisher Scientific, UK
Propidium Iodide Sigma, Poole, UK
Ponceau solution Sigma, Poole, UK
Potassium acetate Sigma, Poole, UK
Protein-A Sepharose Pharamcia, UK
Protein-G Sepharose Sigma, Poole, UK
RNAzol Amos Biotechnology, Oxon, UK
RPMI-1640 Gibco, BRL, UK
SEB (superantigen) Sigma, Poole, UK
Sodium Azide Sigma, Poole, UK
Sodium orthovanadate Sigma, Poole, UK
Small trypsin inhibitors Sigma, Poole, UK
Sucrose Fisher, UK
Tetra butyl ammoniumhydrogen Sigma, Poole, UK
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sulphate (TBAS)
TEMED Sigma, Poole, UK
Tris HCI Sigma, Poole, UK
Triton X-100 Fisher, UK
Troglitazone Alexis, Cambridge, UK
Trypsin/EDTA Gibco, BRL, UK
Trypan Blue Sigma, Poole, UK





[32-P]-orthophosphoric acid (5 
mCi/ml)
NEN, Stevenage, UK
[“ -P]y ATP (5 nCi/ml) NEN, Stevenage, UK





ANTIBODY SOURCE WORKING DILUTION
Anti-CD28 (9.3) Mouse/C. June, Naval 
Medical institue, Bethedsa, 
USA
Used at 10 pg/ml
Anti-murine CD3 
(2C11)
Mouse/D. Olive, INSERM, 
Marseille
Used at 10 pg/ml
Anti-CD3 (UCHT-1) Mouse/D. Cantrell, ICRF, 
UK
Used at 10 pg/ml
Anti-CD2 Mouse/ M. Glennie 
Southampton, UK
Used at 10 pg/ml
Anti-lgG2a Mouse/ Sigma, Poole, UK Used at 10 ng/ml
Anti-mouse/rabbit-
hrp












Rabbit/ Kind gift from Mark 
Coggeshall
1:1000 TBS/1 % Milk
Anti-SHP-2 Mouse/Santa Cruz 1:2000 TBS/1 % BSA
Anti-PTEN Mouse/Santa Cruz 1:2000 TBS/1 % BSA
4G10 (ANTI-Y-P) Mouse/Upstate, NJ, USA 1:10000 TBS/1 %BSA
Anti-p62dok Mouse/Santa Cruz 1:2000 TBS/1 % BSA
Anti-P-PKB Rabbit/NEB, New England, 
USA
1:1000 TBS/1% BSA
Anti-P-GSK3 Rabbit/NEB, New England, 
USA
1:1000 TBS/1% BSA
Anti-PAN-PKB Mouse/NEB, New England, 
USA
1:5000 TBS/1% BSA
Anti-PAN-GSK3 Mouse/NEB, New England, 
USA
1:5000 TBS/1% BSA
Anti-PPAR gamma Rabbit/ Santa Cruz 1:1000/TBS 5% Milk
Anti-GRID Rabbit/ J. Ellis 
GlaxoSmithkline, UK
1:1000/TBS 3% Milk
Anti-p85 (U5) Mouse/ D. Cantrell ICRF 1:10000 T B S /1% BSA
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Appendix 2: Buffer/solution recipes
Lysis buffer: 0.5% v/v NP-40, 65mM NaCI, 10 mM Tris pH 7.5, 1% p-glycerol 
phosphate, 5 mM NaF, 5 mM iodoacetamide, 1mM phenylmethyl- 
sulfonylflouride, 1 pg/ml leupeptin, 1 pg/ml pepstatin, 1 pg/ml small trypsin 
inhibitors, 1 jug/ml Na orthovanadate
Running buffer: 192 mM glycine, 25 mM Tris, 0.1% SDS
Semi-dry transfer buffer: 39 mM glycine, 48 mM Tris, 0.037% SDS
Stripping buffer: 200 mM Tris pH 6.8 with 60 pM (3-2 Mercaptoethanol
In Vitro protein kinase assay buffer: 100 mM NaCI, 25 mM HEPES pH 7.4, 
10 mM MgCh, 5 mM MnCh, 100 pM sodium orthovanadate
In Vitro phosphatase assay buffer: 10 mM TE pH 7.5, 10 mM MgCh








T GAACATT CTCCGGTT CCTG XM 096169
SHIP REVERSE
(5-3’)
TAAGACT GACACACCACGT G As above
PTEN FORWARD
(5-3’)
GTACTTT GAGTT CCCT CAGC AF143312
PTEN REVERSE
(5-3’)
GGAGAAAAGTAT CCGTT GGC As above
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Appendix 4
Critical values for Spearman’s rank correlation coefficient
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